Genetic Basis of Inherited Eye Diseases by Ajmal, M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/106926
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
  
GENETIC BASIS 
OF 
INHERITED EYE DISEASES 
 
 
MUHAMMAD AJMAL 
 
 
Genetic Basis of Inherited 
Eye Diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MUHAMMAD AJMAL 
 
 
 
 
 
2 
Muhammad Ajmal, 2013  
 
Genetic Basis of Inherited Eye Diseases  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright: 2013, Muhammad Ajmal, Nijmegen, The Netherlands 
Printed by: Ridderprint BV, Ridderkerk, the Netherlands 
ISBN: 978-90-5335-679-1 
 
 
 
 
3 
Genetic Basis of Inherited Eye Diseases 
 
 
 
Doctoral Thesis 
 
 
 
to obtain the degree of doctor  
jointly awarded by 
Radboud University Nijmegen  
on the authority of the Rector Magnificus prof. dr. S.C.J.J. Kortmann,  
according to the decision of the Council of Deans, 
 
 
and 
 
 
COMSATS Institute of Information Technology,  
on the authority of the Rector dr. S.M. Junaid Zaidi,  
to be defended in public on Thursday, April 18, 2013 
at 10.30 hours  
 
 
by 
 
 
Muhammad Ajmal 
born on 31 December 1975 
in Gujrat, Pakistan 
 
 
4 
Supervisors 
Prof. dr. F.P.M. Cremers 
Prof. dr. R. Qamar (COMSATS Institute of Information Technology, Islamabad) 
 
Co-supervisor 
Dr. R.W.J. Collin 
 
Doctoral Thesis Committee 
Prof. dr. C.B. Hoyng (chair) 
Dr. M. Ali (University of Leeds, Leeds, United Kingdom) 
Prof. dr. A.A.B. Bergen (Netherlands Institute for Neuroscience, Amsterdam) 
Prof. dr. D.W. Swinkels 
Dr. L.E.L.M. Vissers 
 
 
 
 
 
 
 
 
 
 
5 
TABLE OF CONTENTS 
 
Chapter 1 General introduction 7 
Chapter 2 Identification of known and novel mutations in 
TULP1 in Pakistani families with early-onset 
retinitis pigmentosa 41 
Chapter 3 Novel mutations in RDH5 cause fundus 
albipunctatus in two consanguineous Pakistani 
families 63 
Chapter 4 Exome sequencing identifies a novel and a known 
BBS1 mutation in Pakistani families with Bardet-
Biedl syndrome 87 
Chapter 5 Homozygosity mapping identifies genetic defects in 
four consanguineous families with retinal dystrophy 
from Pakistan 107 
Chapter 6 Genetic causes of retinal dystrophies in Pakistan 123 
Chapter 7 Exome sequencing identifies a DHX38 missense 
mutation associated with severe early-onset retinitis 
pigmentosa in a Pakistani family: a new RNA 
splicing gene defect associated with a macular 
coloboma 155 
Chapter 8 General discussion 173 
Summary  193 
Samenvatting  199 
Publications  205 
About the author  209 
Acknowledgements  211 
List of abbreviations  213 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
Chapter 1 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
                                                                                                                                                 General introduction 
9 
The eye is a vital organ of the human body as vision is the basic necessity of a human being. 
Interestingly, a significant portion of the human brain is involved in interpreting the visual 
signals received in the form of nerve impulses from the photosensitive cells of the eye.1 A 
diseased eye cannot perform its function properly and thus vision is impaired, which 
subsequently results in the disability of the affected individual. Unlike in the western world, 
in the third world, affected individuals are thought to be a burden on the family because they 
cannot cope with the hardships of life, socially as well as economically. 
Visual impairment that results from minor refractive errors can usually be corrected using 
artificial lenses but in other cases usually the loss of vision is irreversible and cannot be 
treated. Diseases that result in irreversible loss of vision can be sub-divided into two groups; 
traumatic eye diseases resulting from injuries and inherited eye diseases (either monogenic or 
multifactorial). Traumatic injuries may lead to blindness if they are severe enough and 
sometimes even minor injuries, if not treated properly, may end up in a major dystrophy. 
Similarly, genetic mutations may result in apoptosis-mediated cellular death. Before going 
into the details of eye diseases an overview of the anatomical features of the eye is called for. 
1.1. Anatomical structure of the human eye 
Almost all vertebrate species have a pair of eyes situated in the skull below the forehead. The 
human eye is a semi-spherical ball-like structure composed of three layers; the outer layer is 
the sclera, the middle layer is the choroid and the innermost layer is the retina (Figure 1.1). 
The transparent portion of the sclera in front of the eye is known as the cornea. Next to the 
lens, the cornea is partially responsible for the refraction of light. Behind the cornea there is a 
ring-like structure, the iris, which contains a central opening, the pupil. The latter contracts in 
response to the intensity of the incoming light, and thus controls the amount of light entering 
into the lumen of the eye. The lumen between the cornea and iris is filled with aqueous 
humor, while the lens is situated posterior to the iris. Ciliated muscles hold the lens in its 
proper place; these muscles are also involved in focusing the lens for near and distant vision. 
Posterior to the lens is the interior chamber of the eye, which is filled with a viscous vitreous 
humor. The innermost part of the eye is the retina, which is involved in image processing. The 
central part of retina is the macula where the images are formed. The center of the macula, 
which is responsible for colour vision and high acuity vision, is the fovea. The fovea is the 
cone-rich region of the retina and contains a trough in the center to allow maximal penetration 
of light that can trigger the densely packed cone photoreceptors. 
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Figure 1.1 Structure of the human eye (adapted and modified from Jacobson and 
Cideciyan2). 
1.1.1. The retina 
The innermost and multi-layered structure of the eye, which contains the photoreceptor cells 
responsible for image processing, is the retina. In 1583 Felix Plater was the first person who 
described the retina as a target tissue for the incoming light.3 The retina is further divided into 
different layers, which include an outer layer the retinal pigment epithelium (RPE), followed 
by an outer segment layer, an outer limiting membrane, an outer nuclear layer, an outer 
plexiform layer, an inner nuclear layer, an inner plexiform layer, a ganglion cell layer, an 
optic nerve fiber layer, and an inner limiting membrane (Figure 1.2). Of these, the RPE 
consists of a single layer of hexagonal cells that separates the neural retina from the choroid. 
The RPE, among many other functions, is involved in supplying nutrients to the other internal 
layers of the retina.4 In addition, the RPE has a pigment, melanin, which helps in the 
absorption of reflected light that is not used by the photoreceptor cells. The RPE is also 
involved in the phagocytosis of shed outer segments of the photoreceptors. Next to the RPE is 
the photoreceptor layer consisting of rods and cones, with their outer segments embedded in 
the RPE, and their cellular bodies being present in the outer nuclear layer. Axons of the rods, 
the cones, and their associated bipolar and horizontal cells, which are present in the inner 
nuclear layer, exchange synaptic signals in the outer plexiform layer. The inner nuclear layer 
also harbours amacrine and Müller glial cells. Bipolar cells transfer signals to the amacrine 
                                                                                                                                                 General introduction 
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Figure 1.2 Arrangement of retinal layers. The retina consists of ten distinct layers. The 
outermost layer is the retinal pigment epithelium (RPE), into which outer segments of rod (R) 
and cone (C) photoreceptors are embedded. Next to the RPE is the layer that contains the 
outer segments of the rod and cone photoreceptors, whereas their cell bodies constitute the 
outer nuclear layer. The axons of photoreceptors terminate in the outer plexiform layer. The 
inner nuclear layer contains horizontal cells (H), bipolar cells (B), Müller cells (M) and 
amacrine cells (A). The inner plexiform layer consists of the synaptic terminals of bipolar, 
amacrine and ganglion cells (G). The ganglion cell layer lies between the inner plexiform 
layer and optic nerve fiber layer. Next to the ganglion cell layer is the optic nerve fiber layer. 
Inner and outer limiting membranes contain the endings of Müller glial cells (adapted and 
modified from Swaroop et al.5). 
 
and ganglion cells via the synapses in the inner plexiform layer. The ganglion cells transfer 
the signal to the brain through the optic nerve. The inner and outer limiting membranes 
contain endings of the Müller glia cells.5 Input from the retina is sent to the brain where the 
midbrain controls different parameters of the visual process including eye movements, pupil 
size, and circadian photoentrainment, in response to the signals received from the neuronal 
retinal network of cells.6 Finally, the retinal information reaches the visual cortex, where it 
results in the interpretation of the signals by the brain.7 
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1.1.1.1. Photoreceptors 
One of the most common etiologies of blindness worldwide is the degeneration of 
photoreceptor cells.8 Photoreceptors are light sensitive modified-cilia like bodies, which are 
involved in the visual signal transduction. These cells differentiate at later stages of retinal 
development just before the Müller glial cells.9 In the process of vision the signal is received 
in the form of photons that enter the eye through the cornea, pass through the aqueous humor 
of the anterior chamber, cross the lens, enter into the vitreous and finally excite the 
photoreceptors in the retina. 
Max Schultze in 1866 described photoreceptors as functional entities that are involved in the 
vision process and named them rods and cones,10 which have diverse structures and functions 
in different living organisms.11 The rod photoreceptors are of one type only, whereas three 
different types of cones are used to differentiate between different colours.12 
Rod photoreceptors 
The rod photoreceptors (Figure 1.3) are highly sensitive to light as compared to the cone 
photoreceptors13 and have the ability to detect even a single photon of light.14 This remarkable 
light sensing ability is ideal for low light conditions.12 Moreover, the number of rod cells 
(approximately 125 million) is much higher than the number of cones (approximately 7 
million). 
The rod photoreceptors are mostly responsible for night vision and remain inactive during 
bright light conditions.15 Recovery of the sensitivity phase, known as dark adaptation, of rod 
photoreceptors is relatively slower than that of the cone photoreceptors and may take up to an 
hour.16,17 
Cone photoreceptors 
The cone photoreceptors (Figure 1.3) are concentrated in the macula and are more densely 
packed in the foveal region. The cone photoreceptors are mainly responsible for colour vision 
and visual acuity during day time and under bright light conditions. There are three types of 
cone cells, red, green and blue, based on the presence of different photopigments. Red cones 
respond to long wavelengths of 564-580 nm, green cones respond to medium wavelengths of 
534-545 nm and blue cones respond to short wavelengths of 420-440 nm, and are thus used to 
discriminate among the different colours. The cone photoreceptors are mostly functional 
                                                                                                                                                 General introduction 
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during bright light conditions and the light sensing ability of the cone photoreceptors is almost 
one hundred times less than that of the rod photoreceptors.18,19 Because of this much lower 
sensitivity, cone photoreceptors can easily adapt to varying intensities of light and remain 
light sensitive during the entire day time period, relaying messages to the brain.12,20 
1.2. Mechanism of vision 
The process of vision in the rods begins with the photo-isomerization of the opsin-bound 
chromophore (rhodopsin) in the outer segment of the photoreceptors.7 The photo-activated 
visual pigment rhodopsin then initiates a cascade of reactions, which result in the closure of 
the cationic ion channels situated in the plasma membrane, leading to hyperpolarization of the 
cells.11 The mechanism of vision can be divided into two distinct steps, the phototransduction 
and the retinoid cycle. 
                               
    Rod             Cone 
Figure 1.3 Structure of rod and cone photoreceptors. Rod and cone outer segments (OS) 
are embedded in the retinal pigment epithelium (RPE). Inner segments (IS) are mainly 
involved in metabolic processes. Cell bodies (CB) contain the nucleus and are involved in 
gene regulation. Synaptic transmission takes place through the synapses (Syn) of rods and 
cones (adapted and modified from Swaroop et al.5). 
 
 
 
Disc shedding 
 
 
 
 
 
OS biogenesis 
Transport 
 
 
 
 
Metabolism 
 
 
 
 
Gene regulation 
 
 
Synaptic transmission 
Chapter 1                                                                                                                                                                   c 
14 
1.2.1. Mechanism of phototransduction 
The phototransduction cascade takes place in the photoreceptor outer segments (OS) where 
light absorption results in the photo-isomerization of the opsin-bound chromophore 11-cis 
retinal to all-trans retinal, and activation of the visual pigment rhodopsin (Figure 1.4).7,21 This 
activated rhodopsin then catalyzes the exchange of transducin-bound guanosine diphosphate 
(GDP) by guanosine triphosphate (GTP) leading to activation of transducin,21-23 which is a 
heterotrimeric G protein. Upon activation of transducin, the GTP-bound alpha subunit 
dissociates from the other two subunits exposing its active site, which subsequently binds to 
and activates the cyclic guanosine monophosphate (cGMP) phosphodiesterase. The cGMP 
phosphodiesterase hydrolyzes cGMP to 5’GMP resulting in the intracellular depletion of 
cGMP levels, which then triggers the closure of cyclic nucleotide gated (CNG) channels. 
Closure of CNG channels finally leads to the hyperpolarization of the photoreceptors, which 
results in a decrease in synaptic release of the neurotransmitter glutamate.7,24-26 
After hyperpolarization, the rhodopsin recovery phase begins with its phosphorylation by 
rhodopsin kinase and binding of arrestin.21 The level of cGMP is also restored with the help 
of guanylyl cyclase (GC) that is activated by calcium-binding protein guanylyl cyclase 
activating protein (GCAP). This GC-mediated increase in cGMP level subsequently results in 
the opening of the CNG channel due to which the cell becomes depolarized again. Opening of 
CNG channel results in the elevation of intracellular Ca2+, which results in the inactivation of 
GC. Intracellular Ca2+ levels are regulated through the Na+/Ca2+-K+ exchanger that is present 
in the plasma membrane.27 
1.2.2. Retinoid cycle 
The rod specific retinoid cycle occurs in the rod outer segment and RPE (Figure 1.5). In the 
rod photoreceptor OS, arrestin binding to rhodopsin results in the dissociation of all-trans 
retinal into the disc membranes of the rod photoreceptor. From the disc membranes of the 
outer segment, ATP binding cassette subfamily A member 4 (ABCA4) transports all-trans 
retinal to the cytoplasmic space, where it is subsequently reduced into the all-trans retinol by 
retinol dehydrogenase 12 (RDH12). From the cytoplasmic space all-trans retinol is released 
into the interphotoreceptor matrices with the help of interphotoreceptor binding protein 
(IRBP). All-trans retinol binds cellular retinol-binding protein-1 (CRALBP1) and diffuses 
into the RPE where it is converted into all-trans retinyl ester by lecithin retinol acyl 
transferase (LRAT). All-trans retinyl ester is then converted to 11-cis retinol by RPE-specific 
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Figure 1.4 Mechanism of mammalian phototransduction from light perception to hyperpolarization of the photoreceptors. 
Photoisomerization of 11-cis retinal to all-trans retinal starts a cascade of reactions leading to the hyperpolarization of the cell. Different 
intracellular signaling molecules and membrane channels including guanosine diphosphate (GDP), guanosine triphosphate (GTP), 
phosphodiesterase (PDE), cyclic guanosine monophosphate (cGMP), 5’ guanosine monophosphate (5’GMP), cyclic nucleotide gated (CNG) 
channel and sodium/calcium and potassium (Na+/Ca2+ K+) exchangers take part in the whole process (adapted from Shichida and Matsuyama21). 
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Figure 1.5 Retinoid cycle showing the regeneration of the visual chromophore 11-cis 
retinal in the RPE by the action of different stereospecific enzymes. In the rod 
photoreceptor cell (PC) outer segment 11-cis retinal (11-cis-RAL) is converted to all-trans 
retinol (all-trans-ROL) by the action of different enzymes. Rhodopsin (RHO) is a 
chromophore bound photosensitive membrane protein that is activated by photoisomerization 
of 11-cis RAL to all-trans RAL. ATP binding cassette subfamily A member 4 (ABCA4) is 
required for chromophore transport into the cytoplasm. Retinal dehydrogenase 12 (RDH12) is 
a stereospecific enzyme present in the photoreceptor outer segment. Interphotoreceptor 
binding protein (IRBP) is present in interphotoreceptor matrix. In the retinal pigment 
epithelium (RPE) several stereospecific enzymes including lecithin retinol acyl transferase 
(LRAT), retinal pigment epithelium specific 65 kDa protein (RPE65), retinal G protein 
coupled receptor (RGR), 11-cis retinol dehydrogenase (RDH5) and cellular retinaldehyde 
binding protein (CRALBP) are involved in the regeneration of the chromophore (adapted 
from den Hollander et al.30). 
 
65 kDa protein (RPE65) that is an isomerase, the activity of which is thought to be controlled 
by a non-photoreceptor opsin known as the retinal G protein coupled receptor (RGR).28 The 
11-cis retinol dehydrogenase (RDH5) catalyzes the oxidation of 11-cis retinol into 11-cis 
retinal, which is then transported back into the interphotoreceptor matrices by binding with 
IRBP. From the interphotoreceptor matrices 11-cis retinal diffuses into rod photoreceptor 
outer segment where it binds to the opsin to take part in another round of phototransduction.29-
31 
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In the rod photoreceptors the conversion of the all-trans retinol to 11-cis retinal takes place in 
the RPE, whereas in the cone photoreceptor cells this conversion is not fully dependent on the 
RPE, and this part of the retinoid cycle also takes place in the Müller cells.32 
1.3. Inherited eye diseases 
Monogenic retinal diseases are relatively rare with an estimated worldwide prevalence of 
1/2000 persons.33 In comparison, the multifactorial eye diseases glaucoma and age-related 
macular degeneration affect 2% and 1.5% of the population, respectively.34 The monogenic 
retinal diseases often are progressive and affect young persons, and thereby have a significant 
negative impact on the quality of life of the affected persons and represent a huge economic 
burden on the society. These retinal anomalies may involve different cell types of the retina 
including photoreceptors and the RPE. Based upon which cell types degenerate first, retinal 
dystrophies can be further classified into cone dystrophy, cone-rod dystrophy or rod-cone 
dystrophy. In addition, several other features including age of onset and clinical phenotypes 
are also considered. 
1.3.1. Non-syndromic eye diseases 
Isolated eye disease phenotypes without any other anomaly are known as non-syndromic, 
which are mostly monogenic but rare digenic forms and mitochondrial inheritances have also 
been reported. Retinitis pigmentosa is a common example of a genetically inherited non-
syndromic eye disease. Below, only the retinal phenotypes that were studied in this thesis are 
described. 
1.3.1.1. Retinitis pigmentosa 
The Dutch ophthalmologist F.C. Donders was the first person who used the term “retinitis 
pigmentosa” (RP) in 1857,2 which is described as a heterogeneous disorder, both clinically as 
well as genetically, and is one of the most frequent monogenic retinal diseases worldwide 
with a prevalence of 1 in 3500 to 4000.35,36 Clinically, RP is characterized by night blindness 
and an initial progressive loss of mid-peripheral vision, which further expands towards the 
periphery and central parts of the retina37,38 leading to legal blindness in the mid-forties and 
ultimately can lead to complete blindness.39,40 In RP a rod-cone pattern of photoreceptor 
degeneration is seen, in which the rod photoreceptor degeneration precedes cone 
degeneration.34 
Chapter 1                                                                                                                                                                   c 
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The diagnosis of RP mainly depends on two basic evaluations, fundus examination and 
measurement of electrophysiological responses of rods and cones. Fundus examination of the 
RP patient mostly reveals the presence of bone spicules in the peripheral region of the retina 
and attenuation of the retinal blood vessels, whereas measurement of electrophysiological 
responses of rods and cones help in assessing the health of the different types of 
photoreceptors. At early stages, RP is diagnosed by night blindness and mild attenuation of 
retinal vessels, because bone spicules mostly develop at later stages of the disease. Sometimes 
when patients with normal fundi complain about night blindness and there are no other 
symptoms of the disease then the disease is diagnosed as RP sine pigmento.35 
The inheritance pattern of RP includes autosomal dominant (15-20% of cases), autosomal 
recessive (20-25%), and X-linked (10-15%), whereas isolated RP accounts for 40-55% of RP 
cases.41 RP is mostly inherited as a single gene disorder34 but digenic forms42 and rare 
mitochondrial inheritance patterns have also been observed.43 
The heterogeneous nature of RP is reflected by the growing number of causative genes, which 
determine the molecular etiology of the disease. Eight disease-linked loci and 55 different 
genes have been implicated in non-syndromic RP (https://sph.uth.tmc.edu/retnet/). 
1.3.1.2. Fundus albipunctatus 
Lauber described the fleck retina disease fundus albipunctatus (FA) for the first time in 
1910.44 FA is a rare genetically inherited condition and is considered a sub-type of congenital 
stationary night blindness (CSNB). Clinical symptoms of FA include the presence of 
yellowish white spots or flecks in the mid-peripheral region of the retina or scattered 
throughout the fundus and delayed dark adaptation.45 In some cases of FA, cone dystrophy 
and macular degeneration have also been observed along with the presence of white dots but 
the degree of severity in such cases is highly variable.46-48 
Symptoms of FA overlap with those of retinitis punctata albescens (RPA), which is another 
form of retinal disease. Common features of both conditions are the presence of yellowish 
white spots on the retina and loss of night vision.49 FA is a stationary disease whereas RPA is 
progressive in nature. The only way to distinguish between these two is to measure the 
electrophysiological responses of rod and cone photoreceptor cells. The rod photoreceptors of 
FA patients take more than three hours to attain their normal state during the recovery phase 
while the rod photoreceptors of RPA patients fail to recover al all.45 Alternatively, a regular 
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follow up examination of patients presenting with white spots on the fundus and normal 
visual acuity may be helpful in establishing the correct diagnosis. 
1.3.2. Syndromic eye diseases 
The presence of additional clinical features outside the eye is termed as syndromic forms of 
the disease. The most common syndromic eye disorder is Usher syndrome in which deafness 
and RP occur at the same time.50 Another syndromic form of retinal dystrophy is Bardet-Biedl 
syndrome (BBS),51,52 which is a highly complex ciliary disease involving many organs. As 
BBS was part of this thesis, more details of this disease follow below. 
1.3.2.1. Bardet-Biedl syndrome 
BBS is clinically characterized by the presence of four out of six primary characteristics, 
which include rod-cone dystrophy, polydactyly, obesity, intellectual disability, hypogonadism 
and renal malformation. In cases where three of these primary features are present, the 
diagnosis of BBS can only be established when at least two additional secondary features are 
also present. Secondary features include liver anomalies, diabetes mellitus, reproductive and 
developmental disorders, growth retardation, speech delays, and cardiovascular 
malfunctions.51 
The inheritance pattern of BBS is mostly autosomal recessive, whereas digenic forms with tri-
allelic inheritance have also been identified.53-56 Genetic modifiers play an important role in 
modifying the disease phenotype in BBS patients.57 Modifying effects of a third allele have 
been studied for BBS and a protective role of other alleles has also been elucidated.58,59  
The prevalence of BBS is variable in different world populations, in the Faroe Islands it is 1 
in 3,700, which is the highest in the world,60 whereas in Switzerland BBS is prevalent at 1 in 
160,000 individuals.61 
Mutations in 17 different genes have been shown to be associated with BBS62 pointing to the 
genetic heterogeneity of the disease. Most BBS genes express proteins, which are part of a 
protein complex known as the BBSome, which include BBS1, BBS2, BBS4, BBS5, BBS7, 
BBS8 and BBS9. Although the BBSome complex is thought to be involved in the biogenesis 
of the ciliary membrane and membrane trafficking across the primary cilium, its exact 
functions are not yet completely understood.63 
 
Chapter 1                                                                                                                                                                   c 
20 
1.4. Techniques used to identify the genetic basis of eye diseases 
Presently, different gene mapping techniques are in use to identify the mutated genes in 
patients with inherited disorders. Selection of the gene mapping technique usually depends on 
two factors, i.e., pedigree structure and disease phenotype. When the pedigree analysis reveals 
no ambiguity about the inheritance pattern and the clinical phenotype has also been properly 
diagnosed then the next step is the selection of a suitable gene localization strategy. 
1.4.1. Sanger sequencing of candidate genes 
Sanger sequencing is considered the gold standard in determining the aberrations in the 
deoxyribonucleic acid (DNA) sequence because of its nucleotide level resolution.64 The 
principle is based on the incorporation of dideoxynucleotides when copying a single-stranded 
DNA molecule, which results in random termination of the chain and the generation of 
fragments of different sizes. The fluorescently labelled fragments are then electrophoretically 
separated, fluorescence induced by a laser scanner and detected by a diode array. 
Candidate gene sequencing by the Sanger method is a useful strategy when the disease is 
associated with an obvious causative gene. This is the case in e.g. familial 
hypercholesterolemia, for which the low density lipoprotein receptor gene (LDLR) is the most 
commonly mutated gene,65 so it is convenient to first analyse LDLR by sequence analysis, 
instead of using other expensive techniques as a first step. Similarly, persons with RP with a 
perifoveal annular ring in the fundus need to be screened first for tubby like protein 1 
(TULP1) mutations, and patients with FA should initially be tested for RDH5 mutations.66,67 
Although Sanger sequencing is the gold standard it cannot be used for large scale sequencing 
projects due to its lack of cost-effectiveness. 
1.4.2. Linkage analysis 
If the clinical phenotype in a family does not directly point towards the involvement of a 
specific gene, and mutations in one of many genes need to be considered, linkage analysis can 
be used to determine genomic regions that are shared by affected individuals within a family 
but are different in non-affected relatives. Linkage analysis is a classic genetic mapping 
technique commonly used to map disease associated loci and genes.68 Establishment of 
genetic linkage primarily depends on the assessment of recombination events between two 
different loci. In addition, linkage analysis also depends on the availability of suitable genetic 
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markers.69 These genetic markers should be highly polymorphic and distributed over the 
entire genome to allow a whole genome search for disease loci. 
1.4.2.1. Homozygosity mapping 
Homozygosity mapping is a technique used to locate stretches of homozygosity in the 
genome, mostly for recessive diseases, that are shared by the affected individuals in a family. 
Next, these regions are searched for the obvious disease-causing genes, which are sequenced 
to identify the possible disease causing mutations. 
Homozygosity mapping can be performed using several hundred microsatellite markers 
spread over the entire genome, but more recently, single nucleotide polymorphism (SNP)-
microarrays are employed that contain between 10,000 and 1,000,000 SNPs equally spread 
over the genome.70  
Genotyping microsatellite markers 
Simple sequence repeats known as microsatellite markers are highly polymorphic DNA 
sequences composed of di-, tri- and tetra-nucleotide repeats located on different 
chromosomes. Because of the genome-wide distribution of these microsatellite markers they 
are commonly used to map different disease causing genes across the human genome. In this 
method of homozygosity mapping microsatellite markers are used to genotype the individuals 
to find the homozygous stretches of DNA on different chromosomes, known as haplotype 
blocks, which are shared by all the affected individuals of a family. These shared regions are 
further investigated to locate the candidate genes, which harbour the disease causing 
mutations. 
Significance of linkage is tested by calculating logarithm of the odds (LOD) score, using 
genotyped haplotype blocks in affected as well as healthy individuals.71 Different linkage-
analysis softwares are used to calculate LOD score, where a LOD score of at least 3.3 in a 
genome-wide analysis is considered to be significant .69 
Genotyping single nucleotide polymorphisms 
Normal humans carry 23 pairs of chromosomes, one pair of which is inherited from each 
parent.72 These chromosomes together carry approximately 25,000 genes that encode different 
proteins required for life. The genomic sequences of two unrelated individuals are ~99.5% 
identical, while the remaining 0.5% is different due to naturally occurring structural 
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variations, among which are the copy number variants (CNVs; insertions, deletions), 
inversions, and single nucleotide polymorphisms (SNPs). The latter in most cases represent 
natural variations that do not render any functional effects. Levy et al., identified nearly 3.2 
million SNPs scattered throughout the genome of an individual,72 which were present in the 
coding as well as non-coding DNA sequences. In the protein coding regions of the genome, 
SNPs can either be synonymous (i.e. there is no change in amino acid) or nonsynonymous 
(the amino acid is changed). Ng et al., identified 10,400 nonsynonymous SNPs in a human 
exome, of which only ~1500 were predicted to (slightly) affect protein function.73 Because of 
the distribution of the SNPs throughout the genome they can potentially be a useful tool in the 
determination of homozygous regions in linkage analysis. 
Any single defect or change in the genetic information stored on the chromosomes in the form 
of genes may result in the expression of a disease condition. In the case of autosomal 
recessive disorders, affected individuals inherit mutant alleles from both parents (i.e. they 
carry two different mutations and are compound heterozygous, or carry two identical 
mutations and are homozygous for this variant), whereas when a single allele is responsible 
for the manifestation of the abnormal phenotype it is classified as an autosomal dominant or 
X-linked recessive disease. 
High-density SNP microarray analysis is a recently developed technique used for 
homozygosity mapping.74 This technique allows the detection of smaller regions of 
homozygosity as compared to microsatellite markers because of the higher density of the 
SNPs compared to the microsatellite markers. 
1.4.3. Exome sequencing 
Exome sequencing employing next generation sequencing (NGS) platforms is the most recent 
technique used to identify novel disease associated genes. This technique is now becoming 
popular and is widely used in diagnostics as well as in research because of its robustness, high 
throughput, cost effectiveness and high turnover rate.75,76 Exome sequencing can be employed 
to identify the genetic cause of rare as well as commonly inherited genetic disorders. In this 
technique exonic sequences of all genes are first enriched and then sequenced. Presently, there 
are a number of different NGS platforms, which are being used for enrichment and 
sequencing purposes.77,78 A brief description of exome sequencing using the SOLiDTM 
(sequencing by oligonucleotide ligation and detection) platform in combination with Agilent 
enrichment kits is given here. Enrichment is carried out by shearing the DNA sample to 
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produce smaller fragments of 150-200 bps. Ends of these fragments are repaired to produce 
blunt ends with 5’ phosphorylation, adenine overhangs are then added to the blunt-ended 
DNA fragments with the help of the Klenow fragment of DNA polymerase. Indexing-specific 
adaptors are ligated to these fragments, which are then PCR amplified followed by 
hybridization to the enrichment probe library, which contains biotinylated ribonucleic acid 
(RNA) probes. Hybridized fragments are selected by streptavidin coated magnetic beads, 
RNA probes are then digested and enriched DNA is eluted to be used in further downstream 
process. For DNA sequencing in a SOLiDTM sequencer from Life Technologies, a ligation 
mediated di-base detection system along with a set of five universal sequencing primers is 
used.77,79 The sequence read length generated by the SOLiDTM sequencer was initially 35 bp, 
which has now been improved to 50 bps. In the first step universal sequencing primers are 
annealed that bind to adapter sequences, followed by annealing and ligation of the 8-mer 
probe, which contains two colour-encoded bases at the 3’ end and a fluorescent label at the 3’ 
end. Fluorescence detection follows cleavage and removal of three bases at the 3’ end of the 
8-mer probe along with the fluorescent label. This cycle is repeated ten times followed by 
denaturation and removal of the first synthesized oligonucleotides. Each universal primer is 
then offset by a base followed by probe annealing, ligation, fluorescence detection and 
cleavage of fluorescent label to detect the remaining bases. The DNA template sequence is 
retrieved by decoding the sequence of detected colours. Sequencing reads are then aligned 
against a reference assembly to find the variants. The exome sequencing data are filtered to 
narrow down the number of variants to ease the identification of the causative mutation. 
This technique can be highly advantageous in novel gene discovery, when used in 
combination with homozygosity mapping data, by selecting exome sequencing present in the 
identified linkage regions or, in case of recessively inherited disorders, in the homozygous 
regions. In addition, this technique is also suited for the identification of compound 
heterozygous mutations. 
1.5. Treatment and prevention of inherited eye diseases 
With the advent of modern techniques in molecular biology, our knowledge base has 
increased enormously in the field of disease genetics. A large number of studies are now 
being conducted to correct the non-functional or aberrant copy of the causative genes using 
different techniques. Currently patients are benefitting from successful gene therapy 
experiments in the western world. In addition to these genetic corrections, some of the genetic 
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diseases like FA can be treated with oral supplementation. Another option for the patients 
with end stage disease is retinal transplantation. Electronic devices are also being developed 
for the treatment of inherited retinal disorders. However, genetic counseling is the foremost 
option available to the patients and affected families for disease prevention in the next 
generations. 
1.5.1. Gene therapy 
Being an easily accessible and highly compartmentalized organ,80 the eye is most suitable for 
gene-augmentation therapy for the treatment of inherited ocular disorders like Leber 
congenital amaurosis (LCA), RP, cone dystrophy (CD), cone-rod dystrophy (CRD), Usher 
syndrome, and BBS. Gene therapy involves delivery of a functional copy of the defective 
gene into the target tissue through an appropriate vector. To date, adeno-associated viruses 
(AAVs) are the most commonly used vector for retinal gene delivery80 because AAV not only 
has the ability to transduce RPE as well as rod and cone photoreceptors,81,82 but also remains 
extranuclear (episomal) thereby posing no threat of insertion in critical human genes, such as 
tumor suppressor genes. 
After successful trials of AAV-mediated gene therapy of the RPE65 gene in Rpe65-/-dogs83 
LCA patients were selected for phase 1 clinical trials.84-86 This therapy was found to be safe as 
no toxic effect or immune responses were noted, and the treated persons showed moderate 
visual improvements. AAV-mediated RPE65 gene augmentation therapy has provided hope 
that similar future trials can be conducted for other disease causing genes.87 At the moment, 
gene augmentation trials are also underway for Stargardt disease (ABCA4), choroideremia 
(CHM), LCA and arRP (RPE65), Usher syndrome type 1B (USH1B; MYO7A) and retinal 
disease patients with mer tyrosine kinase (MERTK) mutations 
(http://clinicaltrials.gov/ct2/home). 
In addition to the above mentioned genes for which gene therapy trials are in progress in 
humans after success in animal models, several other genes are in line to be tested for gene 
therapy in animal models.30 
Another option to restore visual function is to orally administer 9-cis retinal, as this oral 
supplementation has shown improvement in visual function in Rpe65-/- mice88 and should be 
considered as a potential therapeutic option for patients. 
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1.5.2. Food supplementation 
According to Jacobson and Cideciyan2 slowing down the degeneration of photoreceptors by 
using different food supplements and other pharmacological agents is another useful strategy 
for the treatment of inherited eye disorders. Use of molecules that inhibit the apoptotic 
pathway significantly reduces the accumulation of toxic compounds in the retinal cells, as a 
result of which photoreceptor degeneration slows down. Vitamin A supplementation is also 
an option helpful in reducing photoreceptor damage.89 
1.5.3. Retina transplants and electronic devices 
In patients with advanced retinal degenerations in which the photoreceptors or RPE are 
completely lost, there is an option of retinal transplants from donors.2 In a recent study, 
patient-specific induced pluripotent stem cells were shown to differentiate into RPE-like 
tissue and when transferred to the subretinal space resulted in the restoration of visual 
function in mice.90 Therefore, subretinal injection of genetically engineered regenerated non-
retinal cells can also be potentially used to treat the patients.2 
Although gene therapy and food supplementation are good preventive measures to restore 
vision, when the photoreceptors are completely degenerated these techniques cannot make 
any significant improvement and electronic retinal implants remain the only option left for the 
patients.91 These implants are positioned subretinally or epiretinally and stimulate the inner 
retinal neuronal cells by converting light signals into electric impulses.91 Recently an 
electronic device with 16 electrodes was successfully implanted in patients with encouraging 
results and has prompted the development of devices with a higher number of electrodes to 
improve vision to a level to allow the patients to perform daily activities.92 In the future it is 
hoped that the electronic retinal implants will become a robust therapeutic alternative, 
especially for individuals with severe eye diseases. 
1.5.4. Genetic counseling 
In molecular genetic research, individuals and families with inherited disorders are enrolled to 
determine the molecular basis of the diseases by identifying the causative mutations in their 
genomes. After determination of the causative mutation the results can be conveyed to the 
respective families, who can then be advised to take acceptable measures to prevent further 
disease occurrence in the family. Additionally, when there is a possibility of therapeutic 
intervention, patients can be referred to a consultant for suitable medication and treatment. 
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This whole process of disseminating information and suggestions to the respective families is 
known as genetic counseling. 
Genetic counseling is very important in managing the disease in affected individuals and for 
preventing the further spread of the disease in the family. Genetic counseling is basically a 
communication process or psychotherapeutic intervention in individuals based on the results 
of genetic testing or screening outcomes.93 
Depending upon the inheritance pattern of the disease, carriers of genetic mutations should 
ideally select their spouses carefully so as to minimize the chance of bearing affected 
children. Recessively inherited retinal diseases mostly have severe consequences whereas 
dominantly inherited disorders are mostly milder in nature. Inherited diseases that result from 
mutations in genes that reside on the autosomes affect males and females equally, but genes 
on the X-chromosome behave in a different way. Males with an X-linked disorder have a 
more severe phenotype as compared to the females because of the presence of a single X-
chromosome in males.34 In addition, X-linked inheritance can have a dominant or recessive 
mode of inheritance. Affected males usually have healthy parents since their mothers remain 
asymptomatic carriers of the genetic defect.69 
The success of genetic counseling remains dependent on the correct diagnosis and appropriate 
genetic testing. Counseling can be very accurate for genes that have established genotype-
phenotype correlations but it becomes challenging when there is a greater genetic and 
phenotypic heterogeneity. Thus, the medical advisor or geneticist who deals with families and 
individuals regarding their genetic testing must be a trained genetic counselor. It must be kept 
in mind that genetic counseling of families with de novo mutations is a challenging task for 
genetic counselors because of the absence of a family history and healthy parents not carrying 
the disease causing mutations. 
In Pakistan, genetic counseling services are rare and because of consanguineous marriages the 
occurrence of genetic diseases cannot be properly managed, therefore, the number of affected 
individuals is increasing every day. In addition, there is no established prenatal diagnosis 
service for families with severely affected individuals. Establishment of functional genetic 
counseling services is urgently needed to manage genetic disorders in Pakistan, in order to 
convince and educate the affected families about the utility of the services. 
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1.6. Molecular genetics of eye diseases 
In the last couple of decades significant volume of scientific work has been conducted in the 
field of ophthalmogenetics. As a result of combined efforts of life scientists worldwide, 
scientific knowledge has grown rapidly and developments in the field of molecular biology 
have enabled molecular geneticists to identify the mutated genes, which are the underlying 
cause of different genetic disorders. To date more than 200 genes and loci have been 
identified to be associated with retinal eye diseases (https://sph.uth.tmc.edu/retnet/). 
1.6.1. Genetics of eye diseases in Pakistan 
In Pakistan, because of the custom of consanguineous marriages and lack of knowledge about 
inherited disorders, such diseases are becoming more frequent. A number of research groups 
are now working in Pakistan to explore the genetics of inherited eye disorders. The most 
common inherited eye disorder in Pakistan is RP;94-101 other less commonly found diseases 
include LCA,102-107 fundus albipunctatus,67,108 Oguchi disease109,110 and achromatopsia.111-113 
In addition to these non-syndromic forms of retinal diseases, some syndromic forms are also 
found including Usher syndrome,114-117 BBS118-123 and Senior-Loken syndrome.124  
An overview of the genes, that have thus far been found to be mutated in non-syndromic and 
syndromic retinal diseases in the Pakistani population, is given in Table 1. 
Table 1.1 Overview of genes associated with non-syndromic and syndromic forms of 
retinal diseases in Pakistan 
Gene Disease Function Reference 
ABCA4 arRP Visual cycle den Hollander, et al.,125 
Sun, et al.,126 Sun, et 
al.127 
AHI1 JBTS Unknown Louie, et al.128 
AIPL1 EORP Intracellular transport van der Spuy, et al.,129 
Ramamurthy, et al.,130 
Akey, et al.131 
ARL13B JBTS Ciliogenesis Larkins, et al.132 
BBS2 BBS Intracellular transport Nishimura, et al.133 
BBS3/ARL6 BBS Intracellular transport Pretorius, et al.,134 
Pasqualato, et al.135 
BBS4 BBS Intracellular transport Kim, et al.136 
BBS5 BBS Ciliogenesis Li, et al.137 
BBS8/TTC8 BBS Ciliogenesis Tadenev, et al.138 
BBS10 BBS BBSome assembly Seo, et al.139 
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BBS12 BBS BBSome assembly Seo, et al.139 
BEST1 adRP Ion exchange Burgess, et al.,140 
Marmorstein, et al.141 
CC2D2A JBTS Ciliogenesis Bachmann-Gagescu, et 
al.142 
CDH23 USH1 Organization of stereocilia Holme, et al.143 
CEP290 (NPHP6) JBTS Transport across CC Sayer, et al.144 
CERKL arRP Unknown Tuson, et al.145 
CLRN1 arRP Unknown Khan, et al.101 
CNGA1 arRP Phototransduction cascade Dhallan, et al.146 
CNGA3 arCRD (ACHM) Phototransduction cascade Kohl, et al.147 
CNGB1 arRP Phototransduction cascade Korschen, et al.148 
CNGB3 arCRD (ACHM) Phototransduction cascade Nishiguchi, et al.149 
CRB1 arLCA Photoreceptor morphogenesis Pellikka, et al.150 
EYS arRP Integrity of photoreceptors Collin, et al.,151 Abd 
El-Aziz, et al152 
GNAT1 arCSNB Phototransduction cascade Dryja, et al.153 
GRK1 arCSNB Phototransduction cascade Khani, et al.154 
 
IMPG2 arRP Interphotoreceptor matrix 
organization 
Bandah-Rozenfeld, et 
al.155 
IQCB1 (NPHP5) SLSN Ciliogenesis Otto, et al.156 
LCA5 arLCA Transport across CC den Hollander, et al.105 
MERTK arRP Rod outer segment 
phagocytosis  
Vollrath, et al.157 
NMNAT1 arLCA Biosynthesis of NAD Koenekoop, et al.158 
NPHP4 SLSN Unknown Mollet, et al.159 
PCDH15 USH1 Retinal and cochlear 
maintenance 
Ahmed, et al.,116 
Alagramam, et al.160 
PDE6A arRP Phototransduction cascade Huang, et al.161 
PDE6B arRP Phototransduction cascade McLaughlin, et al.162 
PROM1 arRP Gene regulation Yang, et al.163 
RDH12 arLCA/EORD Visual cycle Haeseleer, et al.164 
RDH5 arCSNB (FA) Visual cycle Yamamoto, et al.45 
RHO adRP Phototransduction cascade Nathans, et al.165 
RLBP1 arCSNB (FA) Visual cycle Sparkes, et al.166 
RP1 arRP Rod outer segment 
morphogenesis 
Liu, et al.,167 Liu, et 
al.168 
RPE65 arLCA Visual cycle Xue, et al.,169 
Moiseyev, et al.170 
RPGR xlRP Intracellular transport  Linari, et al.171 
RPGRIP1 arCRD Transport across CC Castagnet, et al.172 
SAG arCSNB (Oguchi) Phototransduction cascade Yamaki, et al.173 
SEMA4A arRP/arCRD Cell to cell communication Rice, et al.174 
SLC24A1 arCSNB Ion exchange Riazuddin, et al.175 
SPATA7 arLCA/arRD Unknown Wang, et al.176 
TCTN2 JBTS Ciliogenesis  Sang, et al.177 
TMEM67 MKS Ciliogenesis Smith, et al.178 
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TTC8 arRP Ciliogenesis Riazuddin, et al.179 
TULP1 arRP Transport across CC Hagstrom, et al.180 
USH1G (SANS) USH1 Retinal and cochlear 
maintenance 
Weil, et al.181 
Legend: ACHM, achromatopsia; ad, autosomal dominant; ar, autosomal recessive; BBS, 
Bardet-Biedl syndrome; CSNB, congenital stationary night blindness; CRD, cone-rod 
dystrophy; EORD: early onset retinal dystrophy; EORP, early onset arRP; FA, fundus 
albipunctatus; JBTS, Joubert syndrome; LCA, Leber congenital amaurosis; MKS, Meckel 
syndrome; NAD, nicotinamide adenine dinucleotide; CC, connecting cilium; RD, retinal 
dystrophy; RP, retinitis pigmentosa; SLSN, Senior Loken syndrome; USH1, Usher 
syndrome type 1; xlRP, X-linked RP 
Populations with a higher rate of consanguineous marriages are at a greater risk of having 
genetic disorders, and therefore are considered as a useful source for studying the molecular 
basis of the diseases. According to an estimate more than 60% marriages in Pakistan are 
consanguineous, of which nearly 80% are estimated to be among first cousins.182,183 Because 
of this high rate of consanguinity, there are higher chances of inheriting a disease causing 
variant in the homozygous state by offspring of heterozygous carrier parents, which can lead 
to disease.183 As most of the families included in this thesis were consanguineous, 
homozygosity mapping was employed to identify the causative variants. 
1.7. Structure of this thesis 
The aim of the work presented in this thesis was to identify genetic causes of inherited eye 
diseases in the Pakistani population. This study mainly focuses on the genetics of RP, FA and 
BBS. Homozygosity mapping combined with Sanger sequencing was mainly used to identify 
the different disease causing mutations in the affected families. In addition, exome sequencing 
was employed to find the underlying genetic cause of the disease in two BBS families and one 
RP family. 
In the second chapter, two large consanguineous families with TULP1 mutations are 
discussed. In addition, an overview of all the TULP1 mutations identified so far has been 
given. The frequency of TULP1 mutations in Pakistani patients has also been calculated. 
The third chapter describes the genetics of FA in two Pakistani families. This is a rare genetic 
disease for which mutations have mostly been reported in RDH5. Although two other genes, 
RLBP1 and RPE65, are also known to be associated with FA, their occurrence is very rare.  
The possibility of FA treatment is also discussed. 
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The fourth chapter consists of a description of a novel splice site mutation and a recurrent 
missense mutation identified in the BBS1 gene that were identified through exome sequencing 
in two families segregating BBS. It also highlights the use of exome sequencing in identifying 
genetic mutations. 
In the fifth chapter, mutations in ABCA4, AIPL1, CERKL and PDE6A are described to be the 
underlying genetic causes of retinal dystrophy in four consanguineous families. A novel 
mutation was identified in PDE6A whereas previously identified mutations were present in 
ABCA4, AIPL1 and CERKL. 
In the sixth chapter, the genetics of syndromic and non-syndromic retinal dystrophies in 
Pakistan was reviewed along with reporting two novel mutations in CNGB1 and CNGA1. In 
addition, several novel loci for RP were identified. 
In the seventh chapter, a novel candidate gene for severe RP, DHX38, encoding a protein 
involved in RNA splicing (PRP16), was reported. 
In the eighth chapter, the general discussion, the broader impact of the current research was 
provided. The power of homozygosity mapping, genetic heterogeneity, phenotypic variability 
and the possibility of modifier alleles were discussed. In addition, genotype-phenotype 
correlations, possibility of therapeutic intervention; linking clinician and geneticist; benefits 
to the patients and families; and future research directions were addressed. 
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ABSTRACT 
Purpose: To identify the genetic defects underlying retinitis pigmentosa (RP) in Pakistani 
families. 
Methods: Genome-wide high-density single-nucleotide-polymorphism microarray analysis 
was performed using the DNA of nine affected individuals from two large families with 
multiple consanguineous marriages. Data were analyzed to identify homozygous regions that 
are shared by affected sibs in each family. Sanger sequencing was performed for genes 
previously implicated in autosomal recessive RP and allied retinal dystrophies that resided in 
the identified homozygous regions. Probands from both families underwent fundus 
examination and electroretinogram measurements. 
Results: The tubby-like protein 1 gene (TULP1) was present in the largest homozygous 
region in both families. Sequence analysis identified a previously reported mutation 
(c.1138A>G; p.(Thr380Ala)) in one family and a novel pathogenic variant (c.1445G>A; 
p.(Arg482Gln)) in the other family. Both variants were found to be present in a homozygous 
state in all affected individuals, were heterozygous present in the unaffected parents, and 
heterozygous present or absent in normal individuals. Affected individuals of both families 
showed an early-onset form of RP. 
Conclusions: Homozygosity mapping, combined with candidate-gene analysis, successfully 
identified genetic defects in TULP1 in two large Pakistani families with early-onset retinitis 
pigmentosa. 
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2.1. Introduction 
The major cause of inherited blindness in humans is retinitis pigmentosa (RP; OMIM 
268000). The clinical symptoms of RP are the loss of night vision in the early phase of 
disease, later followed by peripheral vision loss, tunnel vision, and sometimes complete 
blindness.1 Progression of the disease is mainly caused by the gradual loss of rod 
photoreceptor cells, which are mostly responsible for vision under low light conditions, and 
the subsequent loss of cone photoreceptor cells, which are involved in color vision under 
bright light conditions. The clinical diagnosis is based on fundus examination and 
electrophysiological analysis of rod and cone photoreceptor-cell function by measuring the 
scotopic and photopic responses, respectively, using electroretinography (ERG). The 
disease’s characteristics are the presence of pigmentary deposits (bone spicules) in the 
peripheral fundus, diminished or no ERG responses from rod and cone photoreceptor cells, 
and attenuation of the retinal blood vessels.1 
The disease is highly genetically heterogeneous, since 55 different genes and three loci have 
been identified as being associated with nonsyndromic RP (RetNet, Nov. 8, 2011). All 
Mendelian forms of inheritance have been observed for RP. Digenic forms and rare 
mitochondrial inheritance have also been reported.1-4 
Tubby-like protein 1 (TULP1; OMIM 602280) belongs to the tubby-like protein family. The 
TULP1 gene is located on the short arm of chromosome 6.5 TULP1 is expressed specifically 
in the retina,5,6 and the encoded protein is thought to be involved in protein trafficking, such 
as the transport of rhodopsin from the inner segment to the outer segment via the connecting 
cilium.7 
The aim of the current study was to identify the underlying genetic causes of autosomal 
recessive RP (arRP) in Pakistani families by using genome-wide homozygosity mapping and 
Sanger sequencing of known retinal disease genes in the homozygous regions. We identified 
disease-causing mutations in TULP1 in two large families. 
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2.2. Methods 
2.2.1. Ethics committee/institutional review board approval 
Before initiating this study, approval for this work was granted by the Ethics 
Committee/Institutional Review Board of the Shifa College of Medicine/Shifa International 
Hospital, Islamabad, Pakistan, and signed informed consent was obtained from all 
participating individuals in both families. 
2.2.2. Ascertainment of families and clinical analysis 
Two families from the Punjab province with individuals having night vision and daytime 
vision loss were included in the study. Their pedigrees were drawn (Figure 2.1A,B) using 
HaploPainter,8 and venous blood samples were collected in acid citrate dextrose-containing 
vacutainers (Becton Dickinson, Franklin Lakes, NJ). Fundus examinations were done, and 
ERG9 measurements were made for probands in both families. 
2.2.3. Genotype analysis and homozygosity mapping 
DNA was extracted by using a standard phenol chloroform extraction protocol10 and stored at 
4 °C. HumanOmniExpress (>700K) single nucleotide polymorphism (SNP) microarrays from 
Illumina Inc. (San Diego, CA) were employed to search for homozygous regions in six 
affected individuals (Figure 2.1A) in family A and three affected individuals (Figure 2.1B) in 
family B. Genotype data were analyzed with Homozygosity Mapper,11 an online tool for 
homozygosity mapping using SNP genotyping data. Haplotype comparisons were also done 
for affected and normal individuals to identify the homozygous regions that were identical in 
all the affected individuals in each family. 
2.2.4. Sequence analysis and mutation detection 
Prior to Sanger sequencing, the 15 protein-coding exons of TULP1 (NM_003322.3) and their 
flanking intronic sequences were amplified by PCR using standard conditions and reagents. 
PCR primers were designed with the online primer-designing tool Primer312 (available on 
request). Amplified PCR products were electrophoresed in 2% agarose gels containing 
ethidium bromide, and DNA bands were visualized on an ultraviolet transilluminator. PCR 
products  were  purified on PCR clean-up purification plates (NucleoFast™ 96 PCR, Cat. No. 
743100.10; MACHEREY-NAGEL, Düren, Germany), according to the manufacturer’s
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Figure 2.1 Pedigrees and TULP1 genotyping results for families A and B. A: This is the 
pedigree of family A in which the presence of the c.1138A>G variant (M) was found in a 
homozygous state in all affected individuals. As expected for causal autosomal recessive 
variants, unaffected parents are heterozygous, and normal individuals carry one or no mutant 
allele. B: This is the pedigree of family B in which the presence of the c.1445G>A variant 
(M) was shown in a homozygous state in the 6 affected individuals, and in heterozygous state 
in an unaffected sibling, parents and grandparents of affected persons. C: This is the sequence 
electropherogram showing the nucleotide change from adenine to guanine in the proband of 
family A (upper panel), and sequence electropherogram of a control individual showing the 
wild-type adenine (lower panel). D: This is the sequence electropherogram of the proband 
carrying the mutant adenine in family B (upper panel); and the sequence electropherogram of 
a control individual with the normal guanine (lower panel). Probands are indicated with 
arrows; asterisks indicate the individuals that were tested using HumanOmniExpress (>700K) 
SNP microarrays. M/M, homozygous c.1138A>G (in family A) or homozygous c.1445G>A 
(in family B); +/M, heterozygous mutations present; +/+, two wild-type alleles present.
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protocol. Purified PCR products were subsequently used for Sanger sequencing in an 
automated DNA sequencer (BigDye Terminator, version 3, on a 3730 DNA analyzer; Applied 
Biosystems, Foster City, CA). 
Sequencing results were analyzed by using Vector NTI Advance™ 2011 software from Life 
Technologies/Invitrogen (Bleiswijk, Netherlands), by assembling the sequenced contigs and 
then visualizing the aligned sequences of the exons. 
2.2.5. Pathogenicity assessment of identified variants 
Identified missense variants were assessed for possible causality by using Sorting Intolerant 
from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.html) analysis and 
Polymorphism Phenotyping v-2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2/). 
2.2.6. Restriction fragment length polymorphism analysis 
Restriction fragment length polymorphism analysis was performed to detect the presence or 
absence, of the identified mutations, in 100 ethnically matched control individuals. For the 
mutation identified in family A, restriction enzyme HpyCH4III was used, whereas in family 
B, restriction enzyme MspI was used. In both families, restriction enzyme recognition sites 
were abolished in the mutant sequences. Purified PCR products were used for restriction 
enzyme digestion, according to the manufacturer’s protocol (New England BioLabs, Ipswich, 
MA). 
2.2.7. Evolutionary conservation of amino acids 
To check the evolutionary conservation of the mutated amino acids, the TULP1 orthologous 
protein sequences of the following species were aligned with the Vector NTI Advance™ 2011 
software: humans (Homo sapiens, ENSP00000229771); chimpanzees (Pan troglodytes, 
ENSPTRP00000007764); mice (Mus musculus, ENSMUSP00000049070); dogs (Canis 
familiaris, ENSCAFP00000001922); chickens (Gallus gallus, ENSGALP00000009613); 
frogs (Xenopus tropicalis, ENSXETP00000000899); tetraodons (Tetraodon nigroviridis, 
ENSTNIP00000004001); fruitflies (Drosophila melanogaster, FBpp0088961); honeybees 
(Apis mellifera, GB19892-PA); roundworms (Caenorhabditis elegans, F10B5.4), blood flukes 
(Schistosoma mansoni, Smp_058730__mRNA); and Arabidopsis (Arabidopsis thaliana, 
AT1G76900.1). 
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2.2.8. Three-dimensional structure prediction 
Project HOPE13 (http://www.cmbi.ru.nl/hope/home) was used to predict the possible 
structural changes in the mutant TULP1 proteins identified in our study using a normal human 
TULP1 structure (PDB-file 3C5N). 
2.3. Results 
In both families, the average age of disease onset was in the first decade of life. Ophthalmic 
examination of affected individuals from both families revealed the presence of attenuated 
retinal vessels and the optic disc to have a waxy, pale appearance (Figure 2.2). A yellow 
perifoveal annular ring, a characteristic feature of individuals carrying TULP1 mutations, was 
also clearly visible in family A (Figure 2.2A,B). 
In family B, the perifoveal ring was in the process of development (Figure 2.2C,D). Upon 
ERG, scotopic and photopic electrophysiological responses of rod and cone photoreceptors, 
respectively, were diminished in affected members of both families (Table 2.1). Neither 
nystagmus nor eye poking were present in either family. 
Genome-wide SNP microarray data of six affected individuals of family A were analyzed 
with the help of Homozygosity Mapper, which revealed a single homozygous region (Figure 
2.3A) of 3.9 Mb (from 32.9 Mb to 36.8 Mb; hg19) on chromosome 6, flanked by SNPs 
rs3132131 and rs236411. This homozygous region harbored TULP1, a gene known to be 
mutated in patients with Leber congenital amaurosis (LCA) and arRP. The sequence analysis 
identified a previously reported mutation, c.1138A>G (p.Thr380Ala)14,15 in this family 
(Figure 2.1C). 
Similarly, genome-wide SNP microarray data analysis of three affected individuals of family 
B, resulted in the identification of six homozygous regions (Figure 2.3B). After haplotype 
comparison, two regions, a 4.8 Mb region on chromosome 6 (from 33.8 Mb to 38.6 Mb, 
flanked by  SNPs  rs9296102  and  rs7761629) and a 1.4 Mb region on chromosome 7 (from 
132.3 Mb to 133.7 Mb, flanked by SNPs rs924368 and rs10249912), were found to be 
identical in all the affected individuals. TULP1 resides in the homozygous region on 
chromosome 6, and the sequence analysis revealed a novel mutation, c.1445G>A 
(p.(Arg482Gln); Figure 2.1D). The homozygous chromosomal region on chromosome 7 did 
not contain a gene previously implicated in an inherited retinal disease such as arRP or LCA. 
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Figure 2.2 Fundus photographs of affected individuals from both families and of a 
normal individual. A, B: Right and left fundus, respectively, of the proband of family A (see 
arrow, Figure 2.1A), representative of the fundus appearance of all affected members of this 
family. Arrows indicate yellow perifoveal annular rings. C, D: Right and left fundus, 
respectively, of the proband of family B (see arrow, Figure 2.1B). Arrowheads point to the 
developing perifoveal annular rings. E, F: Right and left fundus, respectively, of a normal 
individual. 
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Table 2.1 Comparison of ERG responses of affected individuals of families A and B with a control individual. 
Measured parameters using monopolar 
electrodes 
Adaptation Flash strength 
(cds/m2) 
Proband 
Family A 
Proband 
Family B 
Control Normal values 
(Age=20 years) 
Scotopic 25 dB b-wave amplitude (µV) Dark 0.01 13.30 21.80 244.40 >185 
Scotopic 0 dB b-wave amplitude (µV) Dark 3.0 22.70 22.20 650.00 >419 
Oscillatory potential amplitude (µV) Dark 3.0 56.40 47.90 187.70 >110 
Photopic 0 dB b-wave amplitude (µV) Light 3.0 12.00 15.70 86.90 >102 
Photopic 30 Hz flicker amplitude (µV) Light 3.0 6.10 1.46 65.60 >70 
Age of affected individuals from families A and B at the time of investigation was 20 years. 
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Figure 2.3 Homozygosity mapping results for families A and B. Homozygosity-mapper plots show the homozygous regions in the affected 
individuals in both families (red lines). Homozygous regions that show identical haplotypes for all affected individuals within a family are 
indicated by arrows. Panel A represents family A and panel B represents family B. 
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In families A and B, the variants c.1138A>G and c.1445G>A, respectively, were found to be 
present in a homozygous state in all affected individual, were heterozygous present in the 
unaffected parents, and absent or heterozygous present in normal individuals (Figure 2.1A,B). 
Both wild-type nucleotides were shown to be highly conserved, as evidenced by their 
phylogenetic P-value16 scores of 2.87 (c.1138A) and 6.10 (c.1445G) for family A and B, 
respectively. In addition, the encoded amino acids, p.Thr380 and p.Arg482, located in the C-
terminal tubby domain, are highly conserved among different vertebrate and invertebrate 
species, while in a plant (Arabidopsis), isoleucine is present instead of threonine (Figure 2.4). 
These amino acids are completely conserved among the tubby, TULP1, TULP2, and TULP3 
proteins.17 SIFT predicts that both TULP1 variants are “not tolerated” whereas PolyPhen-2 
predicts that both are “probably damaging” with prediction scores of 0.827 and 1.000 for 
p.(Thr380Ala) and p.(Arg482Gln), respectively. 
A three-dimensional-structure prediction analysis by project HOPE predicts that the 
p.(Thr380Ala) mutation, due to the smaller size of the alanine residue, causes an empty space 
in the protein and possible rearrangements of surrounding residues (Figure 2.5A,B). Any 
hydrogen bonds made by threonine will also be lost, because alanine is a hydrophobic residue. 
Very close to Thr380 is a predicted inositol triphosphate binding site that might also be 
influenced by local conformational changes. The p.(Arg482Gln) variant changes a positively 
charged amino acid (arginine) to a neutral residue (glutamine), which results in the loss of 
interactions with negatively charged residues in its vicinity (Figure 2.5C). In view of its 
location in the three-dimensional structure, these changes may result in a loss of external 
interactions. The p.(Thr380Ala) and p.(Arg482Gln) variants were not detected in 100 healthy 
ethnically matched control individuals. 
2.4. Discussion 
In the current study, we report on two large families with several consanguineous marriages 
and multiple individuals with early-onset RP that were found to carry TULP1 mutations. 
Family A had 27 affected individuals who resided in the northern part of the Punjab province. 
This family had a strong custom of marrying inside the family. TULP1 mutations were 
previously reported to cause LCA, a congenital form of severe vision impairment or 
blindness, and early-onset RP.14,15,18-31 There is clinical and genetic overlap between (early-
onset) arRP and LCA,32,33 and often it is very difficult to differentiate between these two 
conditions. Mutations in Crumbs homolog 1 (CRB1), Lecithin retinol 
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Figure 2.4 Conservation of mutated amino acids among different species. Amino acids 
identical to human tubby-like protein 1 (TULP1) amino acids are shaded in gray. The 
positions of the amino acids in the respective polypeptides are indicated. 
acyltransferase (LRAT), Mer tyrosine kinase protooncogene (MERTK), Retinal pigment 
epithelium-specific protein, 65-KD (RPE65), Spermatogenesis-associated protein 7 
(SPATA7), and TULP1 have been identified in individuals with LCA and arRP.18-21,34-47 If a 
severe form of rod–cone dystrophy is observed beyond early childhood, and when there are 
no features reminiscent of LCA, such as nystagmus, or eye poking, the phenotype is classified 
as early-onset RP. 
TULP family proteins (TUB, TULP1, TULP2, and TULP3) have crucial roles in embryonic 
development in vertebrates and take part in the proper functioning of the central nervous 
system.6,48 TULP1 is expressed specifically in the rod and cone photoreceptor cells,5,6 and is 
involved in the transport of rhodopsin.7 In Tulp1−/− mice, photoreceptor degeneration precedes 
synaptic malfunction, and thus TULP1 may have a function in photoreceptor synapse 
development.49 A mutation of the same residue (p.(Arg482Trp)) was earlier found in 
combination with p.(Leu504fs*141) in five affected individuals with severe early-onset RP.50 
The structural analyses of the TULP1 C-terminal domains of the mutant proteins suggest that 
the missense mutations identified in our study might have resulted in the destabilization of the 
mutant proteins, or might have influenced the putative interactions of the tubby domain. 
Among different species of animals and plants, p.Arg482 is located in the signature sequence 
(F-[KRHQ]-G-R-V-[ST]-x-A-S-V-K-N-F-Q) of the Tubby family of proteins, and this
p.(Thr380Arg)                             p.(Arg482Gln) 
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Figure 2.5 Three-dimensional domain architecture of the tubby domain of TULP1 wild-
type and mutant proteins. A: Preferred predicted secondary structure of normal tubby-like 
protein 1 (TULP1) with Thr380 and Arg482 indicated in green. In yellow, the inositol 
triphosphate molecules that are predicted to bind the tubby domain of TULP1. B: Predicted 
structure of part of the p.(Thr380Ala) mutant protein in affected individuals of family A. The 
smaller size of the alanine residue may lead to rearrangements of surrounding residues and 
thereby affect putative inositol triphosphate binding. C: Part of the predicted structure of the 
p.(Arg482Gln) mutant protein found in affected individuals of family B. The p.(Arg482Gln) 
variant changes a positively charged amino acid (arginine) to a neutral residue (glutamine), 
which leads to loss of interactions with two negatively charged residues in its vicinity. Wild-
type interactions are indicated with yellow blocks. 
signature sequence contains 11 invariant amino acids that are highly conserved (Prosite).5 
Replacement of the wild-type residue with the mutant glutamine might affect the signature 
sequence; this might ultimately prevent the mutant TULP1 protein from functioning normally. 
In family A, the presence of a typical yellow-colored perifoveal annular ring was also 
indicative of TULP1 involvement;24 whereas in family B, the ring formation was incomplete 
(Figure 2.2C,D). The bone spicules absent from both families might still develop later in life. 
The age of both individuals who were clinically evaluated was 20 years.  
The previously identified mutation p.(Thr380Ala) has only been reported in two unrelated 
Pakistani families.14,15 Our findings concerning this mutation in yet another Pakistani family 
suggested that c.1138A>G might be a Pakistani founder mutation, although no link was 
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established between any of these families. One family belonged to a northern area of 
Pakistan14 while the other belonged to the southern part of Punjab.15 Our family belonged to 
the northern part of Punjab, which, however, does not exclude the possibility that this 
mutation represents a founder mutation in Pakistan. 
Including our findings, 26 different TULP1 mutations have been identified in 33 families 
(Table 2.2). TULP1 mutations were found in 4.3% (10/231) of LCA families14,18,24,25,27,29,30 
and 2.4% (23/948) of arRP families.15,19-24,26,28,30,31,50 TULP1 mutations causing arRP or LCA 
include two nonsense, two frame-shift, and seven splice-site mutations; a six-base-pair 
duplication; and 14 missense mutations (Table 2.2). Splice-site and protein-truncating 
mutations are distributed throughout the gene (Figure 2.6A), whereas the missense mutations 
are only present in the C-terminal tubby domain of TULP1 (Figure 2.6B). 
TULP1 mutations are a frequent cause of LCA and arRP, and therefore represent an attractive 
therapeutic target. Thus far, TULP1 mutations have been found in a total of 136 individuals 
with LCA or arRP (Table 2.2). Through our studies, 33 additional patients with TULP1 
mutations might benefit from genetic counseling and future gene-augmentation therapy. 
In conclusion, we were able to identify one novel (c.1445G>A; p.(Arg482Gln)) and one 
previously identified (c.1138A>G; p.(Thr380Ala)) disease-causing mutation in TULP1 in 
Pakistani families with early-onset RP.  
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Table 2.2 TULP1 mutations causing arRP or LCA. 
Exon/intron Mutations: Allele 1/Allele 2 Phenotype No. of families No. of cases Reference 
Intron 2, Exon 12 c.99+1G>A; p.(?)/                               
c.1204G>T; p.(Glu402*) 
LCA 1/179 1/179 Hanein, et al.18 
Intron 4, Exon 5, 
10 
c.350-2_350del; p.(?)/                            
c.901del; p.(Gln301Argfs*9) 
arRP 1/49 2/49 Paloma, et al.22** 
Intron2, Exon 14 c.99+1G>A; p.(?)/                              
c.1376T>A; p.(Ile459Lys) 
arRP 1/536 1/536 Hagstrom, et al.20 
Intron 7 c.718+2T>C; p.(?)/                           
c.718+2T>C; p.(?) 
juvenile RP 2/86 2/86 den Hollander, et al.24 
Exon 10 c.901C>T; p.(Gln301*)/                      
c.901C>T; p.(Gln301*) 
LCA 5/37 42/117 Li, et al.29 
Exons 10, 11 c.932G>A; p.(Arg311Gln)/               
c.1025G>A; p.(Arg342Gln) 
arRP 1/2 2/4 Hebrard, et al.31 
Intron 10 c.999+5G>C; p.(?)/c.999+5G>C; p.(?) juvenile RP 1/86 1/86 den Hollander, et al.24 
Exon 11 c.1102G>T; p.(Gly368Trp)/              
c.1102G>T; p.(Gly368Trp) 
LCA 1/179 1/179 Hanein, et al.18 
Exon 12 c.1138A>G; p.(Thr380Ala)/            
c.1138A>G; p.(Thr380Ala) 
LCA, early onset arRP 1/14, 1/5, 1/2 3/64, 4/23, 27/33 Mckibbin, et al.,14 Iqbal, et 
al,15 and this study 
Exon 12 c.1145T>C; p.(Phe382Ser)/               
c.1145T>C; p.(Phe382Ser) 
arRP 1/59 2/59 Kondo, et al.23 
Exon 12 c.1199G>A; p.(Arg400Gln)/             
c.1199G>A; p.(Arg400Gln) 
arRP 1/34 2/34 Singh, et al.28 
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Exon 12 c.1198C>T; p.(Arg400Trp)/               
c.1198C>T; p.(Arg400Trp) 
LCA 1/179 1/179 Hanein, et al.18 
Exons 13, 14 c.1259G>C; p.(Arg420Pro)/               
c.1471T>C; p.(Phe491Leu) 
arRP 1/536 2/536 Hagstrom, et al.20 
Exon 14 c.1381C>G; p.(Leu461Val)/              
c.1381C>G; p.(Leu461Val) 
juvenile RP 1/86 1/86 den Hollander, et al.24 
Exon 14 c.1445G>A; p.(Arg482Gln)/           
c.1445G>A; p.(Arg482Gln) 
early onset arRP 1/2 6/33 This study 
Exon 14 c.1466A>G; p.(Lys489Arg)/             
c.1466A>G; p.(Lys489Arg) 
early onset arRP, arRP 4/5, 1/171 19/23, 1/171 Iqbal, et al.,15 Gu, et 
al.19*** 
Intron 14 c.1495+1G>A; p.(?)/                     
c.1495+1G>A; p.(?) 
arRP 2/2 33/33 Banerjee, et al.21 
Intron 14 c.1495+2dup; p.(?)/c.1495+2dup; p.(?) early onset arRP 1/1 3/3 Abbasi, et al.26 
Intron 14 c.1496-6C>A; p.(?)/c.1496-6C>A; p.(?) arRP 1/171 1/171 Gu, et al.19 
Exons 14, 15 c.1444C>T; p.(Arp482Trp)/ c.1511_1521del; 
p.(Leu504Profs*141) 
early onset arRP 1/1 5/5 den Hollander, et al.50 
Exon 15 c.1582_1587dup; p.(Phe528_Ala529dup)/ 
c.1582_1587dup; p.(Phe528_Ala529dup) 
LCA 1/1 7/7 Mataftsi, et al.25**** 
**Variant labelled as c.937delC. ***Same change at protein level but labelled as c.1502G>A at the cDNA level. ****Change labelled as 
c.1593_1594TTCGCC (FA531-532dup). The variants identified in this study are marked in bold. Patients with visual loss, nystagmus and 
night blindness after the age of six months but not later than six years are diagnosed as juvenile RP.24 
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Figure 2.6 TULP1 gene, protein structure, and pathologic variants identified in patients with LCA and arRP. A: Gene organization and 
distribution of splice site variants (above the gene) and nonsense and frame-shift variants (below the gene). B: Protein domain structure of tubby-
like protein 1 (TULP1) showing missense changes and a two-amino acid duplication in the tubby, C-terminal domain. The novel missense 
variant is indicated in bold. 
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ABSTRACT 
Purpose: To identify the underlying genetic causes of fundus albipunctatus (FA), a rare form 
of congenital stationary night blindness that is characterized by the presence of white dots in 
the midperiphery of the retina and delayed dark adaptation, in Pakistan. 
Methods: Two families with FA were identified by fundus examination, and genome-wide 
single nucleotide polymorphism genotyping was performed for two individuals from family A 
and six individuals from family B. Genotyping data were subsequently used to identify the 
identical homozygous regions present in the affected individuals of both families using the 
online homozygosity mapping tool Homozygosity Mapper. Candidate genes selected from the 
homozygous regions were sequenced. 
Results: Three identical homozygous regions were identified in affected persons of family A 
(on chromosomes 8, 10, and 12), whereas a single shared homozygous region on chromosome 
12 was found in family B. In both families, the homozygous region on chromosome 12 
harbored the retinol dehydrogenase 5 (RDH5) gene, in which mutations are known to be 
causative of FA. RDH5 sequence analysis revealed a novel five base pair deletion, 
c.913_917delGTGCT; p.(Val305Hisfs*29), in family A, and a novel missense mutation, 
c.758T>G; p.(Met253Arg), in family B. 
Conclusions: We identified two novel disease-causing RDH5 mutations in Pakistani families 
with FA, which will improve diagnosis and genetic counseling, and may even lead to 
treatment of this disease in these families. 
 
 
 
 
 
 
 
Chapter 3                                                                                                                                                                   c 
66 
3.1. Introduction 
Fundus albipunctatus (FA; OMIM:136880), or flecked retina disease, was described for the 
first time by Lauber.1 FA is a rare form of congenital stationary night blindness and is 
characterized by the presence of typical white dots on the whole fundus or concentrated in the 
midperipheral region of the retina, with or without macular involvement, and a delay in dark 
adaptation. The inheritance pattern of FA is autosomal recessive.2-5 In one family, a male and 
his two daughters showed FA, which could be due to autosomal dominant or pseudo 
dominant (i.e., autosomal recessive) inheritance.6 Mutations in three genes–retinol 
dehydrogenase 5 (RDH5), retinaldehyde-binding protein 1 (RLBP1), and retinal pigment 
epithelium–specific protein (RPE65) - are known to be associated with FA.7-10 Retinitis 
punctata albescens has similar phenotypic characteristics but is progressive in nature and is 
mostly caused by mutations in RLBP1.8 
FA-causing mutations were first identified in RDH5, which is expressed predominantly in the 
retinal pigment epithelium (RPE).7 RDH5 encodes an enzyme that is part of the visual cycle, 
which involves a series of specialized enzymes and retinoid binding proteins that are essential 
for the regeneration of the 11-cis retinal chromophore.11-14 RDH5 consists of 318 amino acids 
and is highly conserved among different species.15 Within the RPE cells, RDH5 resides in the 
smooth endoplasmic reticulum16 where it is principally involved in chromophore regeneration 
by catalyzing the final step in the biosynthesis of 11-cis retinal.7,17-20 
The current study explores the molecular mechanisms behind FA in Pakistani families, using 
high-density single nucleotide polymorphism (SNP) microarrays and sequence analysis of 
known FA genes located in the identified homozygous regions. Using this approach, we 
identified two novel mutations in RDH5 in two families with FA. 
3.2. Methods 
3.2.1. Approval of the study 
Approval for this study was granted by the Ethics Committee/Institutional Review Board of 
Shifa College of Medicine/Shifa International Hospital, Islamabad. Signed informed consent 
was obtained from members of both families participating in the current study. 
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3.2.2. Family collection and clinical evaluation 
Families A and B (Figure 3.1) reside in remote areas of Pakistan and were part of a cohort of 
83 families with retinitis pigmentosa and associated retinal diseases. Blood samples were 
collected from affected and normal individuals of both families and DNA was extracted by a 
standard protocol.21 Pedigrees were drawn using HaploPainter.22 Both families were clinically 
evaluated by fundus examination; in addition, electroretinography (ERG) measurements were 
recorded for family A. 
3.2.3. Homozygosity mapping analysis 
All affected individuals from both families and one healthy person from family B were 
subjected to high-density HumanOmniExpress (>700 K; Illumina Inc., San Diego, CA) SNP 
microarray analysis. Genotyping data were analyzed with the online tool Homozygosity 
Mapper.23 Haplotypes of affected and normal individuals were compared in each family to 
identify the identical homozygous regions shared by all affected individuals. 
3.2.4. Primer design and RDH5 sequence analysis 
The online tool Primer324 was used to design PCR primers (Table 3.1). The five exons of 
RDH5, including their flanking exon-intron boundaries, were amplified by PCR using 
standard conditions and reagents. PCR-amplified exonic fragments were electrophoretically 
separated on 2% agarose gels containing ethidium bromide and DNA bands were visualized 
under ultraviolet transillumination. PCR clean-up purification plates (NucleoFast® 96 PCR; 
Cat. No. 743100.10, Macherey-Nagel, Düren, Germany) were used to purify the amplified 
fragments according to the manufacturer’s protocol. Briefly, 20 µl of each amplified PCR 
product was transferred to Nucleofast 96 PCR plate. Wells were filled up to 100 µl volume 
with RNase-free water to ensure the uniform loading. Contaminants were removed by 
ultrafilteration with the help of a vacuum apparatus for 10 min. Thirty µl of RNase-free water 
was poured in each well and DNA was recovered by thorough mixing with a multi-channel 
pipette. Sanger sequencing was then performed with Big Dye Terminator version 3 and 
analyzed on a 3730 DNA analyzer (Applied Biosystems, Inc., Foster City, CA). 
Vector NTI Advance (TM) 2011 software from Invitrogen Corporation (Carlsbad, CA) was 
used to analyze the sequencing results of RDH5 (NM_001199771.1) exons. 
 
Chapter 3                                                                                                                                                                   c 
68 
 
Figure 3.1 Pedigrees and sequencing results. A: Segregation of the mutation in family A. 
B: Segregation of the mutation in family B. C and D: Sequence electropherograms of affected 
individuals carrying homozygous variants (upper panels) and unaffected heterozygous carriers 
(middle panels) of families A (C) and B (D), along with the results of a control individual 
(wild-type [wt], lower panels). Arrows point to the probands; individuals tested with single 
nucleotide polymorphism (SNP) microarrays are indicated with asterisks. 
3.2.5. In silico analysis 
Sorting Intolerant from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.html), 
Polymorphism Phenotyping v2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2/), and 
Mutation Taster25 were used to assess the possible pathological nature of the missense variant 
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identified in this study. Project HOPE26 (http://www.cmbi.ru.nl/hope/home) was used to 
analyze and predict the structural variations in mutant RDH5. 
Table 3.1 Primer sequences of RDH5 exons. 
Exon Forward primer (5’→3’) Reverse primer (5’→3’) length (bp) 
1 CTAGGCAAATCTGGCCTCTG GGTCCACCTCAGAGTTGTGG 396 
2 GGAAAGGGCTTGAGGGC GACTGTGGGGATCAGGACAC 450 
3 CTCCCAGGAAGAAGAGGGAG CACCTCTGCTGGCCCAC 399 
4 ATGTCCCTCAAAGTCCCCTC AGGCTTATGCAGGACTGGC 301 
5 GGCCCCAGAAGACAGTACC CGTGCAGCTGTAGATGTGAG 589 
 
3.2.6. Amino acid conservation 
RDH5 protein sequences from different species including human (Homo sapiens, 
ENSP00000257895), macaque (Macaca mulatta, ENSMMUP00000017380), mouse (Mus 
musculus, ENSMUSP00000026406), dog (Canis familiaris, ENSCAFP00000000084), cow 
(Bas taurus, ENSBTAP00000056512), cat (Felis catus, ENSFCAP00000012945), tetraodon 
(Tetraodon nigroviridis, ENSTNIP00000022889), and round worm (Caenorhabditis elegans, 
F35B12.2) were aligned using Vector NTI Advance™ 2011 to check the evolutionary 
conservation of the substituted amino acid in RDH5. 
3.3. Results 
3.3.1. Clinical studies 
Initial symptoms of visual complaints in patients from both families were observed from early 
childhood. Fundus examination of affected individuals revealed the presence of white dots 
typical of FA in the midperiphery of the retina (Figure 3.2; Table 3.2). ERG responses of cone 
and rod photoreceptors were diminished in affected individual IV-1 of family A (Table 3.3). 
This individual had daytime vision problems, which confirms that cone photoreceptors were 
also affected. Macular degeneration was also observed in individual IV-1 of family A and 
individual IV-7 of family B. ERG results were not available for family B. The visual acuity 
(VA) of affected individual IV-7 of family B was different from the VAs of other individuals 
(VI-2, VI-3) of this family, and the density of white dots was also variable, which indicates 
intrafamilial phenotypic variability. Affected individuals of family B had normal daytime 
vision. 
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Figure 3.2 Fundus photographs of affected individuals from both families. A, B: Right 
and left eye, respectively, of affected individual IV-1 of family A (see arrow, Figure 3.1A). C, 
D: Right and left eye, respectively, of affected individual IV-7 of family B (see arrow, Figure 
3.1B). E, F: Right and left eye, respectively, of affected individual VI-2 of family B. G, H: 
Right and left eye, respectively, of affected individual VI-3 of family B. 
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Table 3.2 Clinical features of affected individuals in both families. 
Individual Age (years) VA (RE, LE) Fundus Phenotype RPE Degeneration Retinoscopy 
Family A (IV-1) 35 6/12, 6/12 White dots, macular degenerative changes Yes ND 
Family B (IV-7) 45 6/18, 6/12 White dots, macular degenerative changes Yes HM 
Family B (VI-2) 17 6/6, 6/6 White dots, macula healthy No LHM 
Family B (VI-3) 10 6/6, 6/6 White dots, macula healthy No LHM 
 
HM, hypermetropia; LE, left eye; LHM, low hypermetropia; RE, right eye; ND, not determined; RPE, retinal pigment epithelium; 
VA, visual acuity. 
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Table 3.3 ERG responses of affected individual IV-1 of Family A in comparison with ERG responses of a control individual. 
Measured parameters using monopolar 
electrodes 
Adaptation Flash strength (cd.s/m2) Proband Family A Control Normal values (Age=40 years) 
Scotopic 25 dB b-wave amplitude (µV) Dark 0.01 45.1 173.20 >141 
Scotopic 0 dB b-wave amplitude (µV) Dark 3.0 149.1 496.80 >387 
Oscillatory potential amplitude (µV) Dark 3.0 80.3 123.90 >75 
Photopic 0 dB b-wave amplitude (µV) Light 3.0 70.7 80.80 >82 
Photopic 30 Hz flicker amplitude (µV) Light 3.0 49.5 55.90 >56 
 
Age of affected individual at the time of investigation was 35 years 
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3.3.2. Genetic studies 
In family A, three homozygous regions were identified that were shared by the affected 
persons (Figure 3.3A). The largest homozygous region spanned 24.5 Mb (hg19: 3.3–27.8 Mb; 
flanked by SNPs rs4881131 and rs10764698) on chromosome 10. The second and third 
homozygous regions were 10.5 Mb (hg19: 46.4–56.9 Mb; flanked by rs11183300 and 
rs7314300) and 8.1 Mb (hg19: 25.9–34.0 Mb; flanked by rs9521585 and rs9555687) in 
length, and were located on chromosomes 12 and 8, respectively. The second largest region 
(10.5 Mb) on chromosome 12 harbored the FA-associated gene RDH5. RDH5 sequence 
analysis identified a novel homozygous 5 bp deletion (c.913_917delGTGCT; 
p.(Val305Hisfs*29)) in family A (Figure 3.1C). 
The mutation c.913_917delGTGCT; p.(Val305Hisfs*29) segregated in family A (Figure 
3.1A) was consistent with an autosomal recessive inheritance pattern. Both affected 
individuals carried this mutation in a homozygous state, while both parents and an unaffected 
brother carried this variant in a heterozygous state. The mutation causes a frameshift in the 
open reading frame and results in the replacement of the last 14 amino acids of the RDH5 
protein by 28 aberrant amino acids. This mutation is predicted to affect part of the 
transmembrane domain and elongate the cytosolic C-terminal tail. As this deletion is located 
in the last exon of RDH5, nonsense-mediated decay of the mutant mRNA is not predicted. 
In family B homozygosity mapping revealed an 8.9 Mb (hg19: 52.6–61.5 Mb) homozygous 
segment (Figure 3.3B) flanked by SNPs rs1894035 and rs1395538, encompassing the RDH5 
gene. RDH5 sequence analysis revealed a novel homozygous missense mutation (c.758T>G; 
p.(Met253Arg)) in this family. Segregation analysis confirmed that all affected individuals 
were homozygous for the mutation c.758T>G; p.(Met253Arg) (Figure 3.1B), suggesting that 
this variant may be disease causing. The methionine at position 253 is a highly conserved 
amino acid residue among different species (Figure 3.4), and c.758T is an evolutionarily 
highly conserved nucleotide with a PhyloP score of 4.40. SIFT predicted p.(Met253Arg) to be 
a deleterious (score: 0.05) mutation, PolyPhen-2 classified this mutation as probably 
damaging (score: 0.992), and Mutation Taster predicted this mutation to be disease causing. 
Structural analysis showed that there was a difference in charge and size of the wild-type 
Met253 and the mutant Arg253. The wild-type residue is uncharged, whereas the mutant 
residue is positively charged. The wild-type residue is buried in the alpha helix and the mutant 
residue introduces a charge in this buried residue in the core of the protein or protein complex,
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Figure 3.3 Homozygosity mapping results. A: Plot of homozygous regions identified in affected individuals in family A using Homozygosity 
Mapper analysis. B: Plot of homozygous regions identified in affected individuals in family B using Homozygosity Mapper analysis. The red 
lines indicate homozygous regions shared by affected individuals in each family. The arrows indicate the homozygous regions that harbor RDH5.
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Figure 3.4 Conservation of amino acids 245–260 of RDH5 in different species. Gray 
shading indicates amino acids that are identical to human RDH5 amino acids. 
which can lead to misfolding of the protein. The mutant residue is bigger and probably will 
not fit in the core of the protein. The hydrophobicities of the wild-type and mutant residue 
also differ, and therefore, this mutation is likely to cause the loss of hydrophobic interactions 
in the core of the protein. 
Ethnically matched control samples were not tested for these mutations; however, neither 
variant was found in dbSNP or in 1000 Genomes. 
3.4. Discussion 
In this study, we have identified two novel disease-causing mutations in RDH5 in two 
unrelated consanguineous families with FA. Both families exhibited typical FA, as was 
evident from the presence of typical white dots in the midperipheral regions of the retina. In 
both families, the older patients–IV-1 in family A and IV-7 in family B–had macular 
degeneration, which might suggest a progressive disease course in these families. 
Including our findings, 36 different mutations in RDH5 associated with FA have been 
identified to date.7,27-48 FA patients carrying RDH5 mutations exhibit high phenotypic 
variability, ranging from non-progressive to progressive disease, a variable VA, variation in 
the density of white dots, and occasionally macular involvement. FA with or without cone 
dystrophy has also been reported with varying degrees of severity.30,37,48 A total of 85 FA 
patients from 68 different families carrying RDH5 mutations have been identified globally 
(Table 3.4). These persons were found to exhibit a high variability in phenotype, but the 
presence of white dots was a common feature. In comparing the different phenotypes and 
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genotypes associated with RDH5, it is difficult to establish a valid and clear-cut genotype-
phenotype correlation. 
RDH5 is a transmembrane enzyme with a membrane-embedded N-terminal domain, a 
catalytic ectodomain, a C-terminal transmembrane domain, and a cytosolic tail.16 The 
topology of retinol dehydrogenases has been controversial as human retinal reductase-149 and 
mouse retinol dehydrogenase-150 have been reported to have a membrane-embedded N-
terminal domain but no C-terminal transmembrane segment, which supports the presence of a 
cytosolic ectodomain. RDH5 was suggested to have a cytosolic ectodomain without any C-
terminal transmembrane domain.50 However, another retinol dehydrogenase, cis-
retinol/androgen dehydrogenase 1 (CRAD1), has been described in detail to have a RDH5-
like structure with both a luminal ectodomain and cytosolic C-terminal domain, and a similar 
topology has been suggested for most of the retinol dehydrogenases.51 The frameshift 
mutation p.(Val305Hisfs*29) identified in family A is located in the C-terminal 
transmembrane domain, while the missense mutation p.(Met253Arg) is located in the catalytic 
ectodomain of RDH5 (Figure 3.5). As the C-terminal transmembrane region is necessary to 
retain CRAD1 in the endoplasmic reticulum,51 the RDH5 mutation p.(Val305Hisfs*29) might 
affect the endoplasmic reticulum localization of RDH5. Moreover, an elongated C-terminal 
cytosolic tail might also create problems in the proper functioning of RDH5, as the C-
terminus is thought to play a role in enzymatic activity and localization of CRAD1 and 
RDH5.51 
Structural analysis of RDH5 performed with Project HOPE suggests that the missense 
mutation p.(Met253Arg) may cause misfolding of the RDH5 protein because of the loss of 
hydrophobic interactions in the core of the mutant protein. Misfolding of the mutant protein 
may cause it to degrade.52-54 Absence of RDH5 leads to the accumulation of 11-cis retinol20 in 
the RPE, and a reduction of 11-cis retinal in the photoreceptors, which in turn might result in 
the malfunctioning of rod and cone photoreceptor cells. 
RDH5-associated disease can be prevented with proper genetic counseling of carriers of 
RDH5 mutations, and persons with this disease can be treated with 9-cis-β-carotene 
supplementation. Rdh−/− mice were successfully treated with 9-cis retinal,55 and 9-cis-β-
carotene was given to FA patients leading to major visual improvements;56 9-cis-β-carotene is 
converted to 9-cis retinal,57,58 which is more stable than 11-cis retinal.59 The higher stability of 
opsin bound to 9-cis retinal slows down the visual cascade and thus minimizes the toxicity of
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Table 3.4 RDH5 mutations causing fundus albipunctatus. 
Exon/intron Allele 1 Allele 2 Phenotype Families Cases Reference 
Exon 2 Wt c.55A>G; p.(Arg19Gly) DWD 1 1 Sergouniotis, et al.48 
Exon 2, 4 c.95del; p.(Phe32Serfs*29) c.712G>T; p.(Gly238Trp) WD, MA 1 1 Schatz, et al.47 
Exon 2, 3 c.98T>A; p.(Ile33Asn) c.469C>T; p.(Arg157Trp) WD 1 1 Ruther, et al.39 
Exon 2, 4 c.98T>C; p.(Ile33Thr) c.712G>T; p.(Gly238Trp) DWD, RPED 1 1 Sergouniotis, et al.48 
Exon 2 c.103G>A; p.(Gly35Ser) c.103G>A; p.(Gly35Ser) WD, CD, BE 1,1,1 2,1,1 Nakamura, et al.,30 
Wada, et al.,32 
Nakamura, et al.,37 
Querques, et al.46 
Exon 2, 5 c.103G>A; p.(Gly35Ser) c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1, 2 1, 2 Nakamura, et al.,30 
Nakamura, et al.,37 
Niwa, et al.41 
Exon 2, 5 c.124C>T; p.(Arg42Cys) c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1 1 Niwa, et al.41 
Exon 2 c.129del; p.(Leu44Trpfs*17) c.129del; p.(Leu44Trpfs*17) WD 1 1 Driessen, et al.33 
Exon 2, 5 c.211_214dup; p.(Ala72Glyfs*15) c.801C>G; p.(Cys267Trp) WD 1 1 Driessen, et al.33 
Exon 2, 4 c.218C>T; p.(Ser73Phe) c.712G>T; p.(Gly238Trp) WD 1 1 Yamamoto, et al.7 
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Intron 2, 4 c.310+1G>A; p.(?) c.712G>T; p.(Gly238Trp) DWD 1 1 Sergouniotis, et al.48 
Exon 3 c.319G>C; p.(Gly107Arg) c.319G>C; p.(Gly107Arg) WD, MD, SRP 1, 1 2, 1 Hotta, et al.,35 Sato, et 
al.40 
Exon 3, 5 c.319G>C; p.(Gly107Arg) c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD, BE 1 1 Nakamura, et al.30 
Exon 3 c.346_347insGCA; 
p.(Gly116_Ile117insSer) 
c.346_347insGCA; 
p.(Gly116_Ile117insSer) 
DWD, RPED 1 1 Sergouniotis, et al.48 
Exon 3, 4 c.346G>C; p.(Gly116Arg) c.710A>C; p.(Tyr237Ser) NWD 1 1 Sergouniotis, et al.48 
Exon 3 c.382G>A; p.(Asp128Asn) c.382G>A; p.(Asp128Asn) WD 1 1 Schatz, et al.47 
Exon 3, 4 c.382G>A; p.(Asp128Asn) c.712G>T; p.(Gly238Trp) WD 1 1 Iannaccone, et al.43 
Exon 3, 5 c.394G>A; p.(Val132Met) c.839G>A; p.(Arg280His) WD, CD, MD 1, 1, 3 1, 2, 3 Nakamura, et al.,30 
Nakamura, et al.,37 
Nakamura, et al.,38 
Niwa, et al.41 
Exon 3, 5 c.416G>T; p.(Gly139Val) c.955T>C; p.(*319Argext*33) DWD, RPED 1 1 Sergouniotis, et al.48 
Exon 3 c.470G>A; p.(Arg157Gln) c.470G>A; p.(Arg157Gln) DWD, RPED 1 1 Sergouniotis, et al.48 
Exon 3, 4 c.470G>A; p.(Arg157Gln) c.712G>T; p.(Gly238Trp) WD 1 1 Hajali, et al.45 
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Exon 3 c.490G>T; p.(Val164Phe) c.490G>T; p.(Val164Phe) WD, MA 1 1 Yamamoto, et al.36 
Exon 3, 5 c.530T>G; p.(Val177Gly) c.839G>A; p.(Arg280His) WD 1 1 Kuroiwa, et al.29 
Exon 3, 5 c.530T>G; p.(Val177Gly) c.928_930delinsGAAGTT; 
p.(Leu310delinsGluVal) 
WF 1 1 Hayashi, et al.42 
Exon 4 c.625C>T; p.(Arg209*) c.625C>T; (p.Arg209*) WD 1 1 Schatz, et al.47 
Exon 4, 5 c.689_690delinsGG; p.(Pro230Arg) c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1 1 Wang, et al.44 
Exon 4 c.712G>T; p.(Gly238Trp) c.712G>T; p.(Gly238Trp) WD, DWD,     
DWF 
1, 1 2, 2, 1 Yamamoto, et al.,7 
Gonzalez-Fernandez, et 
al.,27 Sergouniotis, et 
al.48 
Exon 4, 5 c.718dup; p.(Ala240Glyfs*19) c.841T>C; p.(Tyr281His) WD, BE, MD 1, 1 1, 1 Nakamura, et al.,30 
Niwa, et al.41 
Exon 5 c.758T>G; p.(Met253Arg) c.758T>G; p.(Met253Arg) WD, MD 1 5 This study 
Exon 5 c.791T>G; p.(Val264Gly) c.791T>G; p.(Val264Gly) WD 1 3 Hirose, et al.28 
Exon 5 c.824_825del; p.(Arg275Profs*60) c.824_825del; p.(Arg275Profs*60) DWD, DWF,    
RPED 
1 1 Sergouniotis, et al.48 
Exon 5 c.839G>A; p.( Arg280His) c.880G>C; p.(Ala294Pro) WD, MD 1 2 Gonzalez-Fernandez, et 
al.,27 
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Exon 5 c.839G>A; p.(Arg280His) c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD 1, 1, 2 1, 1, 2 Nakamura, et al.,30 
Nakamura, et al.,37 
Sato, et al.,40 Niwa, et 
al.41 
Exon 5 c.841T>C; p.(Tyr281His) c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD, MD 1, 1 1, 1 Nakamura, et al.,34 
Niwa, et al.41 
Exon 5 c.880G>C; p.(Ala294Pro) c.880G>C; p.(Ala294Pro) WD 1 1 Schatz, et al.47 
Exon 5 c.913_917del; p.(Val305Hisfs*29) c.913_917del; p.(Val305Hisfs*29) WD, MD 1 2 This study 
Exon 5 c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
c.928delinsGAAG; 
p.(Leu310delinsGluVal) 
WD, BE, PP 1, 4, 1, 1, 
4, 6 
1, 4, 2, 1, 
6, 6 
Hirose, et al.,28 
Nakamura, et al.,30 
Wada, et al.,31 
Nakamura, et al.,37 
Niwa, et al.41 
 
BE, bull’s eye; CD, cone dystrophy; DWD, deep whitish dots; DWF, deep whitish flecks; MA, macular atrophy; MD, macular dystrophy; 
NWD, no white dots; PP, photophobia; RPED, retinal pigment epithelium degeneration; SRP, sectorial retinitis pigmentosa; WD, white dots; 
WF, white flecks. Mutations identified in this study are in bold 
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Figure 3.5 Schematic representation of RDH5 and all mutations thus far published. The 
membrane-embedded N-terminus consists of 18 amino acids and the ectodomain, present in 
the lumen of the smooth endoplasmic reticulum (SER), spans amino acids 19 – 288. A C-
terminal membrane-spanning domain encompasses amino acids 289 – 310, and a small 
cytosolic tail of eight amino acids resides in the cytosol of retinal pigment epithelium (RPE) 
cells. Both missense and protein-truncating mutations are distributed across the entire protein. 
Mutations identified in this study are indicated in red. 
accumulating by-products in the visual cycle.55,60,61 In the rod-photoreceptor outer segments 
9-cis retinol will be converted to all-trans retinal during bleaching. This is subsequently 
reduced to all-trans retinol and, in the RPE, all-trans retinol is isomerically converted to 9-cis, 
11-cis, and 13-cis retinol. A stereospecific enzyme, 9-cis retinol dehydrogenase, is reported to 
be involved in the synthesis of 9-cis retinoic acid by oxidizing 9-cis retinol,62 and 9-cis retinal 
treatment is suggested to induce the endogenous synthesis of 11-cis retinal by its interaction 
with the retinoid X nuclear receptor.56,59,63 
Chapter 3                                                                                                                                                                   c 
82 
Based on our and other studies, we estimate that FA contributes to approximately 2% (4/208) 
of families with retinal dystrophy in Pakistan and a total of 17 patients have been identified 
with FA.9 Two FA families have been reported to carry RLBP1 mutations,9 while two other 
families with FA have RDH5 mutations (this study). In the current study, we have identified 
seven additional FA patients who are candidates for 9-cis-β-carotene therapy.  
In conclusion, we have identified two novel disease-causing mutations, c.913_917delGTGCT; 
p.(Val305Hisfs*29) and c.758T>G; p.(Met253Arg), in two Pakistani families with FA. Our 
study expands the current mutation spectrum of RDH5 and contributes to the existing body of 
knowledge. In addition, this study will help clinicians to improve the diagnosis of FA by 
differentiating FA from retinitis punctata albescens, providing genetic counseling and 
prescribing the correct treatment to patients. 
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ABSTRACT 
Purpose: To determine the genetic cause of Bardet-Biedl syndrome (BBS) in two 
consanguineous Pakistani families. 
Methods: Clinical characterization of the affected individuals of both families was done by 
ophthalmic examination, electroretinography, electrocardiography, liver and renal profile. A 
total of 17 genes are known to be associated with BBS, so exome sequencing was preferred 
over candidate gene sequencing. One affected individual from both families was selected for 
exome sequencing. Identified variants were confirmed by Sanger sequencing. 
Results: Retinitis pigmentosa, obesity and learning difficulties were present in affected 
individuals of both families. In family A, a sixth finger (polydactyly) of the proband’s sister 
was removed by a surgical operation leaving a scar on the little finger. Polydactyly was also 
present in both affected individuals from family B. All diagnostic symptoms were 
characteristic of BBS in both families. In both affected individuals from family A, exome 
sequencing identified a novel homozygous mutation (c.47+1G>T) in BBS1 that inactivates the 
splice donor site at the end of exon 1. In family B, a previously reported mutation, c.442G>A; 
p.(Asp148Asn), was detected. 
Conclusions: Exome sequencing is an efficient technique for the identification of mutations 
in genetically heterogeneous diseases. In addition, intra-familial phenotypic variability in 
family A argues for the modifying effect of some other still unknown modifier alleles.  
Key words: BBS1; phenotypic variability; polydactyly; splice-site mutation; exome 
sequencing. 
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4.1. Introduction 
Bardet-Biedl syndrome (BBS) (MIM: 209900) is invariantly characterized by rod-cone 
dystrophy, and at least three additional non-ocular features such as intellectual disability, 
obesity, polydactyly, hypogonadism or renal anomalies as primary manifestations. In the 
absence of one of these four primary clinical feature, the diagnosis of BBS is made when at 
least two secondary features are observed, including hepatic fibrosis, diabetes mellitus, 
reproductive and developmental abnormalities, growth retardation, speech delays, or 
cardiovascular problems.1  
BBS has been classified as a ciliopathy2 and is inherited mostly in an autosomal recessive 
pattern although digenic (tri-allelic) inheritance has also been reported.3-6 Some studies have 
also demonstrated the epistatic effects of a third protective allele,7,8 while variants in 
RPGRIP1L have been reported as a modifier of the BBS phenotype.9 In only two studies, a 
recessive mode of inheritance for BBS has been argued against.5,10 Very recently, a spectrum 
of phenotypes ranging from full-blown BBS to non-syndromic RP was found to be associated 
with the hypomorphic BBS1 missense mutation p.(Met390Arg).11 
BBS is a severe disorder with the highest prevalence of 1/3,700 in the Faroe Islands.12 While 
in the rest of the world its prevalence varies from 1/13,000 in Newfoundland,13 1/17,000 in 
the Kuwaiti population14 and 1/65,000 in other Arab countries,15 it is rare in the European 
population with a prevalence range of 1/125,000 in the United Kingdom16 to 1/160,000 in 
Switzerland.17 
BBS is genetically heterogeneous, as mutations in 17 different genes have been identified so 
far.18 The BBS1 gene (MIM: 209901) is located on the long arm of chromosome 11 and 
consists of 17 coding exons. The gene is expressed in many tissues including fetal, testicular, 
retinal, adipose, cardiac, skeletal and pancreatic cells, with the highest expression in kidney.19 
BBS1 is part of the BBSome complex that includes BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 
and BBS9. Proteins in this complex are thought to be involved in ciliogenesis, because of 
their function in membrane trafficking in the primary cilium.20 
The current study was designed to find the molecular basis of BBS in two Pakistani families 
(family A and B) using exome sequencing. A novel splice donor site mutation c.47+1G>T in 
BBS1 was identified in family A, and a previously reported BBS1 mutation, c.442G>A; 
p.(Asp148Asn),21 was identified in family B. 
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4.2. Materials and Methods 
4.2.1. Ethics committee/Institutional review board approval 
Approval for this study was granted by the ethics committee/institutional review board of 
Shifa College of Medicine/Shifa International Hospital, Islamabad. Written informed consent 
was obtained from both families before starting the study. In addition, the study conformed to 
the tenants of the declaration of Helsinki. 
4.2.2. Clinical examination 
Clinical examination included ophthalmic examination, electroretinography, 
echocardiography, liver function test and renal profile. Blood sugar was also measured to 
determine the presence or absence of diabetes mellitus. 
4.2.3. Blood sampling and DNA preparation 
Both families (Figure 4.1A, B) were recruited from the central part of Punjab. Venous blood 
of affected and normal individuals of both families was drawn by venipuncture and collected 
in acid citrate dextrose vacutainers (Becton Dickinson, Franklin Lakes, NJ). DNA was 
extracted by a standard phenol-chloroform extraction procedure.22 In brief, it consisted of the 
lysis of white blood cells, followed by protein digestion, extraction of the DNA with the help 
of phenol-chloroform, and precipitation of DNA with isopropanol. 
4.2.4. Exome sequencing 
Probands of each family were selected for exome sequencing, which was performed on a 
5500XL sequencing platform from Life Technologies (Carlsbad, CA). The exomes of the 
probands were enriched according to the manufacturer’s protocol using SureSelectXT Human 
All Exon v.2 Kit (50Mb), containing the exonic sequences of approximately 21,000 genes 
from Agilent Technologies, Inc. (Santa Clara, CA). LifeScope software v2.1 from Life 
Technologies (Carlsbad, CA) was used to map color space reads along the hg19 reference 
genome assembly. The DiBayes algorithm, with high-stringency calling, was used for single-
nucleotide variant calling. The small Indel Tool was used to detect small insertions and 
deletions. Exome sequencing data were filtered as described previously.23,24 Briefly, the 
variants in known BBS genes were selected and analyzed for segregation in the families. 
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Figure 4.1 Pedigrees of families A and B and sequence electropherograms. A: 
Segregation of the identified mutation in family A. B: Segregation of the identified mutation 
in family B. C: Sequence electropherograms of an affected individual (upper panel), a 
heterozygous mutation carrier (middle panel) and a homozygous wild-type healthy individual 
(lower panel) of family A. D: Sequence electropherograms of an affected person (upper 
panel), a heterozygous mutation carrier (middle panel) and a homozygous wild-type healthy 
individual (lower panel) of family B. In family pedigrees, roman numerals indicate generation 
number, arrows indicate probands, M stands for mutation identified, + is wild-type allele, 
M/M indicates genotypes of affected individuals, +/M indicates genotypes of unaffected 
individuals carrying a mutant allele and +/+ indicates genotypes of healthy individuals. 
4.2.5. Sequence analysis 
Variants identified by exome sequencing were confirmed with Sanger sequencing using an 
automated DNA sequencing machine (3730 DNA analyzer; Applied Biosystems, Inc., Foster 
City, CA). PCR primers were designed with the help of the online tool Primer3.25 
4.2.6. Splice site prediction 
NetGene2 World Wide Web Server (http://www.cbs.dtu.dk/services/NetGene2/),26,27 an 
online splice site prediction program, was used to predict the effect of sequence variants 
located in or near the splice sites. 
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4.2.7. In silico pathogenicity assessment of missense variant 
Pathogenicity of the missense variant was assessed using the online prediction tools 
Polymorphism Phenotyping v-2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2/) and 
Sorting Intolerant from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.html). In 
addition, HOPE (http://www.cmbi.ru.nl/hope/home) server was used to predict structural 
consequences in the mutant protein using normal protein structure with accession number 
Q8NFJ9.28 
4.3. Results 
4.3.1. Clinical findings 
Affected individuals underwent extensive clinical examination, including fundus examination, 
which revealed the presence of bone spicules and attenuation of blood vessels (Figure 4.2). 
ERG measurements were recorded for affected individual IV:5 of family A only, which 
showed reduced scotopic and photopic electrophysiological responses in the patient as 
compared to the normal individual (Table 4.1). All other primary and secondary BBS features 
were also investigated (Table 4.2). Retinitis pigmentosa (RP), obesity and learning difficulties 
were present in all the affected persons while polydactyly was present in the affected female 
(IV:4) of family A and the affected persons IV:3 and IV:5 of family B. Developmental delay, 
a secondary feature of BBS was also observed in both families. Echocardiography was normal 
in both affected individuals of family A whereas in family B echocardiography was not 
performed, but affected individuals of family B were found to be hypertensive. Liver function 
was also normal and no renal defects were observed in both families. 
Affected individuals of family B also had intellectual disability and dental crowding. All the 
patients fulfilled the diagnostic criteria of BBS having at least four primary, or three primary 
and two secondary BBS features. 
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Figure 4.2 Fundus photographs of affected and healthy individuals. A, B: Fundus 
photographs of family A, proband IV:5, showing bone spicules, retinal vessel attenuation and 
macular degeneration. C, D: Fundus photographs of the proband’s sister (IV:4) showing salt 
and pepper appearance of both fundi, presence of bone spicules in the mid periphery and 
bull’s eye macular atrophy (indicated by the arrows). E, F: Fundus photograph of family B 
proband IV:5 revealing pigmentary deposits and retinal vessel attenuation. G, H: Fundus 
photographs of a healthy individual from family A (IV:6). 
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Table 4.1 Electrophysiological measurements recorded for individual IV:5 of family A. 
Measured parameters using 
monopolar electrodes 
Adaptation Flash 
strength 
(cd.s/m2) 
Proband* Control Standard 
Values 
(Age=30 
years) 
Scotopic 25 dB b-wave amplitude 
(µV) 
Dark 0.01 9.5 177.5 >163 
Scotopic 0 dB b-wave amplitude 
(µV) 
Dark 3.0 7.1 434.4 >403 
Oscillatory potential amplitude (µV) Dark 3.0 30.2 193.1 >89 
Photopic 0 dB b-wave amplitude 
(µV) 
Light 3.0 7.6 123.6 >92 
Photopic 30 Hz flicker amplitude 
(µV) 
Light 3.0 3.2 53.3 >63 
*Proband’s age was 26 at the time of the measurements. 
4.3.2. Genetic findings 
In order to identify the pathogenic mutation, the exome data sequence variants were filtered to 
reduce the number of potentially pathogenic variants. First, we searched for variants present 
in known BBS genes. In both families variants were found in six BBS genes, including BBS1 
(NM_024649.4), BBS2 (NM_031885.3), BBS4 (NM_033028.3), BBS7 (NM_176824.2), BBS9 
(NM_198428.2) and BBS12 (NM_001178007.1) (Table 4.3). The frequency of variants 
identified in known BBS genes except the BBS1 variants described below, ranged from 13% 
to 99% in an in-house database. 
In family A, a novel splice donor site mutation (c.47+1G>T) in BBS1 was identified (Table 
4.3). This mutation was present in a homozygous state in the exome data with only two reads, 
which was further confirmed as a homozygous change by Sanger sequencing (Figure 4.1C). 
Segregation analysis (Figure 4.1A) revealed that the mutation was homozygous in both 
affected siblings, heterozygous in parents and normal siblings and absent in some other 
unaffected members of the family. The c.47+1G>T variant is predicted to affect one of the 
canonical splice site nucleotides, which might therefore be completely inactivated. Splice site 
prediction software predicted inactivation of the wild type splice donor site at the 3’ end of 
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exon 1 and did not predict an alternative splice donor site in intron 1. The mutant mRNA is 
likely to have a premature stop codon at position 17 (Figure 4.3). 
Similarly in family B, exome data were analyzed for variants in known BBS genes which 
resulted in the identification of a previously reported missense mutation c.442G>A; 
p.(Asp148Asn) in BBS1 (Figure 4.1D; Table 4.3). Segregation analysis (Figure 4.1B) revealed 
that this mutation was homozygous in the affected individuals (IV:3 and IV:5), heterozygous 
in the healthy siblings (IV:1 and IV:2) and their mother (III:2) and absent in one healthy sister 
(IV:4). 
Table 4.2 BBS features in affected individuals of both families. 
BBS features Present 
Primary features Family A 
IV:5 
Family A  
IV:4 
Family B 
IV:5 
1. Rod-cone dystrophy Yes Yes Yes 
2. Polydactyly   No Yes Yes 
3. Obesity   Yes Yes Yes 
4. Learning problems Yes Yes Yes 
5. Hypogonadism No No No 
6. Renal malfunction No No No 
Secondary features    
1. Speech problems No No Yes 
2. Strabismus, cataract, astigmatism Strabismus Astigmatism No 
3. Brachydactyly, syndactyly No No No 
4. Developmental delay Yes Yes No 
5. Polyuria, polydipsia No No No 
6. Diabetes mellitus No No No 
7. Ataxia, imbalance No No No 
8. Mild spasticity No No No 
9. Dental crowding No No Yes 
10. Heart problems No No Yes 
11. Liver disease No No No 
12. Family members with BBS Yes Yes Yes 
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Table 4.3 Variants identified in genes previously implicated in BBS through exome sequencing of families A and B 
 
Family A                     
Chr/Position Reads Var reads % var SNP id Freq Gene AA changes mRNA changes PhyloP GS 
11/66278178 2 2 100 - - BBS1 p.(?) c.47+1G>T 3.03 - 
16/56548501 109 106 97 rs4784677 97.09 BBS2 p.(Ser70Asn) c.209C>T 2.50 46 
16/56545175 119 46 39 rs11373 28.48 BBS2 p.(Ile123Val) c.367T>C 0.23 29 
15/73002035 45 44 98 rs8033604 76.70 BBS4 p.(?) c.77-6G>A -3.73 - 
15/73023937 103 103 100 rs12914333 99.35 BBS4 p.(Phe302Phe) c.906T>C -0.58 - 
15/73027478 20 20 100 rs2277598 78.64 BBS4 p.(Ile354Thr) c.1061T>C -0.39 89 
4/122749541 68 22 32 rs1507994 12.94 BBS7 p.(?) c.1890+16G>A -0.92 - 
7/33388713 87 27 31 rs11773504 35.92 BBS9 p.(Ala455Thr) c.1363G>A 0.31 58 
4/123664204 41 23 56 rs309370 51.46 BBS12 p.(Arg386Gln) c.1157G>A -0.34 43 
4/123664919 99 62 63 rs13102440 36.57 BBS12 p.(Gln624Gln) c.1872A>G -0.05 - 
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Family B 
Chr/Position Reads Var reads % var SNP id Freq Gene AA changes mRNA changes PhyloP GS 
11/66283020 51 51 100 - - BBS1 p.(Asp148Asn)  442G>A 3.54 23 
16/56548501 92 92 100 rs4784677 97.02 BBS2 p.(Ser70Asn)  209C>T 2.50 46 
15/73023937 73 72 99 rs12914333 99.19 BBS4 p.(Phe302Phe)  906T>C -0.51 - 
15/73027478 31 13 42 rs2277598 76.42 BBS4 p.(Ile354Thr)  1061T>C -0.32 89 
4/123664204 49 47 96 rs309370 52.85 BBS12 p.(Arg386Gln)  1157G>A -0.32 43 
4/123664427 50 15 30 rs13135766 29.27 BBS12 p.(Val460Val)  1380G>C 1.66 - 
4/123664457 62 28 45 rs13135445 34.96 BBS12 p.(Cys470Cys)  1410C>T -0.39 - 
4/123664919 84 36 43 rs13102440 36.86 BBS12 p.(Gln624Gln) 1872A>G 0.01 - 
AA, amino acid; Chr, chromosome; Freq, frequency; GS, Grantham score; PhyloP, phylogenetic P-values; SNP id, single nucleotide 
polymorphism identifier; Var, variation  
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Figure 4.3 Predicted effect of splice donor site mutation c.47+1G>T on mutant BBS1 
mRNA splicing. A: Wild type BBS1 and resulting mRNA after splicing are shown. B: 
Mutant BBS1 and inclusion of intron 1 in the mutant mRNA in indicated which might result 
in the production of truncated BBS1 protein followed by non-sense mediated decay. 
PolyPhen-2 predicted the missense mutation p.(Asp148Asn) as “probably damaging” whereas 
SIFT predicted this mutation to be a “tolerated” one. HOPE predicted that the mutation is 
present in the core of a domain; difference in the properties of wild type and mutant amino 
acid residues might disturb the core structure of this domain. 
4.4. Discussion 
In the current study we report on two consanguineous families from Pakistan, with affected 
individuals presenting BBS, which is a rare, clinically and genetically heterogeneous disorder. 
In approximately 75% of BBS families, mutations are detected in known BBS genes.21 BBS1 
is the most frequently mutated BBS gene and accounts for the disease in nearly 24% of 
European patients with BBS.4,29,30 The BBS1 mutation p.(Met390Arg) is a frequent founder 
mutation5,7,19 that is found in 78.3% of families with BBS1 mutations.5,21 
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Including our families, more than 25 different Pakistani families have been described with 
variable BBS phenotypes and different mutations in BBS2, BBS3, BBS4, BBS5, BBS8, BBS10, 
and BBS12.31-36 BBS1 mutations have not been reported previously in Pakistani individuals 
with BBS. 
The exact function of BBS1 in the pathology of BBS is still unclear but being a part of the 
BBSome complex, BBS1 is thought to play a crucial role by interacting with other proteins 
through its beta-propeller domain.37 A detailed model of the assembly of the BBSome 
complex has been proposed recently,38 which describes crucial steps required for the proper 
assembly of BBS proteins to form a functional BBSome complex. BBS1 joins the BBSome 
complex by interacting with BBS9 and BBS2, and the last component (BBS4) completes the 
BBSome complex assembly.38 In the presence of BBS1M390R/M390R mutant protein, BBS4 fails 
to join the BBSome complex, which shows that protein-protein interactions between mutant 
BBS1 and wild-type BBS4 are lost.38 The p.(Met390Arg) is a frequently occurring missense 
mutation in BBS1 in persons with BBS that severely affects these normal protein-protein 
interactions. 
The splice site mutation c.47+1G>T identified in the current study abolishes the splice site 
and is most likely to result in the synthesis of a truncated mutant protein as a consequence of 
intron inclusion. Truncation might result in nonsense-mediated decay of the mRNA because 
of the possible creation of a premature stop codon at position 17 (Figure 4.3); alternatively, 
usage of an alternate downstream translation initiation codon ATG might result in 5’ 
truncation causing synthesis of misfolded/non-functional proteins. Misfolded proteins are 
mostly likely triggered towards the degradation pathways, which safeguard the cells from 
toxicity of the accumulating intermediary molecules.39-41 
In family A, the main intra-familial phenotypic difference was the presence of polydactyly. In 
addition, bull’s eye macular atrophy was observed only in the affected female, which also 
highlights the phenotype variability. Polydactyly is an observable clinical feature of BBS in 
almost all the BBS patients;18 the absence of polydactyly in the proband of family A thus 
could be the effect of a  still unknown modifier allele. A known modifier of ciliopathies 
(RPGRIP1L) has been functionally tested in zebrafish to observe modifying effect of different 
alleles.9 In our family variants were not identified in RPGRIP1L. Moreover, although we did 
not test the functional effect of other identified variants on phenotype, their effect on 
phenotypic variability cannot be ruled out. Ophthalmological examinations revealed severely 
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reduced electrophysiological responses of rods and cones (Table 4.1), and the visual acuity 
was restricted to hand movements only, illustrating the severity of the disease. The proband of 
family B had intellectual disability and did not cooperate in conducting the 
electrophysiological measurements. 
Contrary to our findings, in a recent study BBS1 mutations were reported to be associated 
with milder ocular phenotypes as compared to the mutations in other BBS genes.42 Moreover, 
in another study, milder non-ocular BBS phenotypes were reported in patients with mutations 
in BBS12.35 In addition mutations in BBS1,11 BBS343 and BBS844 are also implicated in non-
syndromic retinitis pigmentosa instead of BBS. 
In a pharmaco-genomic study aberrant splicing caused by a splice donor site  mutation in 
BBS1 (c.479G>A) was corrected in the patient’s fibroblasts by using mutated U1 small 
nuclear RNA.45 U1 snRNA is involved in the recognition of exons during splicing. The 
investigators generated mutant U1 small nuclear RNAs with increased complementarity for a 
mutated splice donor site, which were subsequently used to redirect correct splicing. Using a 
similar strategy, the splice donor site mutation (c.47+1G>T) identified in our study could first 
be assessed in in vitro studies and then in model organisms, which might then lead to the 
development of treatment options for individuals with this particular mutation in the future. 
The missense mutation p.(Asp148Asn) was previously identified in an American and a British 
patient.21 Since then this is the second report of this mutation. Although this mutation is 
distributed worldwide, it is rare in occurrence, being genetic cause of the disease in only four 
patients. 
In the absence of a solved 3D structure or modeling template for the wild type BBS1 protein 
HOPE did not predict a 3D model for the mutant protein; but based on the differences in the 
amino acid properties it was predicted that wild type interactions of the protein might be 
disturbed due to the introduction of a mutant residue. Although in silico analysis is a good 
analytical tool to assess the pathogenicity of missense variants, functional validation is 
mandatory. 
The use of exome sequencing to identify genetic mutations in BBS families was justified in 
our study as we compared the expenses of Sanger sequencing and exome sequencing. 
Expenditure of the Sanger sequencing (2140€) of the coding exons (228 exons; 214 
amplicons) of 17 BBS genes in both directions is comparable with the exome sequencing 
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costs (1500-2000€). In addition Sanger sequencing requires longer hands-on time and more 
effort as compared to exome sequencing. 
In conclusion, in Pakistani families with BBS, exome sequencing proved to be a successful 
and fast method for the identification of a novel as well as a recurrent mutation in BBS1. To 
our knowledge, this is the first report describing BBS1 mutations in the Pakistani population. 
In the future, some of the clinical features might possibly be addressed using gene therapy, 
but currently, only genetic counseling is warranted for carriers of mutations. 
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ABSTRACT 
Purpose: To identify the underlying genetic defects in four consanguineous retinal dystrophy 
families from Pakistan. 
Method: Detailed clinical analysis that included funduscopy, electroretinography (ERG) and 
visual acuity (VA) assessment was done for at least one proband per family. Genome wide 
single nucleotide polymorphism (SNP) arrays were performed for multiple affected 
individuals in the respective families. The genotype data were analyzed to identify 
homozygous regions. Known autosomal recessive retinitis pigmentosa (arRP) and Leber 
congenital amaurosis (LCA) genes residing in the homozygous regions were screened for 
possible pathogenic variants. 
Results: Clinical analysis showed variable signs of retinal degeneration, with and without 
macular involvement. Homozygosity mapping analysis yielded multiple homozygous regions 
per family. The largest or second largest homozygous region in all families contained known 
retinal dystrophy genes, which upon sequence analysis were found to contain pathogenic 
variants in four arRP/LCA genes. In three families previously identified protein truncating 
mutations were found in ABCA4 (c.6658C>T; p.(Gln2220*)), AIPL1 (c.834G>A; 
p.(Trp278*)), and CERKL (c.847C>T; p.(Arg283*)), whereas in one family a novel mutation 
c.1630C>T; p.(Arg544Trp) was found in PDE6A. 
Conclusion: Consanguineous families are a rich resource to find disease causing variants by 
exploiting a homozygosity mapping approach. Four different genes were found to be mutated 
in four arRP families supporting previous observations, that retinal dystrophy is genetically 
heterogeneous in the Pakistani population. 
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5.1. Introduction 
Retinitis pigmentosa (RP) is a progressive retinal degeneration in which the degeneration of 
rod photoreceptor cells precedes that of cone photoreceptor cells. Rod photoreceptor cells are 
responsive to dim light, and therefore affected individuals with RP at early stages experience 
night vision problems. As rod photoreceptor cells outnumber cones in the periphery, patients 
gradually lose their peripheral vision, a condition also known as tunnel vision. At later stages 
of the disease affected individuals completely lose their visual acuity as the neighboring cone 
photoreceptors also degenerate, leaving affected individuals handicapped for the rest of their 
life as currently no treatment is available for the majority of the cases.1 
The fundus of persons with RP typically reveals bone spicule pigmentation prominently in the 
periphery, attenuation of retinal arterioles, and waxy pallor of optic disk. However, clinically 
the disease is very heterogeneous as most of these symptoms overlap with other related 
phenotypes like Leber congenital amaurosis (LCA) or cone rod dystrophy (CRD).2,3 The gold 
standard for the differential diagnosis is electroretinography (ERG) which measures the 
electrical responses of the retina, and is able to differentiate between rod and cone-specific 
responses based upon retinal illumination by varying the intensity of light.4 Genetic 
heterogeneity evidently explains the clinically heterogeneous nature of the disease as 
currently 56 genes are known to cause RP (http://www.sph.uth.tmc.edu/retnet/ January, 
2012). 
Thirty-four genes and three loci are known for autosomal recessive (ar) RP, and the search for 
novel disease genes continues as the known genes are thought to explain the disease in only 
about 50% of the patients.5 Consanguineous families with multiple RP patients are a good 
resource to find novel genetic defects. In this paper; we analyzed four consanguineous 
Pakistani RP families, and identified pathogenic variants using the homozygosity mapping 
approach. 
5.2. Methods 
Four consanguineous families were recruited from different areas of Pakistan (Figure 5.1). 
The basic inclusion criteria were the presence of night blindness, bone spicule pigmentation, 
and tunnel vision. Patients were informed about the aims and objectives of the project before 
obtaining written consent. Detailed clinical analysis, which included visual acuity (VA) 
assessment, funduscopy, and ERG, was done for at least one proband with a phenotype that 
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was representative for all patients in the family.4 Peripheral blood was drawn and was used 
for DNA extraction by the standard phenol-chloroform method.6 
 
Figure 5.1 Segregation of genetic variants in families with autosomal recessive retinitis 
pigmentosa. Pedigrees of retinal dystrophy families and segregation analysis of pathological 
variants M1 (ABCA4; c.6658C>T; p.(Gln2220*)), M2 (AIPL1; c.834G>A, p.(Trp278*)), M3 
(CERKL; c.847C>T, p.(Arg283*)), M4 (PDE6A; c.1630C>T, p.(Arg544Trp)). Individuals 
genotyped using whole genome single nucleotide polymorphism arrays are marked with 
asterisks. Arrows point to the probands. 
Genomic DNA samples of selected probands, which are indicated as asterisks in the 
respective pedigrees were analyzed using whole genome SNP arrays (Figure 5.1). Families 
RP03 and RP27 were genotyped on Illumina 6K while RP48 and RP55 were analyzed on 
Human OmniExpress platform (700K). The genotyping data from families RP03, RP45, and 
RP55 were analyzed with the online mapping tool, Homozygosity Mapper.7 For family RP27 
linkage analysis was performed using the easyLINKAGE software package.8 Thereafter the 
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haplotypes were compared among affected members of each family, and the regions in which 
all the affected individuals had the same SNP alleles were considered to harbor the pathogenic 
mutation. 
Genomic coordinates of the known retinal dystrophy (RD) genes were obtained from the 
UCSC genome browser (http://genome.ucsc.edu) and were used to compare their location 
with the identified homozygous regions in each family. Sanger sequencing was performed to 
identify potential pathogenic variation in all the coding exons including exon-intron 
boundaries using primers designed with the online primer-designing tool ExonPrimer, primer 
sequences are available on request. Sequencing data were analyzed by Vector NTI, and the 
pathogenicity of the variants obtained were assessed based upon the functional consequences, 
nucleotide and amino acid conservation. In addition, the pathogenicity of a PDE6A missense 
variant was determined by publically available tools Polymorphism Phenotyping v2 
(PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2/), Sorting Intolerant from Tolerant 
(SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.html) and Project Hope 
(http://www.cmbi.ru.nl/hope). To access the evolutionary conservation of the mutant residue, 
PDE6A amino acid  sequences of different species were aligned which included humans 
(Homo sapiens, NM_000440.2); chimpanzees (Pan troglodytes, ENSPTRP00000029739); 
orangutans (Pongo abelii, ENSPPYP00000017834); macaque (Macaca mulatta, 
ENSMMUP00000006320), rat (Rattus norvegicus, ENSRNOP00000024171); mice (Mus 
musculus, ENSMUSP00000025468); dogs (Canis familiaris, ENSCAFP00000011716); 
platypus (Ornithorhynchus anatinus, ENSOANP00000014898); frogs (Xenopus tropicalis, 
ENSXETP00000027796); tetraodons (Tetraodon nigroviridis, ENSTNIP00000009080). 
5.3. Results 
5.3.1. Clinical data of the families 
Families RP03, RP48, and RP55 show typical features of classic RP, as evidenced by the 
presence of attenuated retinal vessels, peripheral bone spicule pigmentation, and rod-
dominated ERG abnormalities (Table 5.1; Figure 5.2). In proband of family RP48, a CRD 
pattern cannot be excluded as the macula was also affected at the time of examination (33 
yrs). In family RP27, an early-onset form of RP was observed which is indistinguishable from 
LCA (Table 5.1). 
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5.3.1. Homozygosity mapping and sequence analysis 
5.3.1.1. RP03 
Family RP03 comprises of seven affected individuals one of which is deceased (Figure 5.1). 
Four out of the six available family members were genotyped (indicated by asterisks in the 
pedigree). Homozygosity Mapper analysis yielded eight homozygous regions (Table 5.2). The 
2nd largest homozygous region harbored a known arRP gene, ATP-binding cassette, sub-
family A member 4 (ABCA4; MIM #601691). Sequence analysis of all 50 protein coding 
exons revealed a homozygous nonsense mutation c.6658C>T; p.(Gln2220*) segregating with 
the disease in the family. 
5.3.1.2. RP27 
SNP microarray analysis of five affected individuals from two branches of family RP27 
(Figure 5.1) yielded two homozygous regions (Table 5.2). The region on chromosome 17 was 
the largest and contained two known arLCA genes i.e. aryl hydrocarbon receptor interacting 
receptor protein like 1 (AIPL1; MIM #604392) and guanylate cyclase 2D (GUCY2D; MIM 
#600179). Sequencing of all 20 exons of GUCY2D revealed no variant. Sequence analysis of 
AIPL1 exons revealed a nonsense substitution, c.834G>A; p.(Trp278*), that was segregating 
with the disease. 
5.3.1.3. RP48 
Analysis of genotyping data of four out of seven affected individuals (Figure 5.1) with 
Homozygosity Mapper indicated a single region on chromosome 2 (Table 5.2) that 
encompassed a known arRP gene, ceramide kinase-like (CERKL; MIM #608381). Upon 
sequence analysis of all 14 exons a nonsense substitution, c.847C>T; p.(Arg283*), was 
identified in exon 6 of CERKL, which was segregating in the family with the disease. 
5.3.1.4. RP55 
Homozygosity mapping with the genotype data from three affected individuals (Figure 5.1) 
revealed a single homozygous region on chromosome 5, which contains phosphodiesterase 
6A (PDE6A; MIM #180071), a known arRP gene (Table 5.2). Sequence analysis of all 22 
exons revealed a novel missense variant, c.1630C>T; p.(Arg544Trp), in exon 13. As shown in 
Figure 5.1, the mutation segregated perfectly in the family. The variant was considered to be 
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Table 5.1 Clinical features of affected probands with arRP/LCA 
Family Age at examination 
(yrs) 
Age of onset 
(yrs) 
Fundus ERG VA (OD, OS) Diagnosis 
RP03 30 10-15 ARV, Peripheral BSP Rod-cone pattern 6/60, 6/60 RP 
RP27 35 2-5 prominent macular 
degeneration,widespread BSP 
Extinguished LP Early onset RP/ LCA 
RP48 33 10-20 ARV, BSP, macular involvement Rod-cone pattern CF RP 
RP55 45 25-30 ARV, Peripheral BSP Rod-cone pattern 6/60, 6/60 RP 
ARV, attenuated retinal vessels; BSP, bone spicule pigmentation; CF, counting fingers; LP, light perception; ND, not determined; 
VA, visual acuity 
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Figure 5.2 Fundus photographs of affected individuals from four families. Fundus 
photographs of proband RP03 (A), RP27 (B), RP48 (C), and RP55 (D). Bone spicule 
pigmentation at the retinal periphery (indicated by arrows), attenuation of retinal vasculature 
(indicated by arrow heads), and macular degeneration (indicated by stars) are evident in all 
cases. 
likely pathogenic as it was not detected in 80 ethnically matched controls, the amino acid 
sequence conservation is very high (Figure 5.3), and it was predicted to be damaging and not 
tolerated by PolyPhen-2 and SIFT analysis, respectively. 
5.4. Discussion 
In this paper, four mutations in four different genes were described to be causative for 
arRP/LCA in the respective families. The ABCA4 homozygous null mutation c.6658C>T; 
p.(Gln2220*), identified in arRP family RP03, was previously found in a heterozygous state 
in an isolated CRD patient.9 In that patient subsequent mutation analysis revealed a splice
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Table 5.2 Homozygous regions found in arRP/LCA families 
Family Chr Flanking SNP Position (hg19) Size in 
Mb 
Ranking Known 
arRP/LCA genes 
RP03 1 rs743117;rs716581 94.4-102.3 7.9 2 ABCA4 
 2 rs20349;rs17722726 134.6-137.6 3.0 7 ---------- 
 4 rs730349;rs936232 21.2-25.8 4.6 5 ---------- 
 4 rs543337;rs1461605 82.7-92.0 9.3 1 ---------- 
 6 rs2894891;rs1475270 100.2-106.7 6.5 3 ---------- 
 7 rs4728251;rs1424376 131.8-137.7 5.9 4 ---------- 
 14 rs1007813;rs9324014 96.0-100.2 4.2 6 ---------- 
 14 rs17172;rs872945 101.4-103.5 2.1 8 ---------- 
RP27 17 rs884250;rs1860300 4.3-11.1 6.8 1 AIPLI, GUCY2D 
 21 rs1012959;rs2837536 38.1-41.6 3.5 2 ---------- 
RP48 2 rs6734093;rs12693396 182.2-185.7 3.5 1 CERKL 
RP55 5 rs7711546;rs10515714 143.6-154.9 11.3 1 PDE6A 
 
 
Figure 5.3 Amino acid conservation of arginine residue 544 in PDE6A that is mutated in 
family RP55. The amino acid position of the first residue in the respective protein is 
indicated. 
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defect c.4540-2A>G as the second allele (A. Maugeri and F.P.M.C, unpublished data). 
According to a genotype–phenotype model, two severe ABCA4 mutations, such as a null 
mutation in RP03, causes a severe phenotype like RP, while a combination of a severe and a 
moderately severe mutation causes CRD, and a mild and a severe mutation cause Stargardt 
disease.9-13 Thus far, pan-retinal cone-rod dystrophy or severe RP was exclusively associated 
with two severe ABCA4 variants.11,13,14 The p.(Gln2220*) variant is located in exon 48, which 
predicts that nonsense mediated decay of the RNA will occur and thus we consider this 
variant to be a null allele. This is in agreement with the observed phenotype in three clinically 
investigated affected individuals. 
The AIPL1 mutation c.834G>A; p.(Trp278*) that we found in family RP27 is the most 
common AIPL1 mutation described worldwide.15-17 This mutation was first described in a 
Pakistani family with LCA and more recently, the same mutation was found in three 
additional LCA families from Northern Pakistan.15-17 The patients described in our study were 
diagnosed at a later stage (>30 years) of the disease, but due to the macular involvement, low 
visual acuity and non-detectable ERG of the proband, a LCA phenotype could not be ruled 
out.16 
 In family RP48 the CERKL mutation c.847C>T; p.(Arg283*) was found to be causative for 
arRP. This mutation was described for an isolated CRD patient of French-Canadian origin.18 
At the age of 33, the proband of family RP48 was diagnosed to be at an advanced stage of 
arRP, as the ERG suggested a rod-cone disease pattern. However, as we observed the macula 
and fundus abnormalities (Table 5.1) and as RP and CRD phenotypes tend to converge at late 
stages of disease, we cannot rule out CRD for this family.18 A novel PDE6A variant 
c.1630C>T; p.(Arg544Trp) was identified in family RP55. The family was diagnosed with 
typical arRP, as the patients have prominent peripheral bone spicule pigmentation, arterial 
attenuation, and an intact macula (Table 5.1). PDE6A is part of a heterotetrameric complex, 
containing cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), which is 
involved in mediating the phototransduction cascade as it forms the link between light 
mediated rhodopsin (RHO) activation and cGMP-gated ion channel closure, by hydrolyzing 
the cGMP upon activation.19 Eighteen different mutations have been identified in PDE6A, the 
majority of which (56%; 10/18), are missense variants similar to the novel nucleotide change 
that we found in our family.20-25 
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At the protein level, the wild type arginine 544 is large, positively charged, and hydrophilic. 
This residue is replaced by a tryptophan in family RP5, which is even larger, neutrally 
charged, and hydrophobic. The wild type residue is present on the surface of the protein, close 
to the interaction interface with the other monomer (Figure 5.4A and B). As arginine is 
positively charged and hydrophilic, it can make important hydrogen bonds and ionic 
interactions with residues in the surrounding alpha-helices. These interactions probably 
stabilize the dimer interface necessary for the correct enzymatic function of the protein. Loss 
of these interactions due to the p.(Arg544Trp) mutations will destabilize the local structure, 
affect the interaction surface and hence affect the function of the protein. 
 
Figure 5.4 Protein modeling of PDE6A missense variant. Three-dimensional structure of 
heterotetrameric complex of cyclic guanosine monophosphate phosphodiesterase (cGMP-
PDE). (A) Structure of PDE6A (gray) and PDE6B (tan) protein complex in the native 
conformation. Arg544 is colored green. (B) Part of PDE complex showing the location of the 
mutant residue, on the surface, close to the monomer interaction site. (C) Close-up of the 
mutation. Wild-type and mutant residues are shown and colored green and red, respectively. 
Yellow dots indicate the hydrogen bond formed by the wild-type residue, which will be lost 
due to the mutation. 
                                                                                   Genetic basis of retinal dystrophies in Pakistani families 
119 
In three families the gene with the pathogenic mutation was present in the largest 
homozygous region and in one family RP03, causative gene was present in the second largest 
homozygous region. This observation therefore points towards analyzing the highest ranked 
linkage interval first while searching for the causative variants in consanguineous families 
where several homozygous regions are commonly observed. Similarly, the same information 
can be used to filter variants obtained from next-generation sequencing if linkage data are 
available. 
In conclusion, we have identified the genetic defects in four Pakistani families with retinal 
dystrophy by homozygosity mapping and sequence analysis of ABCA4, AIPL1, CERKL, and 
PDE6A. The present study will improve genetic diagnosis for other genetically 
uncharacterized patients. The identification of genetic defects will not only be helpful in 
counseling of affected individuals but will also be beneficial in selecting patients who are 
eligible for gene therapy in the near future. 
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ABSTRACT 
Homozygosity mapping has been successful in mapping autosomal recessive inherited disease 
loci. The customary consanguineous nuptials in Pakistan underlies the frequent occurrence of 
autosomal recessive (ar) inherited disorders, including retinal diseases (RD). Pakistani 
families with arRD have been instrumental in finding ten RD-associated genes and have 
enabled the recognition of novel genotype-phenotype correlations for three genes. By 
employing homozygosity mapping, we report on the identification of the causal genetic 
defects in 8 families with arRD. In another 9 families, we excluded 8 genes previously 
implicated in ar retinitis pigmentosa and Leber congenital amaurosis that were located in 
significant homozygous regions. For most families more than one homozygous region was 
identified with LOD scores varying between 1.8 and 4.0. Taking into consideration previously 
published studies, we could genetically solve 32 of 41 (78%) families, suggesting that the 
majority of genes underlying inherited non-syndromic RD have been identified. Ninety 
percent of mutations causing non-syndromic RD and all mutations causing syndromic forms 
in Pakistani families have not been reported in other human populations. Based on our 
inventory of all Pakistani RD-associated gene defects, we propose a cost-efficient allele-
specific analysis of 13 RD-associated variants that may capture up to 42% of the genetic 
causes. 
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6.1. Introduction 
Inherited retinal dystrophies (RD) belong to clinically and genetically heterogeneous 
disorders.1 The clinical sub-classification of these diseases is based on the nature of the 
disease (stationary or progressive), the inheritance pattern, and the dysfunctional part of the 
retina.2 The disease is either congenital, occurring early in life like Leber congenital 
amaurosis (LCA; MIM# 204000), or congenital stationary night blindness (CSNB; MIM# 
310500), or might have a later onset such as in retinitis pigmentosa (RP; MIM# 268000), 
cone-rod dystrophy (CRD; MIM# 604116), and cone dystrophy (CD; MIM# 602093).3 In 
addition to disorders that are confined to the eye, there are syndromic forms of the disease in 
which blindness due to retinal cell degeneration is either among the primary clinical 
symptoms or might be manifested at advanced stages. The most common syndromic form of 
RD is Usher syndrome (USH; MIM# 276900), in which RP is coupled with variable degrees 
of hearing loss and vestibular dysfunction.4 Other types of syndromic RD include Bardet-
Biedl syndrome (BBS; MIM# 209900), Senior-Loken syndrome (SLSN; MIM# 266900), 
Joubert syndrome (JBTS; MIM# 213300), and Meckel syndrome (MKS; MIM# 249000), all 
of which exhibit severe overlapping clinical features in addition to retinal degeneration.5,6 
The estimated worldwide prevalence of RD is 1 in 3,000 individuals.7 RP is the most frequent 
among these diseases, affecting 1 in 4,000 individuals.8,9 In Pakistan the frequency of RD is 
not well defined but a hospital-based study estimated it to be 1 in 800 patients, with 
autosomal recessive RP being the most prevalent.10 This is because more than 60% of 
marriages in the country are consanguineous and among them about 80% are between first 
cousins.11 In several developing countries, as opposed to the Western countries, consanguinity 
has always been a major contributing factor in the high prevalence of autosomal recessive 
disorders.12 Such consanguineous families are ideal for homozygosity based genetic mapping 
studies aimed at the identification of the underlying genetic defect.13,14 
Facilitated by several technological advances, to date 185 genes implicated in different 
inherited RD have been identified (http://www.sph.uth.tmc.edu/retnet/sum-dis.htm). Among 
these genes, 119 are linked to non-syndromic forms of the disease with genetic overlap 
between different classes.1,3,15 In the developed countries genetic testing using medium-to-
high throughput genotyping methods is now being used for proper disease diagnosis.16 This 
has resulted in the establishment of many genotype-phenotype correlations.16-18 In the last two 
decades, several studies have described the genetic causes of different retinal dystrophies in 
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consanguineous Pakistani families. However, there is no comprehensive overview of all forms 
of RD that have been studied in Pakistan. In this study we describe homozygosity mapping 
and sequence analysis results for 17 Pakistani RD families, which are part of a cohort of 41 
randomly collected Pakistani RD families. In addition, we provide an overview of all 
published genetic data of syndromic and non-syndromic retinal dystrophies that have been 
described for Pakistani families. 
6.2. Methods 
6.2.1. Genetic analyses of 41 RD families 
This study was dually approved by the institutional Ethics Committee and was conducted in 
accordance to Helsinki declaration. A panel of 41 retinal dystrophy families, including 38 
non-syndromic and 3 syndromic families (i.e., two BBS and one SNLS), were selected for 
single nucleotide polymorphism (SNP) microarray based genotyping. The non-syndromic 
cohort consisted of families with autosomal recessively inherited RP (n=31), CSNB (n=4), 
CD (n=2), and a family with X-linked RP, details of the respective families are presented in 
Table 6.1. Preliminary analysis that included patient recruitment, sample collection and DNA 
isolation have been described previously.19,20 Novel genetic data of 17 families are presented 
here. Twenty-two families from this cohort were published elsewhere.19-28 Genetic mapping 
of the panel of 41 families was carried out using single nucleotide polymorphism (SNP) 
microarrays from Illumina (10K), Affymetrix (6K), or HumanOmniExpress (700K). As most 
of the families were consanguineous and pedigree analysis suggested an autosomal recessive 
mode of disease inheritance, the homozygosity mapping approach was utilized to find the 
causal gene. The genotype data were analyzed using an online Homozygosity Mapper tool.29 
Subsequently, using Gene Hunter in the easyLINKAGE program, parametric linkage analysis 
was performed to calculate the LOD scores for the homozygous regions.30 Haplotypes were 
compared and only the regions that were identical in all the affected individuals of each 
family were considered further. Whenever available, genotype data from healthy individuals 
were used to exclude the regions that were found to be homozygous in both healthy and 
affected individuals. In case no unambiguous homozygous region was identified in families 
with multiple sibships, homozygosity mapping was performed for separate branches of the 
family. After haplotype analysis, regions were prioritized based upon size and/or the presence 
of genes known to be implicated in inherited RDs. Sequencing primers were designed from 
the UCSC genome browser (http://genome.ucsc.edu), using ExonPrimer. Sanger sequencing 
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Table 6.1 Overview of retinal disease phenotypes and affected families 
Phenotypes Clinical characteristics Families analyzed Affected individuals Solved Families Solved patients 
RP early/late onset Peripheral vision loss, night blindness, bone spicule 
pigmentary deposits,  reduced rod response 
32 187 23‡ 144 
CSNB (Oguchi, FA) Congenital stationary night blindness,   
whitish dots in fundus (FA), Mizuo phenomenon 
(Oguchi) 
4 19 4 19 
CD and ACHM Reduced central vision, poor color vision, 
photophobia, nystagmus, bull's eye macula 
2 8 2 8 
BBS Retinal dystrophy, polydactyly, obesity, intellectual 
disability 
2 4 2 4 
SLSN Early onset RP, end stage renal failure in first decade 
of life 
1 3 1† 3 
Total  41 221 32 178 
ACHM, achromatopsia; BBS, Bardet-Biedl syndrome; CD, cone dystrophy; CSNB, congenital stationary night blindness; FA, fundus 
albipunctatus; RP, retinitis pigmentosa; SLSN, Senior-Loken syndrome. ‡7 of these families are part of this study, †part of this study. 
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was carried out to screen exons and flanking intronic sequences of all RD genes residing in 
the homozygous regions in one proband from each family. Segregation analysis of identified 
mutations was also done using Sanger sequencing. Sequence variants were characterized 
based upon nucleotide conservation (PhyloP score), a bioinformatics prediction of the 
biological consequences of amino acid substitutions was performed using Polymorphism 
Phenotyping v2 (Polyphen-2) (http://genetics.bwh.harvard.edu/pph2/), and Sorting Intolerant 
from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.html), and whether the 
change affects an amino acid in a functional domain of the corresponding protein. Novel 
variants were also checked in population-matched healthy controls by restriction fragment 
length polymorphism (RFLP) analysis and/or Sanger sequencing. The exome variant server 
(EVS; a database containing variants retrieved from the National heart, lung and blood 
institute exome sequencing projects), and an in-house exome database were also checked for 
the presence of putative pathogenic variants. 
6.2.2. Literature review 
A comprehensive literature review was performed for mutations and loci which have been 
described previously for Pakistani individuals with syndromic and non-syndromic retinal 
diseases. The Retinal Network (RetNet; https://sph.uth.tmc.edu/retnet/disease.htm), National 
Centre for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/), Online 
Mendelian Inheritance in Man (OMIM; http://www.ncbi.nlm.nih.gov/pubmed/), and The 
Human Gene Mutation Database (HGMD; http://www.biobase-international.com-
/product/hgmd) were used to search for information and published literature. 
6.3. Results 
6.3.1. Homozygosity mapping and implication of previously identified causative 
genes in 8 retinal disease families 
In 7 families with non-syndromic arRD (F01-F07), and one family (F08), with SLSN (Figure 
6.1), homozygosity mapping not only revealed outstanding homozygous regions 
encompassing genes previously implicated in the respective phenotypes, but also enabled us 
to identify the causative mutations (Table 6.2). In two families novel mutations were 
identified in CNGA1 (MIM# 123825: c.1298G>A; p.(Gly433Asp) in F01), and CNGB1 
(MIM# 600724: c.2493-2A>G; p.(?) in F04). In five other unrelated non-syndromic Pakistani 
RP families, previously reported mutations were identified (Table 6.3 and 6.4). These include 
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two mutations in RPE65 (MIM# 180069: c.131G>A; p.(Arg44Gln) in F05 and c.361del; 
p.(Ser121Leufs*6) in F02), one mutation in CRB1 (MIM# 604210: c.2234C>T; 
p.(Thr745Met) in F06), and one variant in TULP1 (MIM# 602280: c.1466A>G; 
p.(Lys489Arg) in F07) (Figure 6.1, Table 6.3). In a family with nine affected individuals in 
four generations (F03; Figure 6.1), X-linked inheritance was plausible. In this family 
sequence analysis of RPGR (MIM# 312610), revealed a previously identified mutation 
(c.2426_2427del; p.(Glu809Glyfs*25); Table 6.3). 
Finally, in family F08, with SLSN, a mutation affecting one of the canonical nucleotides of a 
splice acceptor site (c.488-1G>A; p.(?)) was identified in IQCB1 (MIM# 609237), (Table 
6.4). Mutations in IQCB1 are the most frequent cause of SLSN, and the mutation we 
identified in family F08 has also been previously reported in another Pakistani SLSN 
family.31 
6.3.2. Homozygosity mapping and exclusion of previously identified causative 
genes in 9 retinal disease families 
Homozygosity mapping in three families (F09, F11, and F16), did not yield homozygous 
regions >2 Mb encompassing genes previously implicated in arRP or arLCA (Figure 6.2; 
Table 6.5). In the remaining 6 families, we excluded 8 arLCA or arRP genes located in 
homozygous regions (Figure 6.2; Table 6.5). 
Among these 9 families homozygous regions in two families reached significant LOD scores 
(>3.3) on chromosome 5 (F12), and chromosomes 11 and 10 (F09), respectively, while in two 
families (F10 and F16), LOD scores of 2.7 and 3.0 were observed, which is highly suggestive 
of linkage at chromosomes 1 (F10), and chromosomes 4 and 17 (F16). In the remaining five 
families (Figure 2), the limited number of affected individuals that were tested restricted the 
maximally achievable LOD score. Details about the homozygous regions of the respective 
families are presented in Table 6.5. 
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Figure 6.1 Pedigrees of families with inherited retinal diseases and segregation analysis 
of mutations. In Family 03 an X-linked mutation segregates; in the other families the 
inherited pattern is autosomal recessive. Black symbols represent affected individuals; open 
symbols non-affected persons. M stands for mutation identified, + is wild-type allele, M/M 
indicates affected genotypes, +/M indicates carriers of the mutant allele, and +/+ indicates 
genotypes of normal individuals. 
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Table 6.2 General information of the families describe in this study 
Family affected Homozygous 
regions (n)>2 Mb 
Size of homozygous 
region (Mb) 
Ranking of region arRP/LCA gene 
in region 
Mutation 
identified 
Mutation 
F01 3 4 18.8 1 CNGA1 Yes c.1298G>A; p.(Gly433Asp) 
F02 4 2 5.2 1 RPE65 Yes c.361del; p.(Ser121Leufs*6) 
F03 9 NA NA NA RPGR Yes c.2426_2427del; p.(Glu809Glyfs*25) 
F04 9 1 6.5 1 CNGB1 Yes  c.2493-2A>G; p.(?) 
F05 3 2 1.6 2 RPE65 Yes c.131G>A; p.(Arg44Gln) 
F06 2 5 13.4 2 CRB1 Yes c.2234C>T; p.(Thr745Met) 
4.5 3 LRAT No NA 
3.3 4 GUCY2D No NA 
F07 4 4 9.2 1 TULP1 Yes c.1466A>G; p.(Lys489Arg) 
F08 3 15 30.3 1 IQCB1 Yes c.488-1G>A; p.(?) 
30.3 1 RHO No NA 
LCA, Leber congenital amaurosis; Mb, megabases; NA, not applicable; RP, retinitis pigmentosa.
 
                                                                                                                                                                                                   Genetic causes of retinal dystrophies in Pakistan 
133 
Table 6.3 Mutations identified in Pakistani patients with non-syndromic retinal dystrophies 
Gene Nucleotide variant Protein variant Phenotype # of 
families 
# of 
patients
References 
ABCA4 c.6658C>T p.(Gln2220*) arRP 1 5 Maugeri, et al.,36 Khan et al.28 
AIPL1‡ c.834G>A p.(Trp278*) arEORP 11 25 Damji, et al.,37 McKibbin, et al.,38 Sohocki, et al.,39 Khan et 
al.28 
BEST1‡ c.418C>G p.(Leu140Val) adRP 1 4 Davidson, et al.33 
CERKL c.316C>A p.(Arg106Ser) arRP 1 3 Ali, et al.40 
CERKL c.847C>T p.(Arg283*) arRP 1 6 Avila-Fernandez, et al.,41 Littink, et al.,42 
Khan et al.28 
CLRN1† c.92C>T p.(Pro31Leu) arRP 1 6 Khan, et al.27 
CLRN1† c.461T>G p.(Leu154Trp) arRP 1 6 Khan, et al.27 
CNGA1 c.626_627del p.(Ile209Serfs*26) arRP 1 7 Zhang, et al.43 
CNGA1 c.1298G>A P.(Gly433Asp) arRP 1 3 This study 
CNGA3 c.822G>T p.(Arg274Ser) arCRD (ACHM) 1 4 Azam, et al.24 
CNGA3 c.827A>G p.(Asn276Ser) arCRD (ACHM) 1 6 Saqib, et al.44 
CNGB1 c.412-1G>A p.(?) arRP 1 10 Azam, et al.25 
CNGB1 c.2284C>T p.(Arg762Cys) arRP 1 5 Azam, et al.25 
CNGB1 c.2493-2A>G p.(?) arRP 1 10 This Study 
CNGB3 c.1825del p.(Val609Trpfs*9) arCRD (ACHM) 1 2 Azam, et al.24 
CRB1 c.107C>G p.(Ser36*) arLCA 1 10 McKibbin, et al.38 
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CRB1 c.116C>A p.(Thr39Asp) arLCA 1 6 Khaliq, et al.45 
CRB1 c.2234C>T p.(Thr745Met) arRP 1 2 den Hollander, et al.,46 this study 
CRB1 c.2536G>A p.(Gly846Arg) arRP 1 6 Khaliq, et al.45 
CRB1 c.3101T>C p.(Leu989Thr) arLCA 1 8 Khaliq, et al.45 
CRB1 c.3296C>A p.(Thr1099Lys) arRP 1 9 Azam, et al.25 
CRB1 c.3343_3352del p.(Gly1115Ilefs*23) arRP 1 9 Lotery, et al.47 
CRB1 c.3347T>C p.(Leu1071Pro) arRP 1 7 Khaliq, et al.45 
CRB1 c.3962G>C p.(Cys1321Ser) arRP 1 5 Lotery, et al.47 
EYS c.8299G>T p.(Asp2767Tyr) arRP 1 7 Khan, et al.20 
GNAT1 c.386A>G p.(Asp129Gly) arCSNB 1 1 Naeem, et al.48 
GRK1 c.614C>A p.(Ser205*) arCSNB (Oguchi) 1 9 Azam, et al.19 
GRK1 c.827+623_883del p.(?) arCSNB (Oguchi) 1 3 Zhang, et al.49 
IMPG2‡ c.1680T>A p.(Tyr560*) arRP 1 2 Bandah-Rozenfeld, et al.26 
LCA5‡ c.643del p.(Leu215Tyrfs*11) arLCA 1 4 Ahmad, et al.50 
LCA5‡ c.1151del p.(Pro384Glnfs*17) arLCA 3 13 den Hollander, et al.,51 McKibbin, et al.38 
MERTK c.718G>T p.(Glu240*) arRP 1 4 Shahzadi, et al.52 
NMNAT1‡ c. 25G>A p.(Val9Met) arLCA 1 5 Falk, et al.53 
NMNAT1‡ c.838T>C p. (*280Glnext*16) arLCA 1 8 Koenekoop, et al.54 
PDE6A c.889C>T p.(Arg256*) arRP 1 4 Riazuddin, et al.55 
PDE6A c.1264-2A>G p.(?) arRP 1 5 Riazuddin, et al.55 
PDE6A c.1630C>T p.(Arg544Trp) arRP 1 3 Khan, et al.28 
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PDE6A c.2218-2219insT p.(Ala740Valfs*2) arRP 1 3 Riazuddin, et al.55 
PDE6B c.1160C>T p.(Pro387Leu) arRP 1 6 Ali, et al.56 
PDE6B c.1655G>A p.(Arg552Gln) arRP 1 9 Ali, et al.56 
PDE6B c.1722+1G>A p.(?) arRP 1 4 Azam, et al.25 
PROM1 c.1726C>T p.(Gln576*) arRP 1 6 Zhang, et al.57 
RDH12 c.506G>A p.(Arg169Gln) arLCA/arEORD 2 2 Mackay, et al.58 
RDH12 c.619A>G p.(Asn207Asp) arLCA/arEORD 1 1 Mackay, et al.58 
RDH5 c.758T>G p.(Met253Arg) arCSNB (FA) 1 6 Ajmal, et al.22 
RDH5 c.913_917del p.(Val305Hisfs*29) arCSNB (FA) 1 2 Ajmal, et al.22 
RHO c.448G>A p.(Glu150Lys) arRP 2 6 Azam, et al.23 
RHO c.1045T>G p.(*349Gluext*52) adRP 1 8 Bessant, et al.32 
RLBP1 c.346G>C p.(Gly116Arg) arCSNB (FA) 1 4 Naz, et al.59 
RLBP1 c.466C>T p.(Arg156*) arCSNB (FA) 1 6 Naz, et al.59 
RP1† c.1118C>T p.(Thr373Ile) arRP 2 11 Khaliq, et al.60 
RP1 c.1458_1461dup p.(Glu488*) arRP 2 9 Khaliq, et al.,60 Riazuddin, et al.61 
RP1 c.4555del p.(Arg1519Glufs*2) arRP 1 5 Riazuddin, et al.61 
RP1 c.5252del p.(Asn1751Ilefs*4) arRP 1 4 Riazuddin, et al.61 
RPE65 c.131G>A p.(Arg44Gln) arEORP 1 3 Coppieters, et al.,62 Simovich, et al.,63 this study 
RPE65 c.361del p.(Ser121Leufs*6) arEORP 1 4 Coppieters, et al.,62 this study 
RPE65 c.751G>T p.(Val251Phe) arLCA 1 6 McKibbin, et al.38 
RPGR c.2426_2427del p.(Glu809Glyfs*25) xlRP 1 8 Vervoort, et al.,64 (het); this study 
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RPGRIP1 c.587+1G>C p.(?) arLCA 1 1 McKibbin, et al.38 
RPGRIP1 c.1180C>T p.(Gln394*) arLCA 1 1 McKibbin, et al.38 
RPGRIP1 c.1639G>T p.(Ala547Ser) arCRD 3 12 Hameed, et al.65 
RPGRIP1 c.2480G>T p.(Arg827Leu) arCRD, arLCA 2 8 Hameed, et al.,65 McKibbin, et al.38 
RPGRIP1 c.3620T>G p.(Leu1207*) arLCA 1 1 McKibbin, et al.38 
SAG c.916G>T p.(Glu306*) arCSNB (Oguchi) 1 1 Waheed, et al.66 
SEMA4A c.1033G>C p.(Asp345His) arRP/arCRD 4 4 Abid, et al.67 
SEMA4A c.1049T>G p.(Phe350Cys) arRP/arCRD 4 4 Abid, et al.67 
SEMA4A c.2138G>A p.(Arg713Gln) (het) arRP/arCRD 1 4 Abid, et al.67 
SLC24A1‡ c.1613_1614del p.(Phe538Cysfs*23) arCSNB 1 5 Riazuddin, et al.68 
SPATA7 c.253C>T p.(Arg85*) arLCA/arRD 2 3 Mackay, et al.69 
SPATA7 c.960dup p.(Pro321Thrfs*6) arLCA/arRD 1 6 Mackay, et al.,69 Wang, et al.70 
TTC8† c.115-2A>G p.(?) arRP 1 4 Riazuddin, et al.71 
TULP1 c.1138A>G p.(Thr380Ala) arEORP 3 30 Ajmal, et al.,21 Iqbal, et al.72 McKibbin, et al.38 
TULP1 c.1445G>A p.(Arg482Gln) arRP 1 8 Ajmal, et al.21 
TULP1 c.1466A>G p.(Lys489Arg) arRP 4 19 Gu, et al.,73 Iqbal, et al.,72 this study 
ZNF513 c.1015T>C p.(Cys339Arg) arRP 1 4 Li, et al.,74 Naz, et al.75 
ACHM, achromatopsia; ad, autosomal dominant; ar, autosomal recessive; CSNB, congenital stationary night blindness; CRD, cone rod 
dystrophy; EORD, early onset retinal dystrophy; EORP, early onset RP; FA, fundus albipunctatus; het, heterozygous; LCA, Leber 
congenital amaurosis; RD, retinal dystrophy; RP, retinitis pigmentosa; xlRP, X-linked RP; in bold lettering mutations identified in this 
study; ‡novel gene identification; †novel phenotype association. 
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Table 6.4 Mutations identified in Pakistani patients with syndromic retinal dystrophies 
Gene Nucleotide variant Protein variant Phenotype # of 
families 
# of 
patients 
References 
AHI1 c.2370dup p.(Lys791*) arJBTS 1 2 Utsch, et al.76 
ARL13B c.236G>A p.(Arg79Gln) arJBTS 1 3 Cantagrel, et al.77 
BBS1 c.47+1G>T p.(?) arBBS 1 2 Ajmal et al.78 
BBS1 c.442G>A p.(Asp148Asn) arBBS 1 2 Ajmal et al.78 
BBS10 c.271dup p.(Cys91Leufs*5) arBBS 2 4 White, et al.79 
BBS10 c.1091del p.(Asn364Thrfs*5) arBBS 1 1 White, et al.79 
BBS10 c.1958_1967del p.Ser653Ilefs*4 arBBS 1 2 (Agha et al.80 
BBS10 c.2121dup p.(Lys708*) arBBS 1 1 White, et al.79 
BBS12 c.1589T>C p.(Leu530Pro) arBBS 2 2 Harville, et al.81 
BBS12 c.2102C>A p.(Ser701*) arBBS 1 3 Pawlik, et al.82 
BBS2 c.1237C>T p.(Arg413*) arBBS 1 1 Harville, et al.81 
ARL6 c.123+1119del p.(?) arBBS 1 1 Chen, et al.83 
BBS5 c.2T>A p.(Met1Lys) arBBS 2 2 Harville, et al.81 
TTC8 c.1049+2_1049+4del p.(?) arBBS 1 3 Ansley, et al.84 
CC2D2A‡ c.2003+1G>C p.(?) arJBTS 1 5 Noor, et al.85 
CDH23‡ c.1114C>T p.(Gln372*) arUSH1 1 3 Schultz, et al.86 
CDH23 c.2587+1G>A p.(?) arUSH1 1 4 Bork, et al.87 
CDH23 Not mentioned in paper p.(Arg1305*) arUSH1 1 4 Bork, et al.87 
CDH23‡ c.3106_3106+11delinsTGGT p.(Gly1036delinsTrpCys) arUSH1 1 5 Schultz, et al.86 
CDH23‡ c.6050-9G>A p.(?) arUSH1 4 13 Schultz, et al.86 
CDH23‡ c.6050-1G>C p.(?) arUSH1 1 6 Schultz, et al.86 
CDH23‡ c.6054_6074del p.(Val2019_Val2025del) arUSH1 1 3 Schultz, et al.86 
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CDH23‡ c.6845del p.(Asn2282Thrfs*91) arUSH1 1 3 Schultz, et al.86 
CDH23‡ c.7198C>T p.(Pro2400Ser) arUSH1 1 4 Schultz, et al.86 
CDH23‡ c.8150A>G p.(Asp2717Gly) arUSH1 1 3 Schultz, et al.86 
CDH23‡ c.8208_8209del p.(Val2737Alafs*2) arUSH1 2 11 Schultz, et al.86 
CEP290  c.5668G>T p.(Gly1890*) arJBTS 1 1 Otto, et al.,88 Sayer, et 
al.89 
IQCB1 c.488-1G>A p.(?) arSLSN   Otto, et al.,31 this 
study 
IQCB1 c.1465C>T p.(Arg489*) arSLSN 1 1 Otto, et al.31 
IQCB1 c.1796T>G p.(Leu599*) arSLSN 1 1 Otto, et al.88 
NPHP4 c.3272dup p.(Ser1092Valfs*11) arSLSN 1 1 Otto, et al.31 
PCDH15‡ c.7C>T p.(Arg3*) arUSH1 1 5 Ahmed, et al.90 
PCDH15‡ c.1927C>T p.(Arg643*) arUSH1 1 3 Ahmed, et al.91 
PCDH15‡ c.3389-2A>G p.(?) arUSH1 1 3 Ahmed, et al.91 
TCTN2 c.1873C>T p.(Gln625*) arJBTS 1 4 Sang, et al.92 
TMEM67 c.647del p.(Val217Leufs*5) arMKS 1 2 Smith, et al.93 
TMEM67 c.715-2A>G p.(?) arMKS 1 1 Smith, et al.93 
TMEM67 c.1127A>C p.(Gln376Pro) arMKS 2 2 Smith, et al.93 
TMEM67 c.1575+1G>A p.(?) arMKS 3 5 Smith, et al.93 
USH1G c.163_164+13del p.(Gly56*) arUSH1 1 4 Bashir, et al.94 
ar, autosomal recessive; BBS, Bardet-Biedl syndrome; JBTS, Joubert syndrome; MKS, Meckel syndrome; SLSN, 
Senior-Loken syndrome; USH1, Usher syndrome type 1; in bold, mutations identified in this study; ‡novel gene 
identification; †novel phenotype association. 
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Figure 6.2 Pedigrees of the unsolved arRP families. Black symbols represent affected 
individuals; open symbols non-affected persons. 
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Table 6.5 Homozygosity mapping data of families without mutations in genes associated with arRP and LCA 
Family  Affected 
persons 
Chr. Flanking SNPs Chromosomal positions  (in 
hg19) 
Size of Hz regions 
(Mb) 
Ranking Hz regions LOD Score Excluded 
arRP/LCA genes 
F09 7 11 rs1825015;rs1944086 36,960,292-63,036,867 26.1 1 4.02 - 
  10 rs1986519;rs2181019  101,757,025-108,311,696  17.2 2 3.9 - 
  6 rs2050137;rs1416207  139,491,756-143,889,275  4.6 3 2.81 - 
  6 rs1367669;rs717796  123,647,417-127,789,979  4.1 4 1.65 - 
  12 rs951062;rs3847896  19,988,377-23,159,966  4.1 5 2.04 - 
F10 3 1 rs559809;rs6537756 67,035,336-113,099,290 46.1 1 2.7 ABCA4, RPE65 
F11 2 2 rs1356056;rs744397 170,232,853-178,859,118 8.6 1 1.18 - 
  15 rs782944;rs403844 61,338,477-67,296,638 5.9 2 1.90 - 
  5 rs923898;rs4702266 2,903,307-5,397,628 2.5 5 1.85 - 
F12 5 4 rs894486;rs717614 4,308,513-10,104,788 9.7 1 3.07 PDE6B 
  16 rs957078; rs163235 14,019,704-20,651,378 6.6 2 1.68 - 
  10 rs3852447;rs951308  71,737,065-76,617,479 4.9 3 2.24 - 
  12 rs1525895;rs2320519  33,966,496-38,259,123 4.3 4 2.54 - 
  6 rs1367669;rs717796  123,647,417-127,789,979 4.1 5 2.31 - 
  16 rs724466;rs2188353  22,797,852-26,444,828 3.6 6 1.20 - 
  12 rs934159;rs1042503  100,296,887-103,246,700 2.9 8 2.84 - 
  14 rs721379;rs1861891  75,902,562-78,509,980 2.6 9 1.30 - 
  4 rs1108429;rs1377290  87,165,644-89,719,368 2.5 10 2.30 - 
  5 rs723698;rs368337 146,756,993-148,815,759 2.1 11 3.34 - 
F13 5 9 rs2254168;rs1045287  113,189,213-130,774,369 17.6 1 2.54 - 
  1 rs1768673;rs2136875 220,205,020-226,606,536 6.40 2 2.20 - 
  11 rs2156449;rs2001625 126,533,749-130,598,213 4.1 3 2.51 - 
  17 rs1062935;rs599314 78,939,857-80,728,072 1.8 4 1.63 PDE6G 
                                                                                                                                                                                                   Genetic causes of retinal dystrophies in Pakistan 
141 
F14 2 2 rs1015117;rs1567804 86,740,863-101,343,638 14.6 1 1.8 - 
  10 rs2227551;rs2039305 75,669,190-89,987,183 14.3 2 1.5 RGR 
  10 rs7094359;rs6580 92,304,910-105,206,874 12.9 3 1.5 - 
  12 rs9300302;rs4883148 3,867,471-8,614,238 4.7 4 1.4 - 
F15 5 17 rs1848550;rs1984661 6,745,641-12,650,777 5.9 1 1.8 AIPL1, GUCY2D 
  21 rs1014803;rs2836301 37,094,040-39,677,589 2.6 3 1.8 - 
F16 4 17 rs7946;rs1394385   17,409,560-31,689,618 14.3 1 3.0 - 
  4 rs719786;rs1396539  109,396,732-121,108,516 11.7 2 3.0 - 
  4 rs1118570;rs963065  96,602,391-102,065,631 5.5 3 3.0 - 
F17 3 17 rs11079195;rs8079450 53,904,453-70,355,300 16.4 1 2.4 - 
  15 rs11853534;rs2238292 37,033,338-50,551,632 13.5 2 2.4 - 
  1 rs4255388;rs10920369 188,770,589-202,203,337 13.4 3 2.4 CRB1 
  11 rs11222749;rs2212450 99,968,814-112,826,867 12.8 4 2.4 - 
  16 rs11646672;rs4783573 66,487,206-68,840,588 2.3 5 2.4 - 
Homozygous regions with LOD scores >1.0 are indicated. ar, autosomal recessive; LCA, Leber congenital amaurosis; Mb, mega bases; 
RP, retinitis pigmentosa; Hz, homozygous. Note: Regions with low LOD scores carry haplotypes that are relatively frequent in the 
Pakistani population (data not shown). 
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6.3.3. Overview of molecular genetic studies in non-syndromic RD in Pakistan 
Forty-four studies have thus far reported the genetic causes of non-syndromic RD including 
arCRD, arCSNB, arLCA, and arRP in Pakistani persons, most of which belong to 
consanguineous families. Together with the results presented here, genetic data of a total of 
460 Pakistani RD patients from 106 families (Table 6.3), have been described. Among these 
retinal phenotypes, arRP was found to be the most frequently occurring RD (64%), followed 
by arLCA (18%), arCSNB (8%), and arCRD (7%; Table 6.3; Figure 6.3). Autosomal 
recessive inheritance predominates in the RD families (97%) and only two studies have 
described mutations in RHO (MIM# 180380), and BEST1 (MIM# 607854), causative of 
autosomal dominant RP.32,33 The compiled data showed that out of 119 genes known to be 
involved in non-syndromic RD, 35 different genes have been reported to be mutated in 
families of Pakistani origin (Table 6.3; Figure 6.4), reflecting the genetic heterogeneity of the 
disease in this population. The most frequently mutated genes were AIPL1 (MIM# 604392), 
CRB1, SEMA4A (MIM# 607292), TULP1, RPGRIP1 (MIM# 605446), and RP1 (MIM# 
180100: Figure 6.4). Most of the reported mutations and those we identified in our cohort 
(Tables 6.2, 6.3 and 6.4), were novel to this population except for mutations in ABCA4 
(MIM# 601691), CRB1, CERKL (MIM# 608381), RPE65, RPGR (MIM# 312610), and 
SPATA7 (MIM# 609868), which were initially identified in persons of different ethnicity 
(Table 6.3). 
6.3.4. Overview of molecular genetic studies in syndromic RDs in Pakistan 
Data of 50 syndromic RD families with a total of 127 affected individuals were collected from 
20 studies. Usher syndrome represented about 38% (19/50), of the families in this group, 
whereas BBS (30%), and MKS (14%), JBTS (10%), and SLSN (8%), accounted for the other 
families (Table 6.4; Figure 6.5). The most commonly mutated gene associated with 
syndromic RD in the Pakistani population is cadherin 23 (CDH23: MIM# 605516), mutated 
in persons with Usher type 1, followed by TMEM67 (MIM# 609884), the gene mutated in 
persons with autosomal recessive MKS (Table 6.4; Figure 6.6). 
 
                                                                                                Genetic causes of retinal dystrophies in Pakistan 
143 
 
Figure 6.3 Distribution of non-syndromic Pakistani RD families according to their 
phenotypes. Ad, autosomal dominant; ar, autosomal recessive; CRD, cone-rod dystrophy; 
CSNB, congenital stationary night blindness; LCA, Leber congenital amaurosis; RP, retinitis 
pigmentosa; xl, X-linked. 
 
 
Figure 6.4 Occurrence of gene defects in non-syndromic RD families in Pakistan. 
Numbers of families with mutations in respective genes are indicated between parentheses. 
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Figure 6.5 Prevalence of syndromic RD phenotypes. BBS, Bardet-Biedl syndrome; JBTS, 
Joubert syndrome; MKS, Meckel syndrome; SLS, Senior-Loken syndrome; USH, Usher 
Syndrome. 
 
 
 
Figure 6.6 Occurrence of gene defects in syndromic RD families in Pakistan. Numbers of 
families with mutations in respective genes are indicated between parentheses. 
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6.4. Discussion 
Although the Pakistani population is known for its high rate of consanguinity (>60%), but it 
still is remarkable that 97% of randomly sampled families with inherited RDs had an 
autosomal recessive inheritance model. It therefore is not surprising that Pakistani families 
have been instrumental in pinpointing the underlying gene defects through homozygosity 
mapping.34,35 Genetic studies of Pakistani families with RD have previously resulted or aided 
in the identification of ten novel RD genes, i.e. AIPL1,39 BEST1,33 CC2D2A (MIM# 
612013),85 CDH23 (MIM# 605516),86 IMPG2 (MIM# 607056),26 LCA5 (MIM# 611408),51 
NMNAT1 (MIM# 608700),53,54 ZNF513 (MIM# 613598),74 PCDH15 (MIM# 605514),90 and 
SLC24A1 (MIM# 603617).68 In CLRN1 (MIM# 606397), and TTC8 (MIM# 608132), genes 
previously implicated in the syndromic retinal phenotypes USH3 (MIM# 276902), and BBS 
(MIM# 209900), causal mutations were identified in persons with non-syndromic arRP.27,71 In 
addition, RP1, already known to be mutated in adRP, harbored recessive mutations in 3 
Pakistani families.60 Five RD loci including three non-syndromic, i.e. CORD8 (MIM# 
605549),95 RP29 (MIM# 612165),96 and RP32,97 and two syndromic, i.e. USH1H (MIM# 
612632),98 and USH1K,99 have also been identified in Pakistani families. 
In the 106 families with non-syndromic RDs that have been reported so far from Pakistan, 
mutations were most frequently found in AIPL1 (10%), CRB1 (8%), SEMA4A (8%), TULP1 
(8%), RPGRIP1 (8%), and RP1 (6%; Table 6.3; Figure 6.4). 
A direct comparison with other RD populations is difficult as comprehensive studies of this 
kind are rare. A recent study on the screening of Saudi Arabian RD families showed similar 
results as RP1 (15%), TULP1 (12%), RPGRIP1 (12%), and CRB1 (9%), were found to be 
frequently mutated.100 This should not come as a surprise as these populations share a similar 
genetic background.101 
A general literature study revealed arRP-associated mutations in USH2A (12%; MIM# 
276901), ABCA4 (8%), PDE6B (7%; MIM# 180072), CNGB1 (6%), and PDE6A (5%; MIM# 
180071).102 In a more recent study of 230 Dutch persons with isolated or arRP,103 the most 
frequently mutated genes were EYS (11%; MIM# 602772), and CRB1 (11%), followed by 
USH2A (10%), ABCA4 (9%), and PDE6B (7%). The absence of USH2A variants in Pakistani 
patients is probably due to the fact that the most frequent arRP-associated variant, 
(c.2299delG; p.(Glu767Serfs*21)), invariably is found in compound heterozygous states with 
the second mutation that is considered to be mild,104 precluding its detection in a 
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homozygosity mapping approach. Other differences can only be attributed to divergent 
genetic backgrounds of these populations.105,106 
The four most frequent variants, p.(Trp278*) in AIPL1, p.(Lys489Arg) in TULP1, 
p.(Asp345His), and p.(Phe350Cys) in SEMA4A (Table 6.3), explain about 22% of the non-
syndromic Pakistani RD families. The p.(Trp278*) variant has been identified as the most 
frequent AIPL1 variant in many LCA studies,107,108 suggesting that this variant is relatively 
old. Although 108/115 variants listed in Tables 6.3 and 6.4 have only been identified in 
Pakistani patients, 8 variants (LCA5, p.(Pro384Glnfs*17); RPGRIP1, p.(Ala547Ser) and 
p.(Arg827Leu); SEMA4A, p.(Asp345His) and p.(Phe350Cys); TULP1, p.(Thr380Ala); 
TMEM67, c.1575+1G>A and p.(Gln37Pro)), are more frequent than others and have not been 
identified in other studies. We therefore consider them to be population-specific. Likewise, 
variants such as p.(Met390Arg) in BBS1 (MIM# 209901), and p.(Cys91Leufs*5) in BBS10 
(MIM# 610148), that account for most of the BBS cases in the French population,109 were not 
found in Pakistani BBS cases. The 8 frequent variants mentioned above, together with 5 other 
variants RDH12 (MIM# 608830), p.(Arg169Gln); RHO, p.(Glu150Lys); RP1, p.(Thr373Ile), 
p.(Glu488*), SPATA7, p.(Arg85*), account for approximately 42% of all non-syndromic RD 
families in Pakistan. A cost-effective initial genetic screening for Pakistani persons with RD 
therefore could be to analyze these variants or a larger subset of variants such as listed in 
Tables 6.3 and 6.4, using arrayed primer extension (APEX) analysis or other allele-specific 
genotyping methods110-112 that could be specifically designed for the Pakistani population. 
By employing the approach of homozygosity-mapping and subsequent sequence analysis of 
known RD-associated genes residing in homozygous regions, 32 out of 41 (78%), families 
have been solved (Figure 6.7). These include 17 families (8 solved, 9 unsolved), which are 
described in here and 24 families solved previously.19-28 
In a total of 26 out of 32 families we performed homozygosity mapping and subsequent 
sequence analysis of candidate genes previously implicated in inherited retinal diseases. In 
most of these families 96% (i.e. 25/26), the linked region contained the known retinal disease 
gene that harbored the pathogenic mutations (Tables 6.2 and 6.3). The causative mutation in 
22 of 26 families (85%) was found in the largest homozygous region, which is not unexpected 
as the largest regions generally contain the largest number of genes. Sequence analysis of 
previously identified RD-associated genes that are located in homozygous regions was 
successful in 31 of 40 (78%), families with presumed autosomal recessive inheritance. 
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Figure 6.7 Genes mutated in current cohort of 41 families. Numbers of families with 
mutations in respective genes are indicated between parentheses. *Novel autosomal recessive 
RP genes identified in this cohort. 
In a comparable study of multiplex families, 36/63 (57%) were solved using a similar 
approach.100 
Employing homozygosity mapping and candidate gene analysis, the genetic cause could not 
be determined in 9 families with arRP (Figure 6.2, Table 6.5). For these families LOD scores 
of homozygous regions varied from 1.8 to 4.0. Highly suggestive linkage (LOD >2.7), was 
found for two families (F10 and F16), and significant LOD scores (>3.3), were found for F09 
and F12. However, only in family F10 a single homozygous region of 46.1 Mb was found on 
chromosome 1 (LOD score 2.7), which was found to be overlapping with the RP32 locus 
(MIM# 609913).97 The remaining five families showed multiple homozygous regions due to a 
smaller number of affected individuals. In each of these families, the homozygous regions can 
harbor the causative mutation, but we cannot exclude other possibilities. First, we cannot rule 
out deep-intronic causal variants in the ‘excluded’ RD-associated genes. Second, we assume 
that affected individuals from these consanguineous families carry homozygous mutations 
but, considering that there is consanguinity in ~60% of Pakistani families,11 compound 
heterozygous mutations may also be present in consanguineous families. Similarly, X-linked 
inheritance also can be suspected in families with a preponderance of affected males and no 
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male-to-male transmission of gene defects. Indeed, among 6 tested families (F03, F06, F08, 
F11, F12 and F17), with these characteristics, we identified a causal RPGR mutation in one 
family (F03; Figure 6.1). 
Our systematic approach yielded causal mutations in 78% (32/41), of families with inherited 
syndromic and non-syndromic RDs, suggesting for the first time that the majority of causal 
genes for inherited RDs have been identified. The next steps in our analyses will be the 
exclusion of mutations in genes previously implicated in allied syndromic and non-syndromic 
retinal diseases, and if not successful, next generation sequencing of the respective exomes. 
In conclusion, we have provided a comprehensive overview of genetic causes of non-
syndromic and syndromic retinal diseases in Pakistan, the results of which can be used to 
design a cost-effective screening platform for future genetic testing in Pakistan. In 
consanguineous families homozygosity-directed sequence analysis facilitates mutation 
identification. In addition, under the assumption that homozygous mutations underlie the 
retinal phenotypes, we have identified novel candidate arRP loci in 9 families, which will 
facilitate the identification of novel causal genes. 
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ABSTRACT 
Background: Retinitis pigmentosa (RP) is the most frequent inherited retinal disease, which 
shows a relatively high incidence of the autosomal recessive form in Pakistan. By combining 
several genotyping methods, we investigated the underlying genetic defects in a 
consanguineous Pakistani family with RP. 
Methods: Genome-wide high density single nucleotide polymorphism (SNP) microarrays 
were used to identify homozygous regions shared by affected individuals of the family. DNA 
of three affected and two healthy siblings was used for SNP genotyping. Genotyping data 
were then analyzed by Homozygosity Mapper, an online data analysis tool. DNA of the 
Proband (IV-1) was further analyzed employing exome sequencing. 
Results: Data analysis with Homozygosity Mapper revealed a single significant homozygous 
region on chromosome 16 shared by the 4 affected individuals that did not harbor a gene 
previously implicated in any retinal dystrophy. Linkage analysis yielded a LOD score of 2.65, 
which is highly suggestive for linkage. Subsequent exome sequencing identified a novel 
missense mutation, c.995G>A; p.(Gly332Asp), in DHX38. This mutation was found to be 
present in a homozygous state in four affected individuals while healthy siblings and parents 
of the affected persons were heterozygous for this mutation. This variant was neither detected 
in 180 ethnically matched control individuals, nor in an in-house database that contained the 
exome data of 400 individuals. 
Conclusions: By combining genome-wide homozygosity mapping and exome sequencing, a 
novel missense mutation was identified in the DHX38 gene that encodes the pre-mRNA 
splicing factor PRP16, in a Pakistani family with early-onset autosomal recessive RP. The 
phenotype is different from those associated with other retinal mRNA splicing factors. This is 
the first time a mRNA splicing gene is associated with recessive RP. 
Key words: Homozygosity mapping; exome sequencing; retinitis pigmentosa; DHX38; 
consanguineous; PRP16. 
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7.1. Introduction 
Retinitis pigmentosa (RP) (MIM268000) is a genetically and clinically heterogeneous disease, 
and one of the most frequent subtypes of retinal dystrophy.1,2 Patients with classical RP 
usually experience night blindness in their teens, followed by daytime vision defects (tunnel 
vision), and later central vision loss which, in some cases, may result in complete blindness. 
Rod photoreceptors are affected first, but gradually cone photoreceptors also die. Funduscopic 
characteristics are retinal bone spicules with atrophic areas, attenuation of retinal vessels, and 
optic disc pallor. In patients with early-onset RP (also called juvenile RP or early onset retinal 
dystrophy or EORD), symptoms appear in the first six years of life, and often it is not easy to 
distinguish early-onset RP from Leber congenital amaurosis (LCA), which comprises 
congenital onset retinal dystrophy.2 
RP displays an unusually high degree of allelic and genetic heterogeneity for a Mendelian 
disorder as eight loci and 55 different genes have thus far been identified that are known to 
cause non-syndromic RP (https://sph.uth.tmc.edu/retnet/). Approximately 70% of cases are 
due to autosomal recessive defects, 20% due to autosomal dominant defects, and 10% due to 
X-linked defects.3,4 Our goal is to identify the remaining causal mutated genes for RP, for 
LCA and the other retinal dystrophies. 
The gene encoding DEAH (Asp-Glu-Ala-His) box polypeptide 38  (DHX38: accession# 
NM_014003.3) is located on the long arm of chromosome 16 (q22.2) and consists of 26 
protein-coding exons. DHX38 encodes an ATP-dependent RNA helicase precursor mRNA 
processing factor 16 (PRP16) that contains 1227 amino acids. Human PRP16 is known to be 
involved in pre-mRNA splicing.5 
In this study, we identified the genetic cause of autosomal recessive early-onset RP in a 
Pakistani family and revealed a novel missense mutation in DHX38 associated with early-
onset RP using homozygosity mapping followed by exome sequencing. 
7.2. Methods 
7.2.1. Ethics committee approval and patient consent 
Approval for this study was granted by the ethics committee/institutional review board of 
Shifa College of Medicine and Shifa International Hospital, Islamabad, Pakistan. Approved 
Informed consent was obtained from participating individuals. 
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7.2.2. Patient selection 
A family segregating autosomal recessive RP (Figure 7.1A) was residing in a remote area of 
the Khyber Pakhtunkhwa province of Pakistan. Four affected and four healthy individuals of 
the family (Figure 7.1A) were included in the study. The proband was clinically evaluated and 
fundus photographs were taken (Figure 7.1B). Electrophysiological responses of rod and cone 
photoreceptors were also recorded according to the International Society for Clinical 
Electrophysiology of Vision (ISCEV) protocol.6 
7.2.3. Blood collection and DNA extraction 
Blood samples were collected in vacutainers containing acid citrate dextrose. A standard 
phenol/chloroform extraction method was used to isolate DNA.7 
7.2.4. Homozygosity mapping analysis 
The DNA of two healthy (IV-3 and IV-6) and three affected (IV-1, IV-2 and IV-4) siblings of 
the family were selected for genotyping with HumanOmniExpress (700K) SNP microarrays, 
from Illumina Inc. (San Diego, CA). Data obtained from SNP microarrays were analyzed by 
an online tool, Homozygosity Mapper8 to identify homozygous regions shared by the affected 
individuals. 
7.2.5. Linkage analysis 
The Gene Hunter v2.1r5 program in the easyLINKAGE plus v5.08 software package was 
used to calculate the logarithm of the odds (LOD) scores for the identified homozygous 
regions.9 
7.2.6. Exome sequencing 
The proband’s (IV-1) DNA was subjected to exome sequencing to identify the underlying 
genetic cause of the disease. Massively parallel sequencing of genomic DNA from the 
affected individual was performed on a SOLiDTM 4 sequencing platform (Life Technologies, 
Carlsbad, CA). Enrichment of exonic sequences was achieved by using the SureSelectXT 
Human All Exon v.2 Kit (50Mb), containing the exonic sequences of ~21.000 genes (Agilent 
Technologies, Inc. Santa Clara, CA). Color space reads were mapped to the hg19 reference 
genome with SOLiD LifeScope software version 2.1 (Life Technologies, Carlsbad, CA), 
which uses an iterative mapping approach. Single-nucleotide variants were subsequently 
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Figure 7.1 Genetic and clinical findings in the family. A. Pedigree of the family along with 
segregation of the mutant allele. B. Fundus photographs (left and right eye) of proband 
presenting vascular constriction, bone spicules and macular atrophy in both eyes. White 
arrows indicate macular colobomas. C. Mapped reads with mutant adenine revealing the 
c.995G>A variant (upper panel) and electropherograms of affected individual (IV-1), sibling 
carrying the heterozygous variant (IV-3), and a healthy control. D. Alignment of human 
DHX38 protein sequence (from amino acid 329 to 335) to its orthologous protein sequences 
in different species indicating evolutionary conservation of arginine at position 332 in human 
DHX38. 
called by the DiBayes algorithm using high-stringency calling settings, and small insertions 
and deletions were detected using the SOLiD Small Indel Tool. 
Variant prioritization was performed as described previously.10 In brief, we selected private 
non-synonymous exonic and canonical splice site variants, i.e. we selected for variants that 
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are not included in dbSNP135 and our in-house database (including 400 exomes at the time of 
analysis). Furthermore, under the assumption of the presence of homozygous variants, we 
only selected variants that presented in at least 80% of all reads. 
7.2.7. Candidate gene sequencing analysis 
PCR primers for DHX38 and other genes, for which validation by Sanger sequencing was 
required, were designed by Primer3 online software.11 PCR reactions were performed using 
standard conditions. Amplified PCR products were electrophoresed to check the amplification 
and then purified using PCR purification plates (NucleoFast™ 96 PCR, Cat. No. 743100.10; 
Macherey Nagel, Düren, Germany), according to the manufacturer’s protocol. Sequencing 
was done with an automated DNA sequencing platform (3730 DNA analyzer; Applied 
Biosystems, Inc., Foster City, CA). 
7.2.8. Prediction tools 
The pathogenicity of the missense variant identified in the family was analyzed using the 
online prediction tools Sorting Intolerant from Tolerant (SIFT) 
(http://sift.jcvi.org/www/SIFT_enst_submit.html) and Polymorphism Phenotyping v2 
(PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2/). 
7.2.9. Protein conservation study 
DHX38 orthologous protein sequences from different vertebrate and invertebrate species were 
aligned to study the evolutionary conservation of mutated amino acid p.(Gly332Asp) using 
Vector NTI Advance™ 2011. Homo sapiens (NM_014003), Pan troglodytes 
(ENSPTRP00000014240), Macaca mulatta (ENSMMUP00000000912), Rattus norvegicus 
(ENSRNOP00000019810), Mus musculus (ENSMUSP00000047865), Canis familiaris 
(ENSCAFP00000030010), Bos taurus (ENSBTAP00000042866), Monodelphis domestica 
(ENSMODP00000003098), Gallus gallus (ENSGALP00000037931), Tetraodon nigroviridis 
(ENSTNIP00000004088), and Drosophila melanogaster (FBpp0073717) were included in the 
alignment. 
7.2.10. Protein structure prediction 
For the assessment of possible structural changes in the mutant protein, the HOPE tool was 
used.12 Wild-type human protein PRP16 sequence (Accession number Q92620) encoded by 
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DHX38 was used to predict the mutant protein structure. 
7.2.11. Estimation of non-coverage in the known arRP/LCA genes 
To estimate the non-coverage in exome sequencing of known genes implicated in arRP/LCA, 
colour space reads were visually checked in binary alignment/map format (BAM) file. 
7.3. Results 
7.3.1. Clinical findings 
The age of onset of RP in the family was four years in all affected individuals. The 
ophthalmic examination of the proband’s eyes revealed severely attenuated retinal vessels 
throughout the entire fundus. The maculae of both eyes were severely affected showing 
unusually prominent and deep macular colobomas devoid of neuro-retinal tissue (Figure 
7.1B). All affected individuals were completely blind (no light perception). 
Electrophysiological responses of rod and cone photoreceptors of the proband were also 
severely reduced (Table 7.1). 
Table 7.1 Comparison of electrophysiological responses of rod and cone 
photoreceptors of proband and a healthy individual. 
Measured parameters using 
monopolar electrodes Adaptation 
Flash 
strength 
(cd.s/m2) 
Proband 
(IV-1)* 
Healthy 
Brother 
(IV-6) 
Standard 
Values 
(Age=30 
years) 
Scotopic 25 dB b-wave 
amplitude (µV) 
Dark 0.01 33.1 250.6 >185 
Scotopic 0 dB b-wave amplitude 
(µV) 
Dark 3.0 11.0 533.4 >419 
Oscillatory potential amplitude 
(µV) 
Dark 3.0 18.4 337.8 >110 
Photopic 0 dB b-wave amplitude 
(µV) 
Light 3.0 18.3 135.8 >102 
Photopic 30 Hz flicker amplitude 
(µV) 
Light 3.0 2.1 87.7 >70 
 
*Age of the proband was 22 years at the time of testing. 
7.3.2. Genetic findings 
High-density SNP microarray data analysis with Homozygosity Mapper yielded a single 
homozygous region of 10.9 Mb (hg19: 63.8 Mb - 74.7 Mb) defined by rs10500477 and 
rs12598704 on chromosome 16 (Figure 7.2). Employing SNP data from three affected and 
two unaffected individuals, multipoint LOD score of 2.65 was obtained by Gene Hunter 
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Figure 7.2 Homozygosity mapping results. Single homozygous region identified in the 
family is indicated by red line in the Homozygosity Mapper plot. 
v2.1r5 with marker rs11646282 (72.6 Mb), which is highly suggestive for linkage. 
In total, 29,873 variants were called as a result of exome sequencing, details of which are 
given in Table 7.2. Filtering the data allowed us to narrow down the huge list of variants to 
only two homozygous variants in two different genes, i.e., HYDIN and DHX38. The variant in 
HYDIN, c.4460T>C; p.(Glu1487Gly), was not confirmed by Sanger sequencing whereas the 
variant in DHX38, c.995G>A; p.(Gly332Asp) was confirmed. Sequence analysis (Figure 
7.1C) of this DHX38 variant further confirmed the co-segregation with the disease phenotype 
in the family. All affected siblings were homozygous for the mutant allele; parents and other 
normal individuals were carriers of one mutant allele (Figure 7.1A). The DHX38 variant 
p.(Gly332Asp) was highly conserved in different vertebrate and invertebrate species (Figure 
7.1D). The wild-type nucleotide guanine at cDNA position 995 is also highly conserved, with 
a PhyloP score of 5.34. SIFT predicted p.(Gly332Asp) as “deleterious” whereas Polyphen-2 
predicts this variant as “probably damaging” with a score of 0.998. 
Analysis of project HOPE12 predicted that the wild-type residue glycine at position 332 is the 
most flexible of all residues, and this flexibility might be necessary for the protein's normal 
function. The mutant aspartic acid at this position can abolish this flexibility and thereby 
result in an impaired function of the protein. Moreover, the mutation introduces a charge, 
which can cause repulsion of ligands or other residues with the same charge. The size of the 
aspartic acid is also bigger than the wild-type glycine residue, which might lead to sterical 
hindrance. Because of the flexible nature of the glycine residue it is possible that this residue 
is needed at this position to make a special backbone conformation or to facilitate movement 
of the protein. 
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Table 7.2 Detailed summary of exome variants identified in 
proband’s DNA 
Type of variant Quantity 
Total variants identified 29,873 
Variants in genes 23,680 
Exonic variants 14,130 
Splice site variants 1,645 
Variants in canonical splice sites 34 
Variants in micro RNA 0 
Variants in SNPs 27,449 
 Nonsense variants 47 
 Missense variants 6,152 
 Synonymous variants 6,817 
Transitions 19,653 
Transversions 7,585 
Deletions 1,490 
Insertions 1,144 
Homozyous (>0.95) 9,691 
Variants on chromosome X 470 
Variants on chromosome Y 304 
Variations of 1 bp 28,025 
Variations of 2 bp 217 
Variations of 3 bp 184 
Variations of 4 bp and more 7 
 
The identified variant was not present in 180 ethnically matched healthy controls nor is it 
present in the exome variant server (EVS) database (http://evs.gs.washington.edu/EVS/), the 
1000 genomes project (1092 exomes; (www.1000genomes.org/) and dbSNP 
(www.ncbi.nlm.nih.gov/projects/SNP/). 
To exclude an involvement of compound heterozygous changes located outside the 
homozygous regions, we performed an unbiased analysis of the exome data which resulted in 
only one pair of compound heterozygous mutations, e.g. in SRRM2. These two variants in 
SRRM2 (c.1001C>T; p.(Pro334Leu) and c.5551C>T; p.(Arg1851Cys)) were confirmed in the 
proband by Sanger sequencing, but did not co-segregate with the disease in the family. 
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Manual visualization of BAM file revealed that 57 (~8%) (Table 7.3) coding exons of known 
genes implicated in arRP/LCA were not covered in the exome sequencing. 
We also screened seven additional probands from different families (Table 7.4) in which 
significant overlapping homozygous regions encompassing DHX38 were identified but 
Sanger sequencing did not identify any causative mutation. Hence the variant identified in our 
family might be a private variant, which is causing the severe and unusual early onset RP in 
this family. 
Table 7.3: Details of uncovered exons in known genes 
implicated in arRP/LCA 
Gene Protein coding exons Uncovered exons 
ABCA4 50 4, 30 
AIPL1 6 - 
BEST1 8 3, 9 
C2ORF71 2 1, 2 
C8orf37 6 - 
CABP4 5 1 
CEP290 53 - 
CERKL 14 1 
CLRN1 4 3 
CNGA1 8 1, 2 
CNGB1 32 1, 10, 33 
CRB1 12 - 
CRX 3 1 
DHDDS 8 - 
EYS 40 15, 23, 26-32, 42 
FAM161A 6 - 
GUCY2D 18 2, 3, 4, 11, 16-19 
IDH3B 12 - 
IMPG2 19 1 
IQCB1 13 - 
KCNJ13 2 - 
LCA5 7 - 
LRAT 2 - 
MAK 13 - 
MERTK 19 - 
NMNAT1 4 - 
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NR2E3 9 1, 2, 3, 4 
NRL 2 3 
PDE6A 22 - 
PDE6B 22 1, 16 
PDE6G 3 - 
PRCD 3 1, 4 
PROM1 26 - 
RBP3 4 1 
RD3 2 3 
RDH12 7 - 
RGR 7 - 
RHO 5 - 
RLBP1 7 - 
RP1 3 - 
RPE65 14 - 
RPGRIP1 24 - 
SAG 15 - 
SNRNP200 45 5, 8-12, 30, 32 
SPATA7 12 - 
TTC8 15 - 
TULP1 15 3, 4, 13 
USH2A 71 - 
ZNF513 3 2 
Total 702 57 
  
Table 7.4 Summary of overlapping regions in seven probands along 
with ethnicity and phenotype.  
Proband Size of IBD region (in Mb) Ranking Phenotype 
Dutch 21.1 6 CRD 
French 25.0 10 arRP 
Israeli 22.0 2 arRP 
Canadian 21.2 6 arRP 
Canadian 21.9 1 arRP 
Belgian 34.0 3 USH2 
Belgian 61.5 1 LCA 
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7.4. DISCUSSION 
Here, we report a Pakistani family with early-onset RP that carries a novel missense mutation 
c.995G>A; p.(Gly332Asp) in DHX38, which was identified using homozygosity mapping 
followed by exome sequencing. In-silico prediction tools SIFT and Polyphen results indicated 
that this mutation is a potentially pathogenic mutation, and might affect the normal topology 
of the protein as predicted by HOPE analysis. This variant segregated perfectly in the family 
and was also absent in 180 ethnically matched controls and 1492 exomes of persons with 
several other inherited diseases. Exome sequencing ruled out mutations in approximately 90% 
of exonic sequences of known retinal dystrophy genes, both in a homozygous state (in 
homozygous regions >2Mb) or in a compound heterozygous state. Together, these results 
strongly suggest that DHX38 might be a rare and novel cause of severe early-onset RP in 
Pakistani population. 
DHX38 belongs to the DEAD/DEAH box family of proteins and this family consists of 57 
members.13 DEAD/DEAH box family proteins are involved in a diversity of cellular 
processes including pre-mRNA splicing, spliceosome assembly,5 modification of RNA 
secondary structure,14 cellular growth and ribosomal RNA synthesis.13 DHX38 encodes the 
pre-mRNA splicing factor PRP16 that is involved in catalyzing the second step in pre-mRNA 
splicing,15,16 as it removes the lariat and joins two exons. PRP16 binds and interacts with two 
other splicing factors, G-patch domain and KOW motifs-containing protein (GPKOW), and 
hPRP2, during the second step of pre-mRNA splicing.17 Prp16 has also been reported to have 
an ATP-independent function in the first step of pre-mRNA splicing.18 In the first catalytic 
step yeast Prp16 has a stabilizing effect on the Cwc25 binding to the spliceosome to assist in 
the splicing of branch point mutant pre-mRNAs.18 Mutations in five other spliceosomal 
factors, e.g. precursor mRNA processing factor 3 (PRPF3),19 precursor mRNA processing 
factor 6 (PRPF6),20 precursor mRNA processing factor 8 (PRPF8),21 precursor mRNA 
processing factor 31 (PRPF31)22 and small nuclear ribonucleoprotein 200kDa (SNRNP200),23 
are associated exclusively with autosomal dominant RP. SNRNP200 encoded Brr2p interacts 
with Prp16 and assists the binding of Prp16 to the spliceosome.24 This interaction may be 
affected by mutations in DHX38. Interestingly, we recently identified for the first time an 
autosomal recessive missense variant in SNRNP200 in two affected individuals from a 
consanguineous family with RP (M.I.K. et al. unpublished). This variant, p.(Arg1090Gln), 
affects the same amino acid residue of SNRNP200 that previously was found to be mutated in 
an autosomal dominant family with RP. 
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Interestingly, splicing factor genes are widely expressed but mutations in some of these genes 
exclusively result in retinal dysfunction. A possible explanation is that the vision process due 
to the constant photoreceptor outer segments renewal (10% of discs per day), requires large 
amounts of rhodopsin and other retinal proteins and that this requires higher levels of pre-
mRNA splicing as compared to other cell types.17,23 Alternatively, the splice factors thus far 
implicated in adRP might have a specific role in retinal cells by splicing a subset of pre-
mRNAs.17 Finally, it is also possible that other factors may compensate for the absent or 
lower activity of PRP16 in non-retinal cells during pre-mRNA splicing. The identification of 
a recessively inherited DHX38 mutation in the current study is of interest as it might shed 
further light on the retinal disease mechanism underlying dysfunctional pre-mRNA splicing. 
The mutated amino acid residue aspartic acid has different biochemical properties as 
compared to wild type glycine that might result in misfolding of the mutant protein. 
Misfolded proteins are mostly degraded to protect the cell from toxic effects of misfolded 
proteins.25-27 Despite all these arguments future genetic studies are required to identify 
additional autosomal recessive RP families with DHX38 variants to further strengthen the 
evidence of pathogenicity. Additional functional studies in cell systems and animal models of 
the disease might confirm the pathogenic nature of this DHX38 variation. 
Although exome sequencing is becoming popular and growing at a very fast pace it has 
coverage issues as ~8% exons of the known retinal disease genes were not covered. Hence, in 
families with new discoveries there is still a chance that variants in the known genes might 
have been missed because of coverage limitation of the technology. By comparing the SNP 
haplotypes of all affected individuals, we have excluded the involvement of these uncovered 
exons in this study, but this will most likely not be done on a routine basis. Another issue is 
that exome sequencing is detecting variations in the exonic and flanking intronic regions 
whereas deep intronic variations are missed. 
In conclusion, we identified a novel missense mutation in DHX38 in a Pakistani family with 
affected siblings employing homozygosity mapping and exome sequencing. Future research 
on DHX38 will further elaborate the molecular mechanisms responsible for the severe early 
onset of RP in this family, and improve our understanding on how dysfunction of spliceosome 
components result in non-syndromic retinal dystrophy. 
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In this thesis, a systematic approach of homozygosity mapping, dedicated Sanger sequencing 
of genes previously implicated in retinal disease and residing in significant (>2 Mb) 
homozygous regions, and exome NGS of unresolved families was employed. In this manner, 
disease-causing mutations were identified in 19 different families of which seven were novel 
mutations in known genes, eleven were previously described mutations and one potentially 
pathogenic missense mutation was found in a gene that has not yet been associated with 
retinal disease. 
Below, I will discuss the importance of the clinical evaluation of patients as a major decision-
oriented step in identifying the underlying genetic cause in inherited eye diseases. After this, 
homozygosity mapping and exome sequencing will be discussed as a powerful tool to be used 
in research as well as molecular diagnostics. In further sections, I will discuss: allelic 
heterogeneity, phenotype variability, correlations of different genotypes with specific 
phenotypes, the possibility of therapeutic intervention, linking clinicians and geneticists, and 
benefits to the patients and their families. In the last section future research directions will be 
discussed.  
8.1. Clinical evaluation, a decision making step towards genetic testing 
One of the major hurdles in this study was to obtain reliable clinical data of the affected 
individuals residing in remote areas of the Punjab and Khyber Pakhtunkhwa provinces of 
Pakistan. Good clinical data are necessary to facilitate the genetic testing of an inherited 
disorder. In the case of retinal degenerations, electrophysiological responses of the retinal 
photoreceptors are required to properly diagnose the subtype of retinal degeneration. There 
are a limited number of institutes in Pakistan that offer facilities for these diagnostic tests, 
which are mainly situated in major cities. Most of the families included in this study live in 
remote areas; therefore, only one affected individual was selected from each family for 
detailed clinical evaluation 
The clinical assessment of patients with eye disorders is mostly based on different diagnostic 
tests like the measurement of visual acuity (VA), the visual field (VF), fundus examination, 
and electroretinography (ERG). In addition, the age of the patient at the time of clinical 
evaluation is also important to distinguish between clinical subtypes of some retinal 
dystrophies (RD). Progressive and non-progressive subtypes of RD can only be differentiated 
when the diagnosis is made early and follow-up examinations are well planned and 
documented.1 Families described in the third chapter are a good example of the importance 
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of a regular clinical follow-up testing to distinguish between fundus albipunctatus (FA) and 
retinitis punctata albescens (RPA). FA and RPA are distinguishable by ERG as rod 
photoreceptors of FA patients exhibit delayed dark adaptation but rods of RPA patients fail to 
recover. In addition, RPA is a progressive disease whereas FA is considered as stationary and 
is a subtype of congenital stationary night blindness (CSNB).2 Similarly, in the case of 
syndromic retinal diseases, additional diagnostic tests are needed to establish the correct 
diagnosis. Without proper clinical diagnosis there is the possibility of a misdiagnosis leading 
to erroneous or absent genetic testing results, as in the case of Oguchi disease in which the 
identification of a GRK1 mutation led to a re-appraisal of the clinical phenotype that was 
previously incorrectly established as retinitis pigmentosa (RP).3 
The next step after successfully analyzing the clinical phenotypes is the selection of a suitable 
strategy to find the causative genetic defect, which in our study was homozygosity mapping 
in most of the families. In addition below I will discuss the power of homozygosity mapping 
in identifying the mutations in consanguineous and non-consanguineous families. 
8.2. Homozygosity mapping as a powerful tool for research and diagnosis 
This thesis describes homozygosity mapping analysis of 26 Pakistani families, 16 (61.5%) of 
which were found to have mutations in genes previously associated with retinal diseases 
including 6 novel and 10 previously discovered mutations (chapters 2, 3, 5 and 6). Two large 
consanguineous families with RP described in the second chapter had mutations in TULP1, 
one mutation has previously been reported in the Pakistani population whereas the second 
mutation was novel. In silico analysis predicted these mutations as pathogenic. In the third 
chapter two consanguineous FA families have been described to have two novel mutations in 
RDH5. Patients of these two families are potential candidates for oral supplementation of 9-
cis beta carotene. In the fifth chapter four consanguineous families have been described. In 
one family a novel missense mutation was identified in PDE6A whereas in the remaining 
three families previously identified protein truncating mutations were detected in ABCA4, 
AIPL1 and CERKL. The sixth chapter describes a total of 17 families, of which mutations in 
known retinal disease genes were detected in 8 families whereas 9 families remained 
unsolved. In 6 of the 9 unsolved families we have excluded the presence of mutations in genes 
previously implicated in autosomal recessive RP or LCA that were present in the homozygous 
region. In 3 other families there were no genes previously implicated in inherited retinal 
diseases in the outstanding homozygous regions. Therefore, in these 9 families there is a 
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possibility of identifying mutations in genes not yet implicated in these diseases. However, 
the presence of compound heterozygous mutations as well as deep intronic and promoter 
region mutations in genes previously implicated in inherited retinal diseases cannot be ruled 
out. In one family a novel mutation was identified in a gene (DHX38) that hitherto has not 
been implicated in autosomal recessive RP (chapter 7). 
Similar to a number of previous studies describing the power of homozygosity mapping in the 
identification of disease causing genes in consanguineous families,3-7 we were also able to 
identify the genetic defect in most of our consanguineous families. Similarly, this approach 
can also be used to detect disease causing mutations in non-consanguineous families,4,8-10 
which is evident from the resolution of the two non-consanguineous RP families described in 
the sixth chapter, in which mutations were identified in CNGA1 and RPE65. 
Using homozygosity mapping mutations were detected in 61.5% of families included in this 
thesis. In a previous study 30% of Leber congenital amaurosis (LCA) families were solved 
using homozygosity mapping.4 This difference indicates that the Pakistani population has 
higher potential to be used for mutation detection in known retinal disease genes using 
homozygosity mapping as compared to other populations. Similarly, homozygosity mapping 
is equally beneficial for mutation detection in outbred families as evident from the results of 
two solved families with mutations in CNGA1 and RPE65. 
Therefore, from this thesis it is evident that homozygosity mapping is a powerful tool to 
identify mutations in genes known to be implicated in inherited retinal disease, but for the 
identification of genes not previously associated with these diseases, this technique in most 
cases needs to be followed by exome sequencing.11-14 However, when an obvious candidate 
gene associated with a retinal phenotype in animal models is present in the identified 
homozygous region it can be screened for causative mutations.15-19 
8.3. The use of exome sequencing in molecular diagnosis 
In this thesis, exome sequencing proved to be a powerful technique for the identification of 
novel as well as previously identified mutations in known disease-causing genes. In addition 
exome sequencing successfully identified a potential disease causing mutation in a novel 
gene, DHX38, in a family with severe early-onset RP. 
In the fourth chapter two BBS families have been described with a novel splice donor site 
mutation and a previously identified mutation in BBS1, that were identified through exome 
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sequencing. Affected individuals of both families were diagnosed with BBS. In the patients of 
family A, intellectual disability was not present whereas in family B, patients did show 
intellectual disability. Another notable observation was the presence of polydactyly in the 
affected female but not the affected male of family A. Although exome sequencing was 
performed, this intrafamilial phenotypic variability that is mostly attributed to unknown 
modifiers remained unsolved and needs further analysis. Similarly, in silico analysis indicated 
that both mutations identified in BBS1 are likely pathogenic but in vitro studies as well as in 
vivo studies in model organism are needed to confirm the results of in silico analysis. 
In another consanguineous family (seventh chapter) with severe early-onset RP, 
homozygosity mapping was followed by exome sequencing, which resulted in the 
identification of a missense mutation in a novel putative disease causing gene, DHX38. Since 
to date, no second mutation in DHX38 has been described to be causative for RP, there is as 
yet no conclusive proof that DHX38 variants underlie retinal degeneration. In this family 
initial homozygosity mapping aided in the narrowing down of a huge list of variants that were 
identified in exome sequencing, to prioritize the variants for segregation analysis. In addition, 
uncovered exons of known retinal disease genes were excluded by haplotype comparison that 
was not possible in the absence of homozygosity mapping data. 
Based on these findings, exome sequencing has the potential to be used in the Pakistani 
population for the molecular diagnosis of inherited eye diseases as well as other commonly 
inherited diseases like deafness, microcephaly, familial hypercholesterolemia etc. But for the 
identification of novel disease causing genes homozygosity mapping has its own advantage in 
combination with exome sequencing. The Pakistani population has a high rate of 
consanguineous marriages; therefore, homozygosity mapping can be used as an initial step 
before proceeding to the exome sequencing. Currently, an exome sequencing facility is not 
available in Pakistan. 
As homozygosity mapping is a powerful technique in the identification of disease-causing 
loci/genes and exome sequencing is a comparatively fast and cheap method, a future 
systematic approach that can be used for the genetic screening of Pakistani patients and 
families with inherited retinal as well as other inherited disorders has been proposed in Figure 
8.1. In a molecular diagnostic setup, exome sequencing, followed by bioinformatic analysis 
focusing on the known retinal disease genes, may lead to the identification of the disease 
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causing mutations in more than 60% of the patients. In case of exclusion of the known genes, 
a discovery of novel genes might require further research.  
Exome sequencing can lead to three different possibilities (Figure 8.1). One possibility is the 
detection of homozygous or compound heterozygous protein-truncating mutations in the 
genes that are highly expressed in the retina or involved in a retinal pathway. The second 
possibility is the identification of homozygous or compound heterozygous missense mutations 
in retinal genes. There is a need to optimize a protocol for the evaluation of identified-variant 
pathogenicity to confirm the involvement of a particular variant. The third possibility is to 
filter out a causative mutation from a large number of variants identified in the exome 
sequencing. This last task is the most challenging one as it is difficult to prove the role of a 
large number of mutated genes in the retinal processes. Hence for this issue, homozygosity 
mapping and linkage analysis are of great value. Haplotype comparison and calculation of 
LOD-scores could lead to a valuable conclusion. In the future, it is hoped that pathogenicity 
assessment of most of the identified variants will be easily available but the selection of 
causative variants will still be a challenge in the presence of thousands of variants identified 
in the exome sequencing. 
8.4. Allelic heterogeneity, phenotype variability, and the establishment of genotype-
phenotype correlations 
Inherited eye diseases generally exhibit clinical and genetic heterogeneity, the phenotypes can 
vary between individuals with the same or different genetic variants in the same gene.1,20-23 
Therefore, linking different genetic mutations to the exact phenotypes in affected individuals 
enhances the possibility of finding causative variants. Families described in the second 
chapter were found to carry TULP1 mutations, which is a good example of making use of a 
genotype-phenotype correlation.24 It had previously been observed that the formation of a 
perifoveal ring around the macula of affected individuals was characteristic of TULP1 
mutations.4 During the initial diagnosis of the relevant families we did not notice the 
perifoveal ring. However, after performing the homozygosity mapping, and subsequent 
mutation detection in TULP1, we re-evaluated the clinical findings in the families, upon 
which the perifoveal rings were observed. This again highlights the need for a clinical 
diagnosis by an expert clinician who can critically evaluate the patient phenotypes. 
The perifoveal ring was found to be present on the fundus of all the affected individuals in 
one family carrying TULP1 mutations. However, in the other family this ring was incomplete, 
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Figure 8.1 Flow chart showing proposed steps in the identification of genetic causes of 
inherited diseases in Pakistani population. 
which suggests that when the perifoveal ring is seen on the fundus it is worthwhile to screen 
the TULP1 gene before using other techniques, such as homozygosity mapping, linkage 
analysis or exome sequencing, thereby saving time and money. 
In total three TULP1 mutations, one novel (p.(Arg482Gln)) and two previously identified 
mutations (p.(Thr380Ala) and p.(Lys489Arg)) were identified in the current study.25,26 
Families described in the third chapter are a good example of a genotype-phenotype 
correlation of RDH5 mutations which are associated with typical white dots in the mid-
periphery of the retina. Novel RDH5 mutations (p.(Val305Hisfs*29) and p.(Met253Arg)) 
were identified in two consanguineous Pakistani families with FA patients.27 The FA patients 
of family B carrying the same RDH5 mutation and variable phenotypes exhibit clinical 
heterogeneity. As in the families with the TULP1 mutations, families with RDH5 mutations 
were initially subjected to SNP microarray analysis without detailed clinical evaluation, 
which resulted in the identification of a homozygous region containing the RDH5 gene in 
both families. Upon subsequent clinical evaluation of the affected individuals of both 
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families, they were diagnosed as FA patients. 
An overview of all published RDH5 mutations was analyzed to determine genotype-
phenotype correlations. It was observed that the presence of white dots was the only shared 
clinical feature among persons with RDH5 mutations.27 Thus, it can be concluded that the 
presence of white dots on the fundus are characteristic of persons carrying RDH5 mutations 
and that the initial screening of RDH5 gene is mandatory in FA patients. Upon exclusion of 
RDH5, two other genes, RLBP128 and RPE65,29 can be screened to determine the causative 
mutations. Another important finding was the presence of macular degeneration in elderly 
patients of both families, which might suggest a progressive course of disease. Follow-up 
fundus examination of younger patients who do not have macular degeneration at this stage is 
required and if they develop any signs of macular degeneration then this disease can be 
classified as RPA instead of FA.2 
In the fourth chapter two Bardet-Biedl syndrome (BBS) families with BBS1 mutations 
(c.47+1G>T and p.(Asp148Asn)) are described. Affected individuals of family A were found 
to have the same BBS1 splice donor site mutation but the proband’s sister also had 
polydactyly, which was not present in the proband. This intra-familial phenotype variability 
might be due to some other still unknown genetic modifier present in the family. This is also 
supported by the observation that in Bardet-Biedl syndrome (BBS) families, the effect of 
modifier alleles on the patient phenotype is well documented.30 Affected individuals of both 
families had sufficient clinical features for assigning a BBS status. This points to our 
observation that in clearly diagnosed families genetic testing provides conclusive results. 
In the fifth chapter four consanguineous RD families have been described with recurrent 
nonsense mutations in ABCA4, AIPL1 and CERKL, and a novel missense mutation in PDE6A. 
A previously identified mutation p.(Gln2220*) in ABCA431 was identified in all affected 
individuals of the family. 
A second previously identified nonsense mutation (p.(Trp278*)) was identified in AIPL1 in a 
family with early-onset RP/LCA. AIPL1 mutations are mostly associated with LCA25,32,33 but 
we could not establish a correlation between this mutation and its associated phenotype, 
which can be further used for population screening to identify additional patients carrying this 
mutation. 
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A third previously identified nonsense mutation (p.(Arg283*)) was identified in CERKL in a 
family with RP. Previously this mutation was identified in Spanish patients.34 Comparison of 
phenotypes did not reveal any link between the type of the mutation and the severity of the 
phenotype. 
In the fourth family a novel mutation (p.(Arg544Trp)) was present in PDE6A. In silico 
analysis predicted that this mutation is likely to be pathogenic but like the above mentioned 
three families a genotype-phenotype correlation was not established. 
In the sixth chapter a comprehensive overview of the retinal diseases in the Pakistani 
population highlights the association of different gene defects and corresponding phenotypes. 
A previously identified mutation (c.488-1G>A) in IQCB1 was found in a family of affected 
individuals with retinal vessel attenuation in two affected brothers. Optic disc drusen were 
present in both eyes of the proband only. The youngest brother was diagnosed as RP sine 
pigmento. Although in the absence of any complaints these patients were not tested for renal 
defects, they are likely to develop renal malfunctions later in life, as IQCB1 mutations are 
known to be associated with nephronophthisis.35 Future follow-up studies are needed to 
confirm the severity of the disease in this family. 
Mutations in other retinal disease-associated genes such as NR2E3 and TULP1 have also been 
reported to cause phenotype variability in patients belonging to the same as well as different 
families, and this variability is thought to be a result of modifying effects of unknown trans-
acting alleles.22,23 A modifying effect of variants in RPGRIP1L (p.(Arg744Gln)) and IQCB1 
(p.(Ile393Asn)) have previously been reported in X-linked RP patients with RPGR 
mutations.36 
Two recurrent RPE65 mutations (p.(Arg44Gln) and p.(Ser121Leufs*5)) were identified in 
affected members of two families. Mutations in this gene are known to be associated with 
recessive and dominant forms of RP, as well as autosomal recessive forms of Leber 
congenital amaurosis,37-42 Very recently, compound heterozygous mutations in RPE65 have 
been reported in FA.29 Due to this phenotypic variability it is difficult to establish a 
conclusive relationship between identified mutations and associated phenotypes for these two 
families with RPE65 mutations. 
CNGB1 and CNGA1 are rod specific proteins and are subunits of the cyclic nucleotide gated 
(CNG) channel. In this thesis a novel CNGB1 splice site mutation, c.2493-2A>G, was 
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identified in a large consanguineous family. Previously, CNGB1 mutations have been reported 
to cause RP in families of different ethnic origins.43,44 Currently, as there is no established 
genotype-phenotype correlation for CNGB1 mutations, we were thus unable to establish any 
significant relationship between genotype and phenotype of the affected individuals. Another 
novel mutation was found in CNGA1 (c.1298G>A; p.(Gly433Asp)) in a family with RP 
patients. Mutations in this gene are also known to cause RP in a few families including one 
Pakistani family.45,46 As in persons with RPE65 and CNGB1 variants there are no significant 
differences in the phenotype of patients with CNGA1 mutations as compared to the phenotype 
of patients with mutations in other genes. 
A common recurrent mutation, p.(Thr745Met), in CRB1 was found to be the underlying 
genetic defect in another family in this study. This variant has been found in persons with 
LCA, early-onset RP and classical RP, but no clear genotype-phenotype correlation has been 
established previously.47-49 
In all families in which only males were affected, haplotype analysis of the RPGR and RP2 
containing regions of the X-chromosome could not exclude their involvement. We sequenced 
RPGR and found a previously identified RPGR mutation, p.(Glu809Glyfs*25),50 in one 
family. Clinical data of this family were not available; therefore, follow up examination is 
needed to investigate any genotype-phenotype correlation. 
In the seventh chapter, a novel candidate gene implicated in severe early-onset RP has been 
described. In a consanguineous family, genome-wide homozygosity mapping identified a 
single homozygous region, where there were no previously implicated genes in this region. 
Upon exome sequencing analysis of the proband, a potentially pathogenic homozygous 
missense variant (p.(Gly332Asp)) was identified in DHX38, that segregated in this family. 
DHX38 is also known as PRP16 and is involved in the catalysis of the second step in pre-
mRNA splicing. Previously, splicing factor gene mutations have been shown to cause 
autosomal dominant RP. In the current study we hypothesize the involvement of DHX38 in 
autosomal recessive RP. In addition, this mutation was not found to be present in ethnically 
matched controls. Sequence analysis was conducted of DNAs from other inherited retinal 
disease families with outstanding homozygous regions encompassing DHX38, but we did not 
find any other mutation in DHX38. However, the high evolutionary conservation of the 
mutated nucleotide and amino acid residue, the absence of this variant in 180 ethnically 
matched control individuals, its presence in the largest (10.9 Mb) homozygous region, and the 
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absence of other variants in exome sequencing, argue that DHX38 is a plausible rare genetic 
cause of severe early-onset RP. But, further studies are needed to prove the retinal 
pathogenicity of mutations in DHX38. 
One of the main objectives of the current thesis was to set a foundation towards the treatment 
of inherited eye diseases based on genetic knowledge. Therefore in the following section I 
will discuss different possibilities of therapeutic interventions for the individuals with 
inherited retinal diseases in which the causative variants have been identified. 
8.5. Possibility of therapeutic intervention 
The identification of causal DNA variants is the first step towards the treatment of inherited 
retinal diseases. Based on the type of mutations some of the inherited eye diseases can be 
prevented by oral supplementations, such as the treatment of FA with 9-cis beta carotene.51 In 
our study the affected individuals of two families with RDH5 mutations are good candidates 
for 9-cis beta carotene therapy.27 
Another treatment option is available for individuals with RPE65 mutations as the underlying 
genetic cause of the disease.52-56 RPE65 gene therapy trials have proven to be successful in 
human subjects, which involve the delivery of a recombinant vector containing a normal copy 
of RPE65 to RPE cells. It has been suggested that RPE65 gene therapy is more effective in 
children as compared to adults,52 as in the latter the disease has progressed to a stage where 
gene therapy is ineffective. Besides this, gene therapy patients with RPE65 mutations can 
benefit from the most recently developed oral drug QLT091001, which is a synthetic cis 
retinoid. Patients who received QLT091001 therapy were found to have significant visual 
improvements (http://clinicaltrials.gov/ct2/home). 
In this thesis affected individuals of two families were diagnosed with RPE65 mutations. The 
main hurdle to implement gene therapy in these patients was the lack of expertise. In addition, 
follow up examinations are also required to detect the efficacy of the injected vector. 
Therefore if the patients are to benefit from this intervention it is imperative to establish a 
cost-effective and easily accessible gene therapy facility in Pakistan. 
Based on the above findings different treatment options can be considered for the patients. For 
this purpose the establishment of a strong link is required between clinicians and geneticists. 
Below I discuss the need for establishing a functional link between these two important 
entities of genetic research. 
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8.6. Linking clinicians and geneticists 
One of the major objectives of the current research was to establish a strong link between the 
clinical practice and genetic testing by spreading the knowledge of molecular genetics and 
emphasizing the importance of identifying the genetic defects in affected individuals with 
inherited eye disorders in Pakistan. This objective is not achievable without the consent of 
practicing clinicians as they are the main contact persons for the patients in the hospitals. 
Geneticists can help the clinicians by identifying the genetic causes, and the clinicians can 
implement the results of genetic testing by providing genetic counseling and treating the 
patients with available therapies. 
Exploration of the gene based molecular therapeutic options by clinicians can go a long way 
in the improvement of the society. Although the molecular therapeutics field is an emerging 
field it will take several years before treatments have passed the trial phases and will become 
routinely available. Overall, it is worth to mention that the current experience with gene 
therapy is that it takes at least ten years from gene discovery to first clinical trial, and at least 
another five years for going through these trials. In the mean time, clinicians with knowledge 
of the molecular basis of the patients’ diseases may be able to satisfy the psychological needs 
of the patients. 
The following section is dedicated to the discussion of possible benefits to the participating 
patients and their families. 
8.7. Benefits to the patients and families 
The work presented in this thesis will be beneficial to the participating affected and healthy 
individuals in many ways. Firstly, affected individuals can benefit from readily available 
therapeutic options (oral supplementations etc.). In our study two families with RDH5 
mutations may benefit from oral supplementation of 9-cis beta carotene. Secondly, genetic 
counseling of persons carrying a mutation in a heterozygous or homozygous state may guide 
them to select their future spouses to prevent the disease from spreading in the family. These 
two benefits are the foremost options which can be immediately implemented. Another direct 
benefit to the patients is the monitoring of their disease progression by follow up 
examinations, which might be beneficial in slowing down the disease progression. 
Based on the current knowledge, only a limited number of persons with retinal diseases would 
be amenable for the currently available gene therapy trials, although due to cost issues most of 
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the patients residing in the developing countries are still far from benefitting from this option. 
Therefore, in this situation, genetic counseling remains the only option for people who have 
affected siblings or other near relatives. Proper counseling and documentation of the disease 
based on the genetic testing may aid in the correct diagnosis,57 without which sometimes even 
expert clinicians may misdiagnose a disease. Patients with inherited disorders often become 
hopeless when they keep on visiting a number of health care providers and are unable to 
receive proper therapeutic intervention or advice. 
In this thesis, we identified a mutation in IQCB1 (sixth chapter) in a consanguineous family, 
which has been implicated in Senior-Loken syndrome. Patients with IQCB1 mutations often 
experience kidney malfunction later in life.58,59 Identification of an IQCB1 mutation in this 
family allows a detailed monitoring of renal function, and as a result, proper management is 
possible in order to delay the disease progression, which had not been possible without this 
molecular evidence. In families with mutations in BBS1, CNGA1, CNGB1, CRB1, RPGR and 
TULP1 genetic counseling at this moment is the only option as currently there is no oral 
supplementation or gene based therapy available for patients with mutations in these genes. 
Similarly, a family described in the seventh chapter with a DHX38 variant has the only 
option of genetic counseling to prevent the spread of the disease in the next generations. We 
still need to keep in mind that the DHX38 variants have not been proven beyond doubt that 
they are causative. Another benefit of such research is that affected persons gain knowledge 
of the molecular basis of their disease. This option is not very helpful for illiterate patients, 
but well educated relatives might help to educate them about the disease and its genetic 
etiology. With the spread of genetic knowledge there is the possibility of establishing patient 
support groups that in future may aid in raising funds for the development of therapies for 
inherited eye diseases. 
8.8. Future research directions 
Genetically, inherited eye diseases like many other genetic disorders are a great 
socioeconomic burden on the families with single or multiple affected individuals, as they 
cannot cope with their social liabilities and always remain dependent on their families. This is 
especially so in Pakistan, where the disability of affected individuals exerts extreme 
psychological pressure on them. But with the advent of modern molecular biology techniques, 
modern research has begun to unravel the molecular causes of human diseases, which has 
now lit a candle in the dark for such patients and their families, who are enthusiastically 
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taking part in such genetic screenings. 
Currently, the whole field of molecular genetic research have seen a revolution and new 
methods are continuously being developed that are faster, more accurate and cost effective. 
However, this revolution has still not improved the patients’ quality of life from the genetic 
testing perspective, and the patient is still far from benefiting from the available genetic 
therapies. Hence, there is a need to streamline each and every step of genetic research; the 
first and foremost thing in this regard is the establishment of a central facility to enroll 
patients with inherited eye disease for which currently no treatment is available. The next step 
would be the genetic testing, which is already being done at different laboratories in Pakistan. 
Another important aspect of the future research direction is the development of a cost-
effective method for the screening of 13 most commonly inherited mutations (sixth chapter) 
that are prevalent in the Pakistani population. An arrayed-primer extension (APEX) 
microarray may be the most suitable and cost-effective method for screening purposes. This 
method may identify more than 40% of the genetic causes of inherited retinal dystrophies. 
Although APEX will become obsolete within the next few years and most probably exome 
sequencing and whole genome sequencing in combination with most advanced techniques 
like ion torrent and nano pore technology will completely take over, this can at least bridge 
the gap till the spread of new technologies. 
Further, there is a need to suitably convey the outcome of the genetic testing to the family. For 
this purpose a central patient enrollment facility should be advised to arrange genetic 
counseling experts, who can then advise the families and patients. 
Another important issue is the financial situation of the patient, which should always be kept 
in mind. Establishment of a transparent fund raising agency for genetic testing is likely to 
solve this issue though it is a difficult step. After these issues have been addressed, we can 
proceed further in helping the affected individuals. Although in countries like Pakistan there 
is a shortage of state-of-the-art facilities, it is still possible to solve these issues by 
establishing strong connections with international research organizations that can provide 
access to their facilities. Professionals will need to continue their efforts to convince the 
patients as well as clinicians to participate in genetic screening studies. 
One important issue, which needs to be addressed in the future, is the pathogenicity 
assignment to different mutations identified in affected individuals of different families. 
Currently, in most of the studies and in this thesis pathogenicity is assessed using in silico 
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tools. In addition, segregation analysis and absence of variations in healthy controls are used 
to confirm the pathogenic status of different mutations in genes. With the advent of exome 
sequencing techniques, the number of identified variants has increased tremendously. This 
situation has further complicated the issue of pathogenicity assessment. In the current scenario 
people are concentrating on those variations that are present in the identified homozygous 
regions (in consanguineous families) or compound heterozygous variants (in outbred families) 
and potentially pathogenic according to the in silico tools. 
Finally, we successfully solved 19 (67.8%) families using homozygosity mapping and exome 
sequencing combined with Sanger sequencing. In 9 (32.2%) families, exclusion of known loci 
indicated the presence of novel disease causing genes.  
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Summary 
A total of 26 consanguineous and 2 non-consanguineous families with inherited eye diseases 
and multiple affected siblings were included in the current study. With one exception, 
homozygosity mapping using single nucleotide polymorphism (SNP) arrays was used to find 
genomic regions potentially carrying the mutated genes in the families. In two families, 
exome sequencing was performed directly without first conducting SNP microarray analysis. 
This allowed us to benefit directly from this technology and also allowed us to assess the 
power of exome sequencing in the diagnosis of inherited disorders. In 18 families, mutations 
were identified in genes previously implicated in inherited retinal diseases. Our main focus 
remained on autosomal recessive forms of retinitis pigmentosa (arRP), fundus albipunctatus 
(FA), and Bardet-Biedl syndrome (BBS). In one family, a causative variant was found in the 
X-linked RPGR gene. In the remaining nine families we could not identify causal genes. 
In the general introduction (first chapter), a brief anatomy of the human eye including the 
retina and photoreceptors was described. The mechanism of the phototransduction cascade 
and the retinoid cycle were also explained in detail. Three types of inherited eye diseases, i.e. 
RP, FA and BBS, were introduced. Different techniques used in the identification of genetic 
defects were described briefly as well as the currently available treatment and prevention 
options for persons with inherited eye diseases.  
Chapter 2 describes an early-onset form of autosomal recessive early-onset RP in two large 
consanguineous families, in which recurrent and novel mutations in TULP1 were the 
underlying genetic cause. TULP1 belongs to the tubby like family of proteins and is 
exclusively expressed in retina, where it takes part in the transport of rhodopsin from the 
photoreceptor inner segment to the outer segment. The p.(Thr380Ala) variant identified in one 
of the present families was previously identified in two Pakistani families. Identification of 
the same mutation in a large family with multiple affected siblings in the current study 
highlights the possibility of a Pakistani founder allele. The second mutation identified in 
TULP1, p.(Arg482Gln), was novel, and likely affects the tubby domain of TULP1. Three 
dimensional protein structure modeling also predicted structural modification that may affect 
the normal function of the protein, ultimately impairing vision. 
The third chapter is dedicated to another form of retinal disease known as autosomal 
recessive FA. In this chapter two novel mutations were identified in RDH5 
(p.(Val305Hisfs*29) and p.(Met253Arg)) to be the cause of FA. RDH5 is predominantly 
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expressed in the retinal pigment epithelium (RPE) where the encoded protein is an important 
part of the visual cycle, involved in the regeneration of the chromophore 11-cis retinal. 
Through collecting all published RDH5 variants, this chapter also investigated genotype-
phenotype correlations for RDH5. Mutations in this gene were found exclusively in persons 
with white dots on the fundus. Thus, the presence of white dots on the fundus suggests an 
initial sequence analysis of RDH5, followed by the analysis of RLBP1 and RPE65, two genes 
that have also been associated with FA. Another important finding of the current study was 
the presence of macular degeneration in elderly patients of both families, which may suggest 
the progressive nature of the disease. Follow up fundus examination of younger patients 
without macular degeneration is mandatory and if they show any signs of developing macular 
degeneration then that might confirm the diagnosis of retinitis punctata albescens (RPA) 
instead of FA in these families. 
In the fourth chapter, two families with BBS have been described in which two different 
BBS1 mutations (c.47+1G>T and p.(Asp148Asn)) were identified. BBS is a syndromic form 
of rod-cone dystrophy and most of the genetic subtypes are considered ciliopathies. The 
presence of severe phenotypes in both families contradicts the conclusions of a previous study 
which found the BBS1 mutations to have a less severe phenotype as they had better visual 
acuities and better electrophysiological response of rods and cones (Daniels et al., Archives of 
Ophthalmology, 130, 901-907, 2012; Estrada-Cuzcano et al., Archives of Ophthalmology, 
130, 1425-1432, 2012). Another finding of our study was the intra-familial phenotypic 
variability in one family in which the affected sister had polydactyly whereas the affected 
brother did not. This probably can be attributed to the presence of unknown modifiers. This 
chapter also describes the suitability of exome sequencing for the diagnosis of inherited 
diseases in families where the disease can be caused by mutations in a number of different 
genes. 
In the fifth chapter, four consanguineous families with retinal dystrophy have been described 
to have recurrent and novel mutations in four different genes, respectively. Previously 
described protein-truncating mutations were identified in ABCA4, AIPL1 and CERKL in three 
families, whereas a novel missense mutation was identified in PDE6A in the fourth family. 
This chapter also demonstrates the power of homozygosity mapping in identifying the 
disease-causing mutations in consanguineous families. 
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The sixth chapter provides a comprehensive overview of the genetic causes of syndromic 
and non-syndromic inherited retinal diseases in Pakistan. In addition, the causal variants in 
genes previously implicated in inherited retinal diseases are documented for 8 different 
families. A novel CNGA1 mutation ( p.(Gly433Asp)) and a novel CNGB1 mutation (c.2493-
2A>G) were identified in two RP families, while in 6 other families mutations in CRB1, 
IQCB1, RPE65, RPGR and TULP1 were identified that had been found previously. In 
addition, we also present the data of 9 families with homozygous regions lacking genes 
previously implicated in inherited retinal diseases or in which the latter genes were excluded 
to carry causative variants using Sanger sequencing. For these families LOD scores of 
homozygous regions ranged from 1.8 to 4.0. In two families highly suggestive linkage (LOD 
>2.7), was found whereas for two other families significant LOD scores (>3.3), were found. 
However, in one family a single homozygous region of 46.1 Mb was found on chromosome 1 
(LOD score 2.7), which overlapped with the RP32 locus (Zhang et al., Human Genetics, 118, 
356-365, 2005). The remaining five families contained multiple homozygous regions. 
Although we cannot exclude possibilities of deep intronic and compound heterozygous 
mutations as well as mutations in promoter regions of excluded genes in these families, there 
is a strong possibility of finding mutations in ‘novel’ disease causing genes, and exome 
sequencing analysis is currently ongoing for these families. 
A consanguineous family described in the seventh chapter was found to have a novel 
mutation (p.(Gly332Asp)) in DHX38, which was shown to segregate with the disease in the 
family. DHX38 mutations can be a novel cause of severe early-onset RP. Further, studies on 
additional families as well as functional assays in animal models may shed further light on the 
possibility of establishing a clear genotype-phenotype correlation in this family.  
In the eighth chapter, results of the research presented in this thesis have been discussed 
from different perspectives. First of all the need for correct and timely clinical evaluation has 
been highlighted which can assist the choice of genetic testing. The heterogeneous genetic 
nature and phenotypic variability of inherited retinal eye disorders were also discussed. The 
power of homozygosity mapping in the identification of retinal diseases in consanguineous 
families has also clearly been demonstrated. Genotype-phenotype correlations have been 
shown to be a very useful aspect in genetic screening. Possible treatment and prevention 
options, benefit of this research to patients, and future aspects like facilitating the patients in 
managing the disease, improvement of screening protocols in terms of cost-effectiveness and 
robustness, and financial status of the patients were also discussed. 
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This research will hopefully set the foundation for the better management and prevention of 
inherited retinal diseases in Pakistani patients in the future and will be helpful in improving 
the quality of life of affected persons and their family members. 
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Samenvatting 
In totaal werden 26 consanguine en 2 niet-consanguine families met erfelijke oogziekten 
geïncludeerd in deze studie. Met uitzondering van één familie werd homozygotie mapping 
uitgevoerd bij deze families m.b.v. ‘single nucleotide polymorphism’ (SNP) arrays. Met deze 
techniek werden genomische gebieden gezocht die oorzakelijke mutaties bevatten. In twee 
families werd exome sequencing gedaan zonder dat hieraan een SNP microarray analyse 
vooraf ging. Hiermee konden wij direct deze nieuwe technologie benutten voor het stellen van 
een genetische diagnose. In 18 families werden mutaties gevonden in genen die eerder 
geassocieerd waren met erfelijke netvliesziekten. Onze aandacht ging vooral uit naar 
autosomaal recessieve vormen van retinitis pigmentosa (arRP), fundus albipunctatus (FA), en 
Bardet-Biedl syndroom (BBS). In één familie werd een oorzakelijke variant gevonden in het 
X-gebonden RPGR gen. In de overige 9 families werden geen oorzakelijke mutaties 
gevonden.  
In de algemene inleiding (Hoofdstuk 1), wordt de anatomie van het menselijke oog 
beschreven met speciale aandacht voor het netvlies en de fotoreceptoren. De fototransductie 
cascade en de retinoid cyclus werden in detail beschreven. Drie types van erfelijke 
oogziekten, d.w.z. RP, FA en BBS, worden geïntroduceerd. De verschillende technieken die 
gebruikt worden voor het opsporen van genetische defecten worden gepresenteerd, als ook de 
momenteel beschikbare mogelijkheden voor behandeling en preventie voor personen met 
erfelijke oogziekten. 
Hoofdstuk 2 beschrijft een vroeg optredende vorm van autosomaal recessieve RP in twee 
grote consanguine families, met eerder beschreven en nieuwe TULP1 mutaties. TULP1 
behoort tot de tubby-eiwitfamilie en komt exclusief tot expressie in het netvlies, waar het 
betrokken is bij het transport van rhodopsine van de binnenste naar de buitenste segmenten 
van de fotoreceptoren. De p.(Thr380Ala) variant die werd gevonden in één van de in deze 
studie onderzochte families was eerder geïdentificeerd in twee Pakistaanse families. 
Identificatie van dezelfde mutatie in een grote familie met meerdere aangedane broers en 
zussen ondersteunt het idee dat hier sprake kan zijn van een Pakistaanse mutatie die specifiek 
voorkomt in de Pakistaanse populatie. De tweede mutatie, gevonden in TULP1, 
p.(Arg482Gln), is nieuw en heeft waarschijnlijk een storend effect op het tubby domein van 
TULP1. Ook in een voorspelde 3-dimensionale eiwitstructuur van TULP1 heeft deze 
aminozuur substitutie een negatieve invloed op de functie van TULP1 eiwit.  
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Het derde hoofdstuk is gewijd aan een andere netvliesziekte, nl. autosomaal recessieve FA. 
In dit hoofdstuk worden twee nieuwe mutaties in RDH5 (p.(Val305Hisfs*29) en 
p.(Met253Arg)) beschreven als oorzaak van FA. RDH5 komt vooral tot expressie in het 
retinal pigment epitheel (RPE) waar het eiwit een belangrijke schakel is in de visuele cyclus, 
die zorgt voor de regeneratie van het chromofoor 11-cis retinal. Door middel van het 
verzamelen van alle gepubliceerde RDH5 varianten, werd in dit hoofdstuk ook aandacht 
besteedt aan genotype-fenotype correlaties voor RDH5.  Mutaties in dit gen werden exclusief 
gevonden in personen met witte stippen in de fundus. Indien personen witte stippen vertonen 
in de fundus ligt het voor de hand om eerst met sequentie analyse RDH5 te onderzoeken, 
gevolgd door de analyse van RLBP1 en RPE65, twee genen die ook werden geassocieerd met 
FA. Een andere belangrijke bevinding in deze studie was de aanwezigheid van macula 
degeneratie in oudere patiënten van beide families, hetgeen wijst op een progressief karakter 
van de ziekte. Het is zinvol om de fundus van jonge patiënten zonder macula degeneratie 
regelmatig te onderzoeken. Indien macula defecten worden gevonden, dan verandert de 
diagnose van FA naar retinitis punctata albescens in deze families. 
In het vierde hoofdstuk, worden twee families met BBS beschreven met twee verschillende 
BBS1 mutaties (c.47+1G>T en p.(Asp148Asn)). BBS is een syndromale vorm van staaf-kegel 
dystrofie en de meeste genetische subtypes worden beschouwd als ciliopathieën. De ernstige 
fenotypes die geconstateerd werden in beide families spreken de conclusies tegen van een 
eerdere studie waarin BBS1 mutaties juist waren geassocieerd met een minder ernstig 
fenotype. De aangedane personen in deze andere studies vertoonden een betere 
gezichtsscherpte en ERG waarden electrofysiologische metingen van de staafjes en kegeltjes 
(Daniels et al., Archives of Ophthalmology, 130, 901-907, 2012; Estrada-Cuzcano et al., 
Archives of Ophthalmology, 130, 1425-1432, 2012). Een andere bevinding in onze BBS 
familie was de intrafamiliaire fenotypische variabilititeit omdat een aangedane vrouw 
polydactylie vertoonde en haar aangedane broer niet. Waarschijnlijk spelen onbekende 
‘modifiers’ hierbij een rol. In dit hoofdstuk wordt ook de bruikbaarheid van exome 
sequencing beschreven voor de diagnose van erfelijke ziekten waarbij mutaties in 
verschillende genen betrokken kunnen zijn. 
In het vijfde hoofdstuk worden 4 consanguine families met retina dystrofie bestudeerd met  
eerder gevonden en nieuwe mutaties in vier verschillende genen. Eerder beschreven mutaties 
die tot de afwezigheid van een functioneel eiwit leiden werden gevonden in ABCA4, AIPL1 en 
CERKL in 3 families, terwijl een nieuwe missense mutatie werd gevonden in PDE6A in een 4e 
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familie. Deze bevindingen illustreren de kracht van homozygotie mapping voor het vinden 
van de oorzakelijke mutaties in consanguine families.  
Het zesde hoofdstuk geeft een compleet overzicht van de genetische oorzaken van 
syndromale en niet-syndromale erfelijke netvliesziekten in Pakistan. Tevens werden in 8 
nieuwe families oorzakelijke varianten beschreven in genen die eerder werden geassocieerd 
met erfelijke netvliesziekten. Een nieuwe CNGA1 mutatie (p.(Gly433Asp)) en een niet eerder 
beschreven CNGB1 mutatie (c.2493-2A>G) werden gevonden in 2 RP families, terwijl in 6 
andere families eerder gepubliceerde mutaties werden geïdentificeerd in CRB1, IQCB1, 
RPE65, RPGR en TULP1. Tevens werden gegevens van 9 families gepresenteerd waarin 
m.b.v. SNP microarray analyses homozygote gebieden werden aangetoond. In sommige 
gebieden werden genen gevonden die geassocieerd zijn met erfelijke netvliesziekten, maar 
werden geen mutaties gevonden m.b.v. Sanger sequencing. In andere families omvatten de 
homozygote gebieden geen bekende ‘erfelijke netvlies ziektegenen’. In deze families 
varieerden de LOD scores van de homozygote gebieden tussen de 1.8 en 4.0. In 2 families 
werd zeer waarschijnlijke genetische koppeling  (>2.7) gevonden, terwijl er in 2 andere 
families significante LOD scores (>3.3) werden aangetoond. In één familie werd een enkel 
homozygoot gebied van 46.1 Mb gevonden op chromosoom 1 (LOD score 2.7), welke 
overlap vertoonde met het RP32 locus (Zhang et al., Human Genetics, 118, 356-365, 2005). 
De overige 5 families droegen meerdere homozygote gebieden. Hoewel we diep-intronische, 
samengestelde heterozygote mutaties, en promoter mutaties niet kunnen uitsluiten in deze 
families, is er een gerede kans dat wij m.b.v. exome sequencing mutaties kunnen vinden in 
genen die tot dusver niet geassocieerd zijn met erfelijke netvliesziekten.  
In een consanguine familie beschreven in hoofdstuk zeven wordt een nieuwe mutatie 
(p.(Gly332Asp)) gevonden in DHX38, welke segregeerd met de ziekte in de familie. DHX38 
mutaties kunnen een nieuwe oorzaak zijn van vroeg optredende RP. Vervolgstudies in andere 
families alsmede experimenten in diermodellen zullen definitief bewijs moeten leveren voor 
wat betreft de oorzakelijkheid van de gevonden varianten in dit gen. 
In het achtste hoofdstuk worden de resultaten van dit proefschrift bediscussieerd. Ten eerste 
wordt het belang onderstreept van een correcte en tijdige klinische evaluatie, waardoor een 
afgewogen keuze gemaakt kan worden voor de uit te voeren genetische test. De genetische 
heterogeniteit en de fenotypische variabiliteit van erfelijke netvliesaandoeningen werden 
besproken. De kracht van homozygotie kartering in de identificatie van genen betrokken bij 
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netvliesziekten in consanguine families werd duidelijk aangetoond. Genotype-fenotype 
correlaties hebben hun waarde bewezen bij de genetische screening. Verder werd aandacht 
gegeven aan de mogelijkheden voor behandeling en preventie, het voordeel van dit onderzoek 
voor patiënten, het verbeteren van de screening protocollen wat betreft kostenefficiëntie en 
robuustheid, als ook de financiële status van de patiënten.  
Dit onderzoek vormt de basis voor een betere toekomstige zorg en preventie van erfelijke 
retina ziekten in Pakistaanse patiënten en draagt bij aan het verbeteren van de kwaliteit van 
leven voor aangedane personen en hun familieleden. 
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GC guanylyl cyclase 
GCAP guanylyl cyclase activating protein 
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